

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF FLORIDA**

**IN RE: ZANTAC (RANITIDINE)
PRODUCTS LIABILITY
LITIGATION**

**MDL NO 2924
20-MD-2924**

**JUDGE ROBIN L ROSENBERG
MAGISTRATE JUDGE BRUCE REINHART**

_____ /

**AMENDED CONSOLIDATED MEDICAL MONITORING CLASS ACTION
COMPLAINT**

TABLE OF CONTENTS

I.	INTRODUCTION	11
II.	JURISDICTION AND VENUE.....	14
III.	PARTIES	16
	A. Defendants	16
	B. Plaintiffs	20
IV.	FACTUAL ALLEGATIONS.....	38
	A. The Creation of Ranitidine-Containing Products and Their Introduction to the Market.....	38
	1. GSK Develops Zantac Through a Flurry of Aggressive Marketing Maneuvers	38
	2. NDMA Is a Carcinogen Whose Dangerous Properties Are Well Established.....	43
	3. NDMA Is Discovered in Ranitidine-Containing Products, Leading to Market Withdrawal	54
	B. The Science.....	59
	1. How Ranitidine Transforms into NDMA	59
	2. Formation of NDMA in the Environment of the Human Stomach.....	61
	3. Formation of NDMA in Other Organs of the Human Body	71
	4. Formation of NDMA by Exposure to Heat, Moisture, and/or Time.....	74
	5. Evidence Directly Links Ranitidine to Cancer	78
	C. Defendants' Knowledge of the NDMA Risk.....	80
	D. The Federal Regulatory Landscape	82
	1. Federal Law Required the Defendants to Notify the FDA about the Presence of NDMA in Ranitidine-Containing Products.....	82
	2. Good Manufacturing Practices.....	83
	E. Defendants' Tortious Conduct in Packaging and Labeling	85
	1. Prescription Manufacturer GSK's Failure to Warn and Misrepresentations in the Labeling of Ranitidine-Containing Products.....	85
	2. The Brand OTC Defendants' Failure to Warn and Misrepresentations in the Labeling and Packaging of OTC Ranitidine-Containing Products	90
V.	ADDITIONAL COUNT-SPECIFIC ALLEGATIONS.....	95

A.	Additional Allegations Specific to Plaintiffs’ Counts for Failure to Warn Through Warnings and Precautions	95
B.	Additional Allegations Specific to Plaintiffs’ Counts for Failure to Warn Through Proper Expiration Dates.....	102
C.	Additional Allegations Specific to Plaintiffs’ Counts Regarding Negligent Product Containers	106
D.	Additional Allegations Specific to Plaintiffs’ Counts for Negligent Storage and Transportation.....	108
VI.	PLAINTIFFS’ USE OF RANITIDINE-CONTAINING PRODUCTS AND ADDITIONAL MEDICAL MONITORING ALLEGATIONS	111
VII.	TOLLING / FRAUDULENT CONCEALMENT.....	125
VIII.	CLASS ALLEGATIONS	126
A.	Class Definitions.....	126
1.	Prescription GSK Medical Monitoring Class	126
2.	OTC Medical Monitoring Classes	127
B.	Fed. R. Civ. P. 23 Requirements	130
IX.	CAUSES OF ACTION	133
A.	Causes of Action Against Defendant GSK with Respect to Prescription Zantac....	133
1.	California.....	134
	COUNT 1: Negligence – Failure to Warn Through Warnings and Precautions – California.....	134
	COUNT 2: Negligence – Failure to Warn Through Proper Expiration Dates – California.....	136
	COUNT 3: Negligent Product Containers – California.....	139
	COUNT 4: Negligent Storage and Transportation – California.....	142
2.	Colorado.....	144
	COUNT 5: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Colorado	145
	COUNT 6: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Colorado.....	148
	COUNT 7: Medical Monitoring – Negligent Product Containers – Colorado.....	150
	COUNT 8: Medical Monitoring – Negligent Storage and Transportation – Colorado	153
3.	Florida	156

COUNT 9: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions –Florida.....	156
COUNT 10: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida	159
COUNT 11: Medical Monitoring – Negligent Product Containers – Florida	162
COUNT 12: Medical Monitoring – Negligent Storage and Transportation – Florida	165
4. Indiana.....	167
COUNT 13: Negligence – Failure to Warn Through Warnings and Precautions – Indiana.....	167
COUNT 14: Negligence – Failure To Warn Through Proper Expiration Dates – Indiana.....	170
COUNT 15: Negligent Product Containers – Indiana.....	173
COUNT 16: Negligent Storage and Transportation – Indiana	175
5. Maryland	178
COUNT 17: Negligence – Failure to Warn Through Warnings and Precautions – Maryland	178
COUNT 18: Negligence – Failure To Warn Through Proper Expiration Dates – Maryland	181
COUNT 19: Negligent Product Containers – Maryland	184
COUNT 20: Negligent Storage and Transportation – Maryland.....	186
6. Missouri	189
COUNT 21: Negligence – Failure to Warn Through Warnings and Precautions – Missouri	189
COUNT 22: Negligence – Failure to Warn Through Proper Expiration Dates – Missouri	192
COUNT 23: Negligent Product Containers – Missouri.....	194
COUNT 24: Negligent Storage and Transportation – Missouri.....	197
7. Ohio.....	199
COUNT 25: Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio.....	200
COUNT 26: Strict Liability – Failure To Warn Through Proper Expiration Dates – Ohio.....	202
COUNT 27: Negligent Product Containers – Ohio	205
COUNT 28: Negligent Storage and Transportation – Ohio	208

8.	Pennsylvania	211
	COUNT 29: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Pennsylvania	211
	COUNT 30: Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates – Pennsylvania	214
	COUNT 31: Medical Monitoring – Negligent Product Containers – Pennsylvania	216
	COUNT 32: Medical Monitoring – Negligent Storage and Transportation – Pennsylvania	219
B.	CAUSES OF ACTION AGAINST DEFENDANT GSK WITH RESPECT TO OTC ZANTAC	222
1.	California.....	223
	COUNT 33: Negligence – Failure to Warn Through Warnings and Precautions – California.....	223
	COUNT 34: Negligence – Failure to Warn Through Proper Expiration Dates – California.....	226
2.	Colorado.....	228
	COUNT 35: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Colorado	228
	COUNT 36: Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates – Colorado.....	231
3.	Florida	234
	COUNT 37: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Florida.....	234
	COUNT 38: Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates – Florida	237
4.	Missouri	240
	COUNT 39: Negligence – Failure to Warn Through Warnings and Precautions – Missouri	240
	COUNT 40: Negligence – Failure to Warn Through Proper Expiration Dates – Missouri	243
5.	Nevada.....	246
	COUNT 41: Negligence – Failure to Warn Through Warnings and Precautions – Nevada.....	246
	COUNT 42: Negligence – Failure to Warn Through Proper Expiration Dates – Nevada.....	249

C.	CAUSES OF ACTION AGAINST DEFENDANT PFIZER WITH RESPECT TO OTC ZANTAC	252
1.	California.....	252
	COUNT 43: Negligence – Failure to Warn Through Warnings and Precautions – California.....	252
	COUNT 44: Negligence – Failure to Warn Through Proper Expiration Dates – California.....	255
2.	Colorado.....	258
	COUNT 45: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Colorado	258
	COUNT 46: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Colorado.....	261
3.	Florida	264
	COUNT 47: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Florida.....	264
	COUNT 48: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida	267
4.	Maryland	270
	COUNT 49: Negligence – Failure to Warn Through Warnings and Precautions – Maryland	270
	COUNT 50: Negligence – Failure to Warn Through Proper Expiration Dates – Maryland	273
5.	Missouri	276
	COUNT 51: Negligence – Failure to Warn Through Warnings and Precautions – Missouri	276
	COUNT 52: Negligence – Failure to Warn Through Proper Expiration Dates – Missouri	279
6.	Nevada.....	282
	COUNT 53: Negligence – Failure to Warn Through Warnings and Precautions – Nevada.....	282
	COUNT 54: Negligence – Failure to Warn Through Proper Expiration Dates – Nevada.....	284
7.	Ohio.....	287
	COUNT 55: Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio.....	287

COUNT 56: Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio.....	290
8. West Virginia	293
COUNT 57: Medical Monitoring – Negligent Failure To Warn Through Warnings And Precautions – West Virginia.....	293
COUNT 58: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – West Virginia	296
D. CAUSES OF ACTION AGAINST DEFENDANT BI WITH RESPECT TO OTC ZANTAC	299
1. Arizona.....	300
COUNT 59: Negligence – Failure to Warn Through Warnings and Precautions – Arizona.....	300
COUNT 60: Negligence – Failure to Warn Through Proper Expiration Dates – Arizona.....	303
2. California.....	306
COUNT 61: Negligence – Failure to Warn Through Warnings and Precautions – California.....	306
COUNT 62: Negligence – Failure to Warn Through Proper Expiration Dates – California.....	309
3. Colorado.....	312
COUNT 63: Medical Monitoring – Negligence – Failure To Warn Through Warnings And Precautions – Colorado.....	312
COUNT 64: Medical Monitoring – Negligence –Failure to Warn Through Proper Expiration Dates – Colorado.....	315
4. Florida	318
COUNT 65: Medical Monitoring – Negligence – Failure to Warn Through Warnings and – Precautions—Florida.....	318
COUNT 66: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida	321
5. Indiana.....	324
COUNT 67: Negligence – Failure to Warn Through Warnings And Precautions – Indiana.....	324
COUNT 68: Negligence – Failure to Warn Through Proper Expiration Dates – Indiana.....	327
6. Maryland	329

COUNT 69: Negligence –Failure to Warn Through Warnings and Precautions – Maryland	329
COUNT 70: Negligence – Failure to Warn Through Proper Expiration Dates – Maryland	332
7. Missouri	335
COUNT 71: Negligence – Failure to Warn Through Warnings and Precautions – Missouri	335
COUNT 72: Negligence –Failure to Warn Through Proper Expiration Dates – Missouri	338
8. Nevada.....	341
COUNT 73: Negligence – Failure to Warn Through Warnings and Precautions – Nevada.....	341
COUNT 74: Negligence –Failure to Warn Through Proper Expiration Dates – Nevada.....	343
9. Ohio.....	346
COUNT 75: Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio.....	346
COUNT 76: Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio.....	349
10. Utah	352
COUNT 77: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Utah.....	352
COUNT 78: Medical Monitoring – Negligence – Failure To Warn Through Proper Expiration Dates – Utah	355
11. West Virginia	358
COUNT 79: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – West Virginia.....	358
COUNT 80: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – West Virginia	361
E. CAUSES OF ACTION AGAINST DEFENDANT SANOFI WITH RESPECT TO OTC ZANTAC	364
1. Arizona.....	365
COUNT 81: Negligence – Failure to Warn Through Warnings and Precautions – Arizona.....	365
COUNT 82: Negligence –Failure to Warn Through Proper Expiration Dates – Arizona.....	368

2.	California.....	371
	COUNT 83: Negligence –Failure to Warn Through Warnings and Precautions – California.....	371
	COUNT 84: Negligence – Failure to Warn Through Proper Expiration Dates – California.....	374
3.	Colorado.....	376
	COUNT 85: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Colorado	376
	COUNT 86: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Colorado.....	379
4.	Florida	382
	COUNT 87: Medical Monitoring –Negligence –Failure to Warn Through Warnings and Precautions – Florida.....	382
	COUNT 88: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida	386
5.	Indiana.....	389
	COUNT 89: Negligence – Failure to Warn Through Warnings and Precautions – Indiana.....	389
	COUNT 90: Negligence – Failure to Warn Through Proper Expiration Dates – Indiana.....	391
6.	Maryland	394
	COUNT 91: Negligence – Failure to Warn Through Warnings and Precautions – Maryland	394
	COUNT 92: Negligence – Failure to Warn Through Proper Expiration Dates – Maryland	397
7.	Missouri	400
	COUNT 93: Negligence – Failure to Warn Through Warnings and Precautions – Missouri	400
	COUNT 94: Negligence – Failure to Warn Through Proper Expiration Dates – Missouri	403
8.	Ohio.....	405
	COUNT 95: Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio.....	405
	COUNT 96: Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio.....	408
9.	Utah.....	411

	COUNT 97: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Utah.....	411
	COUNT 98: Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Utah	414
X.	PRAYER FOR RELIEF	417
XI.	JURY DEMAND.....	418

Pursuant to this Court’s Order [DE 3751], Plaintiffs file this Amended Consolidated Medical Monitoring Class Action Complaint on behalf of themselves and all others similarly situated, against the defendants named herein (“Defendants”), and seek equitable relief to remedy the harms caused by Defendants’ unlawful design, testing, manufacture, marketing, packaging, labeling, handling, distribution, storage, and/or sale of over-the-counter (“OTC”) and prescription ranitidine-containing medications sold under the brand name Zantac.¹ Plaintiffs’ allegations are based upon personal knowledge as to Plaintiffs’ own conduct, investigation of counsel based on publicly available information, and the limited discovery conducted to date.

I. INTRODUCTION

Zantac is the branded name for ranitidine, a drug that was touted and sold for nearly four decades as a safe and effective heartburn and indigestion drug. Zantac and other Ranitidine-Containing Products were among the most popular heartburn drugs, used by thousands of people every day. Indeed, Zantac was the first-ever “blockbuster” drug to reach \$1 billion in sales.

But recent scientific studies confirmed what Defendants knew or should have known decades ago: ranitidine transforms over time and under natural conditions into high levels of N-

¹ All prescription and OTC ranitidine-containing medications, whether brand name, store brand, or generic, are referred to collectively as “Ranitidine-Containing Products.” Brand name Ranitidine-Containing Products are referred to as Zantac.

Plaintiffs file this AMMC to comply with the Court’s previous Orders—most recently its order requiring Plaintiffs to file an amended medical monitoring complaint that does not include “any counts that the Court dismissed with prejudice or without leave to amend” and which “fully conform[s] to the Court’s orders of dismissal.” [DE 3751 at 1]. In doing so, Plaintiffs fully reserve all appellate rights. Although “[a]n amended complaint supercedes and replaces the original complaint,” a plaintiff does not waive his right to appeal the dismissal of a claim in the original complaint by amending the complaint and omitting the dismissed claim.” *Reynolds v. Behrman Cap. IV L.P.*, 988 F.3d 1314, 1319-20 (11th Cir. 2021) (holding that a plaintiff “did not waive his right to appeal the district court’s dismissal of [a defendant] by failing to name [that defendant] in the amended complaint because amendment would have been futile”).

Nitrosodimethylamine (“NDMA”), a carcinogen that is potent and dangerous. The U.S. Food and Drug Administration (“FDA”) recognizes NDMA as “a probable human carcinogen”² and the World Health Organization has described it as “clearly carcinogenic.”³ Its only use is to induce cancerous tumors in animals as part of laboratory research and experiments; it has no medicinal purpose.

In 2019, an analytical pharmacy ran tests on Zantac and discovered the link between ranitidine and NDMA and that ranitidine itself is unstable and can break down into NDMA, particularly in the environment of the stomach. On September 13, 2019, the analytical pharmacy filed a citizen petition asking the FDA to recall all products that contain ranitidine. In early October 2019, the FDA ordered testing on Zantac and other Ranitidine-Containing Products and specified the protocols for such testing. Within days of the FDA’s announcement, certain Defendants recalled Zantac and Ranitidine-Containing Products in the United States and internationally. On November 1, 2019, the FDA announced that its recent testing showed “unacceptable levels” of NDMA in Zantac and other Ranitidine-Containing Products and requested that all manufacturers recall Zantac and other Ranitidine-Containing Products. Ultimately, on April 1, 2020, the FDA called for a withdrawal of Zantac and all other Ranitidine-Containing Products in the United States, citing unacceptable levels of NDMA in those drugs.

While any exposure to NDMA can be harmful, the FDA has set an allowable daily limit (“ADI”) of 96 nanograms (ng) of NDMA. Tests conducted by the FDA and on behalf of the Defendants themselves indicate that ranitidine contains NDMA in levels far in excess of the FDA’s

² <https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market>.

³ R.G. Liteplo et al., Concise International Chemical Assessment Document 38: N-Nitrosodimethylamine, World Health Organization (2002), <https://www.who.int/ipcs/publications/cicad/en/cicad38.pdf>.

ADI even prior to ingestion. Thus individuals (including Plaintiffs) who ingested Zantac and other Ranitidine-Containing Products for years have been exposed to unsafe levels of carcinogenic NDMA. And that exposure has significantly increased their (and Plaintiffs') risk of cancer⁴—sometimes by more than 200%. As a result, Plaintiffs and the Classes need medical monitoring that is different than routine medical treatment to permit early detection of the Subject Cancers, as well as treatments and/or medications.

Medical monitoring is a recognized cause of action or form of relief (depending on state law) that allows a plaintiff and class members to obtain diagnostic medical examinations that are funded and/or reimbursed by a defendant, when the defendant's tortious conduct has exposed the plaintiff and class members to an increased risk of harm that proximately causes the need for the comprehensive diagnostic examinations.

In other words, medical monitoring recognizes that plaintiffs and class members can be significantly harmed, notwithstanding the latent exposure of that harm. To obtain relief, plaintiffs generally must prove exposure to a hazardous substance at greater than background levels, caused by the defendant's tortious conduct, which significantly increases the risk of contracting a serious latent disease.⁵ Typically, the proposed monitoring procedure must permit early detection, be reasonably necessary, and differ from routine medical treatment.⁶

Some states do not require a present physical injury as a condition to obtaining medical monitoring relief; rather, the injury is the exposure to the toxic materials and concomitant increased risk of harm, and/or the expensive diagnostic examinations plaintiff will incur as a result of that

⁴ These cancers include serious and potentially fatal bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancers (the "Subject Cancers").

⁵ See, e.g., *Petito v. A.H. Robins Co., Inc.*, 750 So. 2d 103, 106-07 (Fla. Dist. Ct. App. 1999).

⁶ See, e.g., *id.*

increased risk. Other states require a plaintiff to plead a physical manifestation (or present physical injury) of some sort, along with a significantly increased risk of harm.

Plaintiffs and the Classes seek medical monitoring in 13 states where present physical injury is *not* required,⁷ and where a significantly increased risk of harm (and/or related diagnostic examination costs) is a legally sufficient injury.

Here, Defendants *inter alia* designed, manufactured, distributed, packaged, labeled, marketed, and/or sold Zantac without proper expiration dates and appropriate packaging; failed to ensure the proper conditions for the manufacture, transportation, handling, and storage of Zantac; and failed to disclose material facts regarding the safety of Zantac and the dangers and risks associated with its intended use. In doing so, Defendants breached their respective duties to Plaintiffs and the Classes.

This Amended Medical Monitoring Complaint is drafted and organized based on the Court's previous Orders. As detailed below, Plaintiffs, individually and on behalf of the Classes (comprised of individuals who ingested Defendants' Zantac in specific identified States), seek medical monitoring as a result of their exposure to Defendants' prescription and/or OTC Zantac under the law of the State(s) in which each Plaintiff resided at the time of use.

II. JURISDICTION AND VENUE

1. This Court has original subject-matter jurisdiction over this action under 28 U.S.C. §1331 (federal question) and 18 U.S.C. §1964 (civil remedies). This Court also has subject matter jurisdiction over this action pursuant to 28 U.S.C. §1332, as amended by the Class Action Fairness Act of 2005, 28 U.S.C. §1332(d)(2), because: (a) there are at least 100 class members; (b) the

⁷ Plaintiffs have removed their claims under Montana law pursuant to the Court's recent orders. [D.E. 3720, 3751].

matter in controversy exceeds \$5 million, exclusive of interest and costs; and (c) at least one Plaintiff is a citizen of a different state than at least one Defendant. In addition, this Court has supplemental jurisdiction over Plaintiffs' state law claims under 28 U.S.C. §1367.

2. This Court has personal jurisdiction over Defendants under Fla. Stat. Ann. §48.193 and 18 U.S.C. §1965(b) and (d). This Court also has pendent personal jurisdiction over Defendants.

3. In addition and/or in the alternative, Defendants and/or their agents or alter egos each have significant contacts with each of the States and territories of the United States because they designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, and/or sold Ranitidine-Containing Products within each of the States and territories of the United States, and/or they derived revenue from the sale of their Ranitidine-Containing Products in each of the States and territories of the United States, through the purposeful direction of their activities to the States and territories of the United States and purposeful availment of the protections of the laws of the States and territories of the United States, such that personal jurisdiction would be proper in those States and territories under traditional notions of fair play and substantial justice.

4. In addition and/or in the alternative, the district to which each Plaintiff's action may be remanded upon conclusion of these pretrial proceedings pursuant to 28 U.S.C. §1407(a) will have personal jurisdiction over the Defendants who themselves or through an agent or alter ego are incorporated within that district, have a principal place of business in that district, or conduct a substantial amount of business in that district, such that they are essentially at home in that district and, thus, that personal jurisdiction would be proper in that district under traditional notions of fair play and substantial justice.

5. Venue is proper in this District under 28 U.S.C. §1391(b) because a substantial part

of the events or omissions giving rise to Plaintiffs' claims occurred in this District. Defendants designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, and/or sold Ranitidine-Containing Products, and otherwise conducted extensive business, within this District. In addition and/or in the alternative, venue is proper under 28 U.S.C. §1407(a) and the Conditional Transfer Orders of the Judicial Panel on Multidistrict Litigation.

III. PARTIES

A. Defendants

6. Defendants are entities that designed, manufactured, marketed, distributed, labeled, packaged, handled, stored, and/or sold prescription and/or OTC Zantac.

GlaxoSmithKline (GSK)

7. Defendant GlaxoSmithKline LLC is a Delaware limited liability company with its principal place of business located at Five Crescent Drive, Philadelphia, Pennsylvania 19112. Defendant GlaxoSmithKline LLC's sole member is Defendant GlaxoSmithKline (America) Inc., a Delaware corporation with its principal place of business in that state. Defendant GlaxoSmithKline LLC is a citizen of Delaware.

8. Defendant GlaxoSmithKline (America) Inc. is a Delaware corporation with its principal place of business located at 1105 North Market Street, Suite 622, Wilmington, Delaware 19801. Defendant GlaxoSmithKline (America) Inc. is a citizen of Delaware.

9. Defendant GlaxoSmithKline plc is a public limited company formed and existing under the laws of the United Kingdom, having a principal place of business at 980 Great West Road, Brentford Middlesex XO, TW8 9GS, United Kingdom. Defendant GlaxoSmithKline plc is a citizen of the United Kingdom.

10. Defendants GlaxoSmithKline LLC and GlaxoSmithKline (America) Inc. are

subsidiaries of Defendant GlaxoSmithKline plc.⁸ Collectively, all of these entities shall be referred to as “GSK.” Defendant GSK is a manufacturer, distributor, and seller of brand prescription and OTC Zantac.

Pfizer

11. Defendant Pfizer Inc. (“Pfizer”) is a Delaware corporation with its principal place of business located at 235 East 42nd Street, New York, New York 10017. Defendant Pfizer is a citizen of Delaware and New York. Defendant Pfizer is a manufacturer, distributor, and seller of brand OTC Zantac.

Boehringer Ingelheim (BI)⁹

12. Defendant Boehringer Ingelheim Pharmaceuticals, Inc., is a Delaware corporation with its principal place of business located at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Defendant Boehringer Ingelheim Pharmaceuticals, Inc., is a citizen of Delaware and Connecticut.

13. Defendant Boehringer Ingelheim Corporation is a Nevada corporation with its principal place of business located at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Defendant Boehringer Ingelheim Corporation is a citizen of Nevada and Connecticut.

14. Defendant Boehringer Ingelheim USA Corporation is a Delaware corporation with its principal place of business located at 900 Ridgebury Road, Ridgefield, Connecticut 06877. Defendant Boehringer Ingelheim USA Corporation is a citizen of Delaware and Connecticut.

15. Defendant Boehringer Ingelheim International GmbH is a limited liability

⁸ Pursuant to the Joint Stipulation Relating to GlaxoSmithKline PLC [DE 1470], Defendant GlaxoSmithKline LLC stipulated that Defendants GlaxoSmithKline plc is an affiliated company, and that Defendant GlaxoSmithKline LLC is the proper party for purposes of all claims asserted against Defendant GlaxoSmithKline plc in this litigation.

⁹ Defendant Boehringer Ingelheim also manufactured generic ranitidine under ANDA 074662, as well as through its former subsidiary Ben Venue Laboratories Inc. d/b/a Bedford Laboratories (ANDA 074764). Ben Venue Laboratories Inc. is no longer in operation.

company formed and existing under the laws of Germany, having a principal place of business at Binger Strasse 173, 55216 Ingelheim AM Rhein, Rheinland-Phalz, Germany. Defendant Boehringer Ingelheim International GmbH is a citizen of Germany.

16. Defendant Boehringer Ingelheim Promeco, S.A. de C.V. is a foreign corporation organized and existing under the laws of Mexico with its principal place of business located at Maiz No. 49, Barrio Xaltocan, Xochimilco, Ciudad de Mexico, 16090 Mexico. Defendant Boehringer Ingelheim Promeco, S.A. de C.V. is a citizen of Mexico.

17. Defendant Boehringer Ingelheim Pharmaceuticals, Inc. is a direct or indirect subsidiary of Defendants Boehringer Ingelheim Corporation and Boehringer Ingelheim USA Corporation, which are themselves wholly owned, directly or indirectly, by Defendant Boehringer Ingelheim International GmbH.¹⁰ Collectively, all of these entities and Defendant Boehringer Ingelheim Promeco, S.A. de C.V. shall be referred to as “Boehringer Ingelheim” or “BI.” Defendant BI is a manufacturer, distributor, and seller of brand OTC Zantac.

Sanofi

18. Defendant Sanofi-Aventis U.S. LLC is a Delaware limited liability company with its principal place of business located at 55 Corporate Drive, Bridgewater, New Jersey 08807. Defendant Sanofi-Aventis U.S. LLC’s sole member is Defendant Sanofi U.S. Services, Inc., a Delaware corporation with its principal place of business in New Jersey. Defendant Sanofi-Aventis U.S. LLC is a citizen of Delaware and New Jersey.

19. Defendant Sanofi US Services Inc. is a Delaware corporation with its principal

¹⁰ Pursuant to the Joint Stipulation Relating to Boehringer Ingelheim Defendants [DE 1478], Defendants Boehringer Ingelheim Pharmaceuticals, Inc. stipulated that Defendants Boehringer Ingelheim International GmbH and Boehringer Ingelheim Promeco, S.A. de C.V. are affiliated companies, and that Defendant Boehringer Ingelheim Pharmaceuticals, Inc. is the proper party for purposes of all claims asserted against Defendants Boehringer Ingelheim International GmbH and Boehringer Ingelheim Promeco, S.A. de C.V. in this litigation.

place of business located at 55 Corporate Drive, Bridgewater, New Jersey 08807. Defendant Sanofi US Services Inc. is a citizen of Delaware and New Jersey.

20. Sanofi SA¹¹ is a corporation formed and existing under the laws of France, having a principal place of business at 54 Rue La Boetie, 8th Arrondissement, Paris, France 75008. Defendant Sanofi SA is a citizen of France.

21. Defendant Patheon Manufacturing Services LLC is a Delaware limited liability company with its principal place of business located at 5900 Martin Luther King Jr. Highway, Greenville, North Carolina 27834. Thermo Fisher Scientific, Inc. is the sole member of Defendant Patheon Manufacturing Services LLC. Thermo Fisher Scientific, Inc. is a Delaware corporation with its principal place of business in Massachusetts. Defendant Patheon Manufacturing Services LLC is a citizen of Delaware and Massachusetts.

22. Defendant Chattem, Inc. is a Tennessee corporation with its principal place of business located at 1715 West 38th Street Chattanooga, Tennessee 37409. Defendant Chattem, Inc. is a citizen of Tennessee. Defendant Chattem, Inc purchased ranitidine and repackaged and/or relabeled it under its own brand.

23. Defendants Sanofi-Aventis U.S. LLC and Sanofi US Services Inc., and Chattem, Inc. are subsidiaries of Sanofi SA. Defendants Patheon Manufacturing Services LLC and Boehringer Ingelheim Promeco, S.A. de C.V. packaged and manufactured the finished Zantac product for Sanofi. Collectively, all of these entities shall be referred to as “Sanofi.” Defendant Sanofi is a manufacturer, distributor, and seller of brand OTC Zantac.

¹¹ Sanofi, S.A. is not named as a Defendant in this complaint pursuant to the Joint Stipulation Relating to Sanofi Defendants [DE 1450], wherein, Defendants Sanofi-Aventis U.S. LLC and Sanofi US Services Inc. stipulated that Defendant Sanofi SA is an affiliated company, and that Defendants Sanofi-Aventis U.S. LLC and Sanofi US Services Inc. are the proper parties for purposes of all claims asserted against Sanofi SA relief sought in this litigation.

24. Defendants BI, GSK, Pfizer, and Sanofi, shall be referred to collectively as the “Defendants.” At all relevant times, the Defendants have conducted business and derived substantial revenue from their design, manufacture, testing, marketing, labeling, packaging, handling, distribution, storage, and/or sale of Zantac within each of the States and Territories of the United States, Puerto Rico, and the District of Columbia.¹²

B. Plaintiffs

25. Plaintiffs are individuals who purchased and used Defendants’ Ranitidine-Containing Products, as described below and *infra*, Section VI.

26. Plaintiff Ida Adams (for the purpose of this paragraph, “Plaintiff”) is a citizen of Maryland. Plaintiff purchased and used Ranitidine-Containing Products from approximately 2000 to 2019 for heartburn and gastroesophageal reflux disease (“GERD”). The Ranitidine-Containing Products purchased and used by Plaintiff specifically included the following, consumed once to three times daily depending on her condition: (a) OTC 150 mg Zantac tablets and capsules from approximately 2000 to 2005 in West Virginia while a citizen of West Virginia, manufactured by Pfizer and BI; (b) OTC 150 mg Zantac tablets and capsules from approximately 2005 to 2017 in Maryland while a citizen of Maryland, manufactured by Pfizer, BI and Sanofi; and (c) OTC 150 mg Zantac tablets and capsules from approximately 2010 to 2012 in West Virginia while a citizen of Maryland, manufactured by BI. Thus, Pfizer, BI and Sanofi are “Defendants” with respect to purchases made in Maryland while a citizen of Maryland, unless otherwise specified; and Pfizer and BI are “Defendants” with respect to purchases made in West Virginia while a citizen of West Virginia, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a

¹² All references to “States” include Puerto Rico and the District of Columbia.

significantly increased risk for developing the Subject Cancers¹³ and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

27. Plaintiff Virginia Aragon (for the purpose of this paragraph, "Plaintiff") is a citizen of California. Plaintiff purchased and used Ranitidine-Containing Products in California while a citizen of California from approximately 2006 to 2020 for heartburn. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included the following, consumed daily: (a) OTC Zantac tablets and capsules of 75 mg and/or 150 mg from approximately 2006 to 2020 manufactured by Pfizer, BI, and Sanofi; and (b) prescription 300 mg generic ranitidine tablets and capsules from approximately 2006 to 2020. Thus, Pfizer, BI, and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

28. Plaintiff Golbenaz Bakhtiar (for the purpose of this paragraph, "Plaintiff") is a citizen of California. Plaintiff purchased and used Ranitidine-Containing Products in

¹³ As set out above, the Subject Cancers include serious and potentially fatal bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancers ("Subject Cancers").

California while a citizen of California from approximately 2000 to December 2019 for acid reflux and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included the following, consumed up to twice daily, depending on her condition, with occasional gaps of no longer than a week: (a) 150 mg prescription Zantac tablets and capsules beginning in approximately 2000, manufactured by GSK; (b) prescription 150 mg generic ranitidine tablets and capsules from approximately 2000 to 2019 that were used interchangeably throughout the time period with the brand; (c) 150 mg OTC Zantac tablets and capsules from approximately 2000 until 2019, manufactured by Pfizer, BI, and Sanofi, when she needed an extra dose or ran out of her prescription; and (d) OTC 150 mg generic ranitidine tablets and capsules from approximately 2005 to 2019, when she needed an extra dose or ran out of her prescription. Thus, GSK, Pfizer, BI, and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

29. Plaintiff Felicia Ball (for the purpose of this paragraph, “Plaintiff”) is a citizen of Pennsylvania. Plaintiff purchased and used Ranitidine-Containing Products in Pennsylvania while a citizen of Pennsylvania from approximately 2000 to 2020 for irritable bowel syndrome. The Ranitidine-Containing Products purchased and used by Plaintiff during that time specifically included the following, consumed at least once per day: (a) prescription Zantac in 150 mg and/or

300 mg manufactured by GSK beginning in 2000; and (b) prescription 150 mg and 300 mg generic ranitidine tablets and capsules when her insurance would not pay for brand Zantac. Thus, GSK is a “Defendant” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

30. Plaintiff Antrenise Campbell (for the purpose of this paragraph, “Plaintiff”) is a citizen of Missouri. Plaintiff purchased and used Ranitidine-Containing Products in Missouri while a citizen of Missouri from approximately 1998 to 2015 for heartburn and acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed twice daily specifically included (a) prescription 150 mg generic ranitidine tablets and capsules from approximately 1998 to 2008; and (b) OTC 150 mg Zantac tablets and capsules from approximately 2008 to 2013, manufactured by BI. Thus, BI is a “Defendant” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendant’s Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant’s Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus,

Plaintiff has suffered concrete injury as a result of Defendant's wrongful conduct.

31. Plaintiff Teresa Dowler (for the purpose of this paragraph, "Plaintiff") is a citizen of Indiana. Plaintiff purchased and used Ranitidine-Containing Products from approximately 2011 to December 2019 in Indiana while a citizen of Indiana for GERD. The Ranitidine-Containing Products Plaintiff purchased and used daily specifically included (a) prescription 150 mg Zantac tablets and capsules from approximately 2011 to 2013, manufactured by GSK; (b) OTC 150 mg Zantac tablets and capsules from approximately 2013 to 2018 manufactured by BI and Sanofi; and (c) prescription 150 mg generic ranitidine tablets and capsules from approximately 2018 to December 2019. Thus, GSK, BI, and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

32. Plaintiff Jonathan Ferguson (for the purpose of this paragraph, "Plaintiff") is a citizen of Washington. Plaintiff purchased and used Ranitidine-Containing Products from approximately 1996 to 2017 for heartburn and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included the following, consumed daily: (a) OTC Zantac tablets and capsules in approximately 1996 and 1999 in Nevada while a citizen of Nevada, manufactured by GSK and Pfizer; (b) OTC Zantac tablets and capsules from approximately 2007 to 2012 in California while a citizen of California, manufactured by BI; and (c) OTC ranitidine

tablets from 2010 to 2012 in California while a citizen of California. Thus, GSK and Pfizer are “Defendants” with respect to purchases made in Nevada while a citizen of Nevada, unless otherwise specified; and BI is a “Defendant” with respect to purchases made in California while a citizen of California, unless otherwise specified. As a direct and proximate result of consuming Defendant’s Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant’s Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

33. Plaintiff Karen Foster (for the purpose of this paragraph, “Plaintiff”) is a citizen of Virginia. Plaintiff purchased and used Ranitidine-Containing Products from approximately 2013 to 2020 for hernia, heartburn, reflux, sour stomach, and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included the following: (a) OTC 150 mg Zantac tablets and capsules that she purchased approximately a dozen times over the years from 2013 to 2017 in Florida while a citizen of Florida, manufactured by BI and Sanofi; and (b) prescription 150 mg generic ranitidine tablets and capsules in Florida while a citizen of Florida from approximately 2013 to 2017. Thus, BI is a “Defendant” with respect to purchases made in Florida while a citizen of Florida, unless otherwise specified. As a direct and proximate result of consuming these Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed these Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing

the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant's wrongful conduct.

34. Plaintiff Michael Galloway (for the purpose of this paragraph, "Plaintiff") is a citizen of Ohio. Plaintiff purchased and used Ranitidine-Containing Products from approximately 1989 through October 2019 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed up to three times daily specifically included (a) prescription 150 mg Zantac tablets and capsules from approximately 1997 through 1999 in Florida while a citizen of Florida, manufactured by GSK; (b) prescription 150 mg generic ranitidine tablets and capsules from approximately 1997 through 1999 in Florida while a citizen of Florida; (c) OTC Zantac tablets and capsules from approximately 1997 through 1999 in Florida while a citizen of Florida manufactured by GSK and Pfizer; (d) prescription 150 mg generic ranitidine tablets and capsules from approximately 1999 through October 2019 in Ohio while a citizen of Ohio; (e) OTC Zantac tablets and capsules from approximately 1999 through October 2019 in Ohio while a citizen of Ohio manufactured by Pfizer, BI, and Sanofi; and (f) prescription 150 mg Zantac tablets and capsules, beginning in approximately 1999 in Ohio, manufactured by GSK. Plaintiff often supplemented his usage with 2 additional pills a day by using OTC. Thus, GSK and Pfizer are "Defendants" with respect to purchases made in Florida while a citizen of Florida unless otherwise specified; and GSK, Pfizer, BI, and Sanofi are "Defendants" with respect to purchases made in Ohio while a citizen of Ohio unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk

of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

35. Plaintiff Alberta Griffin (for the purpose of this paragraph, "Plaintiff") is a citizen of Maryland. Plaintiff purchased and used Ranitidine-Containing Products in Maryland while a citizen of Maryland from approximately 2000 to March 2020 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff, consumed up to three times a day depending on her condition specifically included the following: (a) prescription Zantac tablets and capsules in increasing dosages beginning in approximately 2000, manufactured by GSK; (b) prescription 150 mg generic ranitidine tablets and capsules from approximately 2013 to March 2020 when her insurance would not pay for brand; and (c) OTC 150 mg Zantac tablets and capsules from approximately 2000 to March 2020, manufactured by Pfizer, BI, and Sanofi when she ran out of her prescription. Thus, GSK, Pfizer, BI, and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

36. Plaintiff Lorie Kendall-Songer (for the purpose of this paragraph, "Plaintiff") is a citizen of Missouri. Plaintiff purchased and used Ranitidine-Containing Products from approximately 2012 to 2020 in Missouri while a citizen of Missouri for acid reflux and heartburn. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included OTC

150 mg Zantac tablets and capsules, consumed once or twice per day, from approximately 2012 to 2020, which were manufactured by BI and Sanofi. Thus, BI and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

37. Plaintiff Ronda Lockett (for the purpose of this paragraph, “Plaintiff”) is a citizen of Texas. Plaintiff purchased and used Ranitidine-Containing Products from approximately 1983 to March 2020 for heartburn, acid reflux, and ulcers. The Ranitidine-Containing Products Plaintiff purchased and used in Missouri while a citizen of Missouri specifically included (a) prescription Zantac tablets and capsules consumed twice daily from approximately 1990 to 1995, which were manufactured by GSK; and (b) OTC Zantac tablets and capsules consumed once daily from approximately 1996 to 2000, which were manufactured by GSK and Pfizer. Thus, GSK and Pfizer are “Defendants” with respect to purchases made in Missouri while a citizen of Missouri, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered

concrete injury as a result of Defendants' wrongful conduct.

38. Plaintiff Marva McCall (for the purpose of this paragraph, "Plaintiff") is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 2007 to December 2019 for heartburn, acid reflux, and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included (a) 300 mg OTC Zantac tablets and capsules consumed once per day from approximately 2007 to 2015 when her prescription ran out, which were manufactured by BI; and (b) prescription 150 mg and 300 mg generic ranitidine tablets and capsules from approximately 2011 to 2019. Thus, BI is a "Defendant" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendant's Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant's Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant's wrongful conduct.

39. Plaintiff Clifton McKinnon (for the purpose of this paragraph, "Plaintiff") is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 2008 to 2020 for acid reflux and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included (a) OTC 75 and 150 mg Zantac tablets and capsules consumed twice per day from approximately 2008 to 2010, which were manufactured by BI; and (b) prescription 150 mg generic ranitidine tablets and capsules from approximately 2010 to 2020. Thus, BI is a "Defendant" for the purposes of Plaintiff's claims,

unless otherwise specified. As a direct and proximate result of consuming Defendant's Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant's Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant's wrongful conduct.

40. Plaintiff Kristen Monger, as power of attorney and on behalf of, Alexander Monger, (for the purpose of this paragraph, "Plaintiff") is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 1999 to 2020 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included (a) prescription 10, 15, 65, and 75 mg/ml Zantac syrup consumed twice per day beginning in approximately 1999, which was manufactured by GSK; (b) prescription Zantac tablets and capsules consumed for approximately a six-month period during a hiatus from taking syrup; and (c) prescription 15 and 75 mg/ml and 65ml/5ml generic ranitidine syrup, consumed twice per day from approximately 1999 to 2020. Thus, GSK is a "Defendant" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendant's Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant's Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant's wrongful conduct.

41. Plaintiff Kristen Monger, as power of attorney and on behalf of, Laura Monger, (for the purpose of this paragraph, “Plaintiff”) is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 1997 to 2020 for acid reflux, heartburn, GERD, and aspiration. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included (a) prescription 15, 25 mg/ml and 75mg/5ml Zantac syrup consumed twice per day, which was manufactured by GSK from approximately 1997 to 1998; and (b) prescription generic ranitidine syrup in various dosages based on Plaintiff’s weight consumed twice per day from approximately 1998 to 2020. Thus, GSK is a “Defendant” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendant’s Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant’s Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant’s wrongful conduct.

42. Plaintiff Ricardo Moròn (for the purpose of this paragraph, “Plaintiff”) is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 1996 to 2020 for heartburn, acid reflux, and stomach discomfort. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included 150 mg OTC Zantac tablets and capsules consumed approximately three to four times a week from approximately 1996 to 2020, which were manufactured by GSK, Pfizer, BI, and Sanofi. Thus, GSK, Pfizer, BI, and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-

Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

43. Plaintiff Richard Obrien (for the purpose of this paragraph, "Plaintiff") is a citizen of California. Plaintiff purchased and used Ranitidine-Containing Products in California while a citizen of California from approximately 1998 to November 2019 for gastritis and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff, consumed twice per day from approximately 1998 to 2008, and consumed once per day from approximately 2008 to 2019, specifically included: (a) OTC 150 mg Zantac tablets and capsules manufactured by GSK, Pfizer, BI, and Sanofi; and (b) OTC 150 mg generic ranitidine tablets and capsules when he occasionally ran out of Zantac brand. Thus, GSK, Pfizer, BI, and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

44. Plaintiff Cesar Pinon (for the purpose of this paragraph, "Plaintiff") is a citizen of Nevada. Plaintiff purchased and used Ranitidine-Containing Products in Nevada while a citizen

of Nevada from approximately 2009 to 2019 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included OTC 75 mg and 150 mg Zantac tablets and capsules, consumed two or three times per day after meals from approximately 2009 to 2015, and manufactured by BI. Thus, BI is the “Defendant” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendant’s Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendant’s Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendant’s wrongful conduct.

45. Plaintiff Jeffrey Pisano (for the purpose of this paragraph, “Plaintiff”) is a citizen of Colorado. Plaintiff purchased and used Ranitidine-Containing Products in Colorado while a citizen of Colorado from approximately 1998 to February 2020 for heartburn. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed twice per day but later consumed as needed specifically included (a) OTC 150 mg Zantac tablets and capsules from approximately 1998 to 2020, which were manufactured by GSK, Pfizer, BI, and Sanofi; (b) prescription 150 mg Zantac tablets and capsules from approximately 1998 to 2003, which were manufactured by GSK; and (c) prescription 150 mg generic ranitidine tablets and capsules from approximately 1998 to 2003. Thus, Pfizer, BI, Sanofi, and GSK are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular

monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

46. Plaintiff Ronald Ragan (for the purpose of this paragraph, "Plaintiff") is a citizen of Colorado. Plaintiff purchased and used Ranitidine-Containing Products from approximately 2012 to 2019 in Colorado while a citizen of Colorado for acid reflux, heartburn, and GERD. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed two times per day specifically included (a) OTC 150 mg Zantac tablets and capsules from approximately 2012 to 2019, which were manufactured by BI and Sanofi; and (b) OTC 150 mg generic ranitidine tablets and capsules from approximately 2012 to 2019. Thus, BI and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

47. Plaintiff Tangie Sims (for the purpose of this paragraph, "Plaintiff") is a citizen of Arizona. Plaintiff purchased and used Ranitidine-Containing Products in Arizona while a citizen of Arizona from approximately 2007 to 2020 for heartburn. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed one to two times per day specifically included: (a) OTC 150 mg Zantac tablets and capsules from approximately 2007 to 2020, which were

manufactured by BI and Sanofi; and (b) OTC generic ranitidine tablets and capsules from approximately 2010 to 2020. Thus, BI and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

48. Plaintiff Michael Tomlinson (for the purpose of this paragraph, “Plaintiff”) is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 2000 to November 2019 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed twice daily specifically included the following: (a) prescription 300 mg Zantac tablets and capsules beginning in 2000 and continuing through at least 2002, manufactured by GSK; (b) prescription 150 mg and 300 mg generic ranitidine tablets and capsules at some point thereafter until 2019; and (c) OTC 150 mg Zantac tablets and capsules from approximately 2000 to 2019, manufactured by Pfizer, BI, and Sanofi when he ran out of or did not have access to his prescription. Thus, GSK, BI, and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly

increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

49. Plaintiff Chris Troyan (for the purpose of this paragraph, "Plaintiff") is a citizen of Ohio. Plaintiff purchased and used Ranitidine-Containing Products in Ohio while a citizen of Ohio from approximately 2002 to 2020 for heartburn and acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed three to four times per week specifically included (a) 75 mg and 150 mg OTC Zantac tablets and capsules beginning in approximately 2002, manufactured by Pfizer, BI, and Sanofi; and (b) OTC generic ranitidine tablets and capsules from approximately 2011 to 2020. Thus, Pfizer, BI, and Sanofi are "Defendants" for the purposes of Plaintiff's claims, unless otherwise specified. As a direct and proximate result of consuming Defendants' Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants' Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants' wrongful conduct.

50. Plaintiff Gustavo Velasquez (for the purpose of this paragraph, "Plaintiff") is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 2000 to February 2020 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included OTC 75 mg and 150 mg Zantac tablets and capsules manufactured by Pfizer, BI, and Sanofi. Plaintiff consumed these Zantac tablets two to six times per week from approximately 2000 to 2016, and thereafter until

2020 on an as-needed basis, approximately once a month. Thus, Pfizer, BI, and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

51. Plaintiff Teresa Waters (for the purpose of this paragraph, “Plaintiff”) is a citizen of Utah. Plaintiff purchased and used Ranitidine-Containing Products in Utah while a citizen of Utah from approximately 2017 to March 2020 for acid reflux. The Ranitidine-Containing Products purchased and used by Plaintiff and consumed daily specifically included the following: (a) OTC 150 mg Zantac tablets and capsules from approximately 2017 to 2020 manufactured by BI and Sanofi; and (b) prescription 150 mg generic ranitidine tablets and capsules from approximately 2017 to 2020. Thus, BI and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

52. Plaintiff Joshua Winans (for the purpose of this paragraph, “Plaintiff”) is a citizen of Florida. Plaintiff purchased and used Ranitidine-Containing Products in Florida while a citizen of Florida from approximately 2000 to 2019 for GERD, dyspepsia, heartburn, upset stomach, and erosive esophagitis. The Ranitidine-Containing Products purchased and used by Plaintiff specifically included OTC 75 and 150 mg Zantac tablets and capsules, consumed daily from approximately 2000 to 2019, manufactured by Pfizer, BI, and Sanofi. Thus, Pfizer, BI, and Sanofi are “Defendants” for the purposes of Plaintiff’s claims, unless otherwise specified. As a direct and proximate result of consuming Defendants’ Ranitidine-Containing Products, which were unsafe for human ingestion, Plaintiff is at a significantly increased risk for developing the Subject Cancers and is in need of regular monitoring. Plaintiff would not have consumed Defendants’ Ranitidine-Containing Products had Plaintiff known that doing so would subject Plaintiff to a significantly increased risk of developing the Subject Cancers, as well as the cost of medical monitoring and subsequent treatment. Thus, Plaintiff has suffered concrete injury as a result of Defendants’ wrongful conduct.

IV. FACTUAL ALLEGATIONS

A. THE CREATION OF RANITIDINE-CONTAINING PRODUCTS AND THEIR INTRODUCTION TO THE MARKET

53. Defendants designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, and/or sold ranitidine under the brand Zantac by prescription and/or OTC.

1. GSK Develops Zantac Through a Flurry of Aggressive Marketing Maneuvers

54. Ranitidine belongs to a class of medications called histamine H₂-receptor antagonists (or H₂ blockers), which decrease the amount of acid produced by cells in the lining of the stomach. Other drugs within this class include cimetidine (branded Tagamet), famotidine (Pepcid), and nizatidine (Axid).

55. GSK-predecessor Smith, Kline & French discovered and developed Tagamet, the first H₂ blocker and the prototypical histamine H₂ receptor antagonist from which the later members of the class were developed.

56. GSK¹⁴ developed Zantac specifically in response to the success of cimetidine. Recognizing the extraordinary potential of having its own H₂ blocker in the burgeoning anti-ulcer market, GSK was all too willing to ensure its drug succeeded at all costs.

57. In 1976, scientist John Bradshaw, on behalf of GSK-predecessor Allen & Hanburys Ltd. synthesized and discovered ranitidine.

58. Allen & Hanburys Ltd., a then-subsiary of Glaxo Laboratories Ltd., is credited with developing ranitidine and was awarded Patent No. 4,128,658 by the U.S. Patent and Trademark Office in December 1978, which covered the ranitidine molecule.

59. In 1983, the FDA granted approval to GSK to sell Zantac, pursuant to the New Drug Application (“NDA”) No. 18-703, and it quickly became GSK’s most successful product—a “blockbuster.” Indeed, Zantac became the first prescription drug in history to reach \$1 billion in sales.

60. To accomplish this feat, GSK entered into a joint promotion agreement with Hoffmann-LaRoche, Inc., [REDACTED]

[REDACTED]¹⁵ More salespersons drove more sales and blockbuster profits for GSK.

61. In June 1986, the FDA approved Zantac for maintenance therapy of duodenal ulcers

¹⁴ GSK, as it is known today, was created through a series of mergers and acquisitions: In 1989, Smith, Kline & French merged with the Beecham Group to form SmithKline Beecham plc. In 1995, Glaxo merged with the Wellcome Foundation to become Glaxo Wellcome plc. In 2000, Glaxo Wellcome plc merged with SmithKline Beecham plc to form GlaxoSmithKline plc and GlaxoSmithKline LLC.

¹⁵ GSKZAN0000348881; GSKZAN0000348871

and for treatment of patients with gastroesophageal reflux disease (“GERD”).

62. In December 1993, GSK (through Glaxo Wellcome plc) entered into a partnership agreement with Pfizer-predecessor company Warner-Lambert Co. to develop and market an OTC version of Zantac.¹⁶ In 1995, the FDA approved OTC Zantac 75 mg tablets through NDA 20-520. In 1998, the FDA approved OTC Zantac 75 mg effervescent tablets through NDA 20-745.

63. In 1998, GSK (Glaxo Wellcome plc) and Warner-Lambert Co. ended their partnership. As part of the separation, Warner-Lambert Co. retained control over the OTC NDA for Zantac and the Zantac trademark in the United States and Canada but was required to obtain approval from GSK prior to making any product or trademark improvements or changes. GSK retained rights to sell OTC Zantac outside of the United States and Canada,¹⁷ and retained control over the Zantac trademark internationally.¹⁸

64. In 2000, Pfizer acquired Warner-Lambert Co. Pfizer controlled the Zantac OTC NDAs until December 2006.

65. In October 2000, GSK sold to Pfizer the full rights to OTC Zantac in the United States and Canada pursuant to a divestiture and transfer agreement. As part of that agreement, GSK divested all domestic Zantac OTC assets to Pfizer, including all trademark rights. The agreement removed the restrictions on Pfizer’s ability to seek product line extensions or the approval for higher doses of OTC Zantac. GSK retained the right to exclusive use of the Zantac name for any prescription Ranitidine-Containing Product in the United States.

66. In October 2003, Pfizer submitted NDA 21-698 for approval to market OTC Zantac 150 mg. The FDA approved NDA 21-698 on August 31, 2004.

¹⁶ GSKZAN0000022775.

¹⁷ GSK also still held the right to sell prescription Zantac in the United States.

¹⁸ PFI00245109.

67. During the time that Pfizer owned the rights to OTC Zantac, GSK continued to manufacture the product.

68. In 2006, pursuant to a Stock and Asset Purchase Agreement, Pfizer sold and divested its entire consumer health division (including employees and documents) to Johnson & Johnson (“J&J”).¹⁹ Because of antitrust issues, however, Zantac was transferred to Boehringer Ingelheim.

69. Pfizer, through a divestiture agreement, transferred all assets pertaining to its Zantac OTC line of products, including the rights to sell and market all formulations of OTC Zantac in the United States and Canada, as well as all intellectual property, research and development, and customer and supply contracts to Boehringer Ingelheim.

70. As part of that deal, Boehringer Ingelheim obtained control and responsibility over all of the Zantac OTC NDAs.

71. GSK continued marketing prescription Zantac in the United States until 2017 and still holds the NDAs for several prescription formulations of Zantac. GSK continued to maintain manufacturing and supply agreements relating to various formulations of both prescription and OTC Zantac. According to its recent annual report, GSK claims to have “discontinued making and selling prescription Zantac tablets in 2017 . . . in the U.S.”²⁰

72. Boehringer Ingelheim owned and controlled the NDA for OTC Zantac between December 2006 and January 2017, and manufactured, marketed, and distributed the drug in the United States during that period.²¹

¹⁹ PFI00191352.

²⁰ GlaxoSmithKline, plc, *Annual Report* 37 (2019), <https://www.gsk.com/media/5894/annual-report.pdf>.

²¹ Boehringer Ingelheim also owned and controlled ANDA 074662.

73. In 2017, Boehringer Ingelheim sold the rights of OTC Zantac to Sanofi pursuant to an asset swap agreement. As part of that deal, Sanofi obtained control and responsibility over Boehringer Ingelheim's entire consumer healthcare business, including the OTC Zantac NDAs. As part of this agreement, Boehringer Ingelheim and Sanofi entered into a manufacturing agreement wherein Boehringer Ingelheim continued to manufacture OTC Zantac for Sanofi.

74. Sanofi has controlled the OTC Zantac NDAs and marketed, sold, and distributed Zantac in the United States from January 2017 until 2019 when it issued a global recall and ceased marketing, selling, and distributing OTC Zantac. In addition, Sanofi has marketed, sold, and distributed ranitidine globally since 1983.²²

75. Throughout the time that Sanofi controlled the OTC Zantac NDAs, Boehringer Ingelheim Promeco, S.A. de C.V. and Patheon Manufacturing Services LLC manufactured the finished drug product.

76. Sanofi voluntarily recalled all Brand OTC Zantac and ranitidine on October 18, 2019.

77. Pfizer and Boehringer Ingelheim have made demands for indemnification per the Stock and Asset Purchase Agreement against J&J for legal claims related to OTC Zantac products.

78. Sanofi has made a demand for indemnification against J&J pursuant to a 2016 Asset Purchase Agreement between J&J and Sanofi.

79. The times during which each Defendant manufactured and/or sold branded Zantac are alleged below:

Manufacturer/ Repackager	Product	Prescription or Over the Counter	Sale Start Date Year	Sale End Date Year
GlaxoSmithKline	Pills, Syrup, and Injection	Prescription	1983	2019

²² SANOFI_ZAN_MDL_0000208478.

GlaxoSmithKline	Pills	OTC	1996	2000
Pfizer	Pills	OTC	1998	2006
Boehringer Ingelheim	Pills	OTC	2007	2019
Sanofi	Pills	OTC	2017	2019

80. As recently as 2018, Zantac was one of the top 10 antacid tablets in the United States, with sales of OTC Zantac 150 totaling \$128.9 million – a 3.1% increase from the previous year.

2. NDMA Is a Carcinogen Whose Dangerous Properties Are Well Established

81. According to the Environmental Protection Agency (“EPA”), NDMA is a semivolatile organic chemical that forms in both industrial and natural processes.”²³ It is one of the simplest members of a class of N-nitrosamines, a family of potent carcinogens. Scientists have long recognized the dangers that NDMA poses to human health. A 1979 news article noted that “NDMA has caused cancer in nearly every laboratory animal tested so far.”²⁴ NDMA is no longer produced or commercially used in the United States except for research. Its only use today is to cause cancer in laboratory animals.

82. Both the EPA and the International Agency for Research on Cancer (“IARC”)

²³ U.S. Environmental Protection Agency, *Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA)* (Nov. 2017), https://www.epa.gov/sites/production/files/2017-10/documents/ndma_fact_sheet_update_9-15-17_508.pdf.

²⁴ Jane Brody, *Bottoms Up: Alcohol in Moderation Can Extend Life*, The Globe & Mail (CANADA) (Oct. 11, 1979); see Rudy Platiel, *Anger Grows as Officials Unable to Trace Poison in Reserve’s Water*, The Globe & Mail (CANADA) (Jan. 6, 1990) (reporting that residents of Six Nations Indian Reserve “have been advised not to drink, cook or wash in the water because testing has found high levels of N-nitrosodimethylamine (NDMA), an industrial byproduct chemical that has been linked to cancer”); Kyrtopoulos et al, *DNA Adducts in Humans After Exposure to Methylating Agents*, 405 Mut. Res. 135 (1998) (noting that “chronic exposure of rats to very low doses of NDMA gives rise predominantly to liver tumors, including tumors of the liver cells (hepatocellular carcinomas), bile ducts, blood vessels and Kupffer cells”).

classify NDMA as a probable human carcinogen.²⁵

83. The IARC classification is based upon data that demonstrates NDMA “is carcinogenic in all animal species tested: mice, rats, Syrian gold, Chinese and European hamsters, guinea-pigs, rabbits, ducks, mastomys, various fish, newts and frogs. It induces benign and malignant tumors following its administration by various routes, including ingestion and inhalation, in various organs in various species.” Further, in 1978, IARC stated that NDMA “should be regarded for practical purposes as if it were carcinogenic to humans.”²⁶

84. The American Conference of Governmental Industrial Hygienists classifies NDMA as a confirmed animal carcinogen.²⁷

85. The Department of Health and Human Services (“DHHS”) states that NDMA is reasonably anticipated to be a human carcinogen.²⁸ This classification is based upon DHHS’s findings that NDMA caused tumors in numerous species of experimental animals, at several different tissue sites, and by several routes of exposure, with tumors occurring primarily in the liver, respiratory tract, kidney, and blood vessels.²⁹

86. The FDA considers NDMA a carcinogenic impurity³⁰ and chemical that “could

²⁵ See EPA Technical Fact Sheet, *supra*, note 23; Int’l Agency for Research on Cancer (IARC), *Summaries & Evaluations, N-NITROSODIMETHYLAMINE* (1978), <http://www.inchem.org/documents/iarc/vol17/n-nitrosodimethylamine.html>.

²⁶ 17 Int’l Agency for Research on Cancer, *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Some N-Nitroso Compounds* 151–52 (May 1978).

²⁷ See EPA Technical Fact Sheet, *supra* note 23.

²⁸ *Id.* at 3.

²⁹ *Id.*

³⁰ ApotexCorp_0000000786.

cause cancer” in humans.³¹ The FDA recognizes that NDMA is “known to be toxic.”³²

87. The World Health Organization states that there is “conclusive evidence that NDMA is a potent carcinogen” and that there is “clear evidence of carcinogenicity.”³³ NDMA belongs to the so-called “cohort of concern” which is a group of highly potent mutagenic carcinogens that have been classified as probable human carcinogens.³⁴

88. NDMA is among the chemicals known to the State of California to cause cancer (Title 27, California Code of Regulations, Section 27001), pursuant to California’s Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65).

89. The European Medicines Agency “(EMA)” has referred to NDMA as “highly carcinogenic.” It recommended that “primary attention with respect to risk for patients should be on these highly carcinogenic N-nitrosamines” (including NDMA), and categorized NDMA as “of highest concern with respect to mutagenic and carcinogenic potential.”³⁵

90. In 1989, the Agency for Toxic Substances and Disease Registry (ATSDR) stated that it is “reasonable to expect that exposure to NDMA by eating, drinking or breathing could cause cancer in humans” and that the “carcinogenicity of orally administered NDMA has been

³¹ FDA Statement, Janet Woodcock, Director – Ctr. for Drug Evaluation & Research, *Statement Alerting Patients and Health Care Professionals of NDMA Found in Samples of Ranitidine* (Sept. 13, 2019), <https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine>.

³² Amneal_prod 1 _ 0000002938.

³³ World Health Org., *Guidelines for Drinking Water Quality, N-Nitrosodimethylamine (NDMA)* (3d ed. 2008), https://www.who.int/water_sanitation_health/dwq/chemicals/ndmasummary_2ndadd.pdf.

³⁴ International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), *Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7(R1)*, March 2017; https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf.

³⁵ Nitrosamines EMEA-H-A5(3)-1490 - Assessment Report (europa.eu) (June 25, 2020), https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf.

demonstrated unequivocally in acute, intermediate and chronic durations studies” in animals and “it is important to recognize that this evidence also indicates that oral exposures of acute and intermediate duration are sufficient to induce cancer.” Moreover, “hepatotoxicity has been demonstrated in all animal species that have been tested and has been observed in humans who were exposed to NDMA by ingestion or inhalation.”³⁶

91. The International Register of Potentially Toxic Chemicals (IRPTC 1988) lists regulations imposed by 13 countries for NDMA for occupational exposure, packing, storing and transport, disposal, and warns of its probable human carcinogenicity and its high level of toxicity by ingestion or inhalation.

92. The Occupational Safety and Health Administration classifies NDMA as “a carcinogen” that requires special and significant precautions along with specific hazard warnings.³⁷

93. A review of Defendants’ own internal documents reveals that there is simply no question of material fact that it has been widely known within the medical and scientific community for over 40 years that NDMA is toxic and a known carcinogen.

94. In September 2019, Defendant GSK [REDACTED]

[REDACTED]

[REDACTED]³⁸ In addition, GSK [REDACTED]

[REDACTED]

[REDACTED] *Id.* GSK

³⁶ ATSDR Toxicological Profile For N-Nitrosodimethylamine (December 1989), <http://www.atsdr.cdc.gov/toxprofiles/tp141.pdf>.

³⁷ 29 C.F.R §1910.1003 (2012).

³⁸ GSKZAN0000236640.

[REDACTED]

[REDACTED] *Id.*

95. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]³⁹ [REDACTED]

[REDACTED]

[REDACTED]⁴⁰

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]⁴¹

96. [REDACTED]

[REDACTED]

[REDACTED]⁴² [REDACTED]

[REDACTED]⁴³

³⁹ GSKZAN0000369506.

⁴⁰ GSKZAN0000257640.

⁴¹ *Id.*

⁴² GSKZAN0000163882.

⁴³ See GSK Dear HCP Letter, (October 3, 2019), publicly available (for example, <https://www.hpra.ie/docs/default-source/Safety-Notices/gsk-hcp-letter-03oct2019.pdf>).

[REDACTED]

[REDACTED]⁴⁴ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]⁴⁵

97. Likewise, Defendant Sanofi [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]⁴⁷ [REDACTED]

[REDACTED] *Id.*

98. Non-Party Dr. Reddy's [REDACTED]

[REDACTED]

[REDACTED]⁴⁸ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

⁴⁴ GSKZAN0000178581.
⁴⁵ GSKZAN0000172037.
⁴⁶ SANOFI_ZAN_MDL_0000169790.
⁴⁷ SANOFI_ZAN_MDL_0000206858.
⁴⁸ DRLMDL0000077291.

[REDACTED] 49 [REDACTED]

[REDACTED]

[REDACTED] 50

99. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] 51 [REDACTED]

[REDACTED] *Id.*

100. Non-Party Apotex [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] 52

101. Non-Party Glenmark admits in its recall notification letter that “a carcinogenic impurity, NDMA, has been found in ranitidine medications at levels exceeding the FDA allowable limit.”⁵³

102.

103. As early as 1980, consumer products containing unsafe levels of NDMA and other nitrosamines have been recalled by manufacturers, either voluntarily or at the direction of the FDA.

104. Most recently, beginning in the summer of 2018, there have been recalls of several generic drugs used to treat high blood pressure and heart failure – Valsartan, Losartan, and

⁴⁹DRLMDL0000070414.

⁵⁰ *Id.*

⁵¹ DRLMDL0000069991.

⁵² ApotexCorp_0000030734.

⁵³ GiantEagle_MDL2924_00000303.

Irbesartan – because the medications contained nitrosamine impurities that do not meet the FDA’s safety standards.

105. This continued in 2020 when the FDA required recalls of numerous generic manufacturers’ metformin, including metformin made by Apotex, Amneal, Granules, Sun Pharmaceuticals, Nostrum, and Teva.⁵⁴

106. NDMA is a genotoxin which interacts with DNA and may subsequently induce mutations. Genotoxins are not considered to have a safe threshold or dose due to their ability to alter DNA.

107. The FDA has set an acceptable daily intake (“ADI”) level for NDMA at 96 ng. That means that consumption of 96 ng of NDMA a day would increase the risk of developing cancer by 0.001% over the course of a lifetime. That risk increases as the level of NDMA exposure increases. However, any level above 96 ng is considered unacceptable.⁵⁵

108. In studies examining carcinogenicity through oral administration, mice exposed to NDMA developed cancer in the kidney, bladder, liver, and lung. In comparable rat studies, cancers were observed in the liver, kidney, pancreas, and lung. In comparable hamster studies, cancers were observed in the liver, pancreas, and stomach. In comparable guinea-pig studies, cancers were observed in the liver and lung. In comparable rabbit studies, cancers were observed in the liver and lung.

109. In other long-term animal studies in mice and rats utilizing different routes of

⁵⁴ U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Metformin* (Jan. 6, 2021), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin>.

⁵⁵ U.S. Food & Drug Admin., *FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)* (Feb. 28, 2019), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan>.

exposures – inhalation, subcutaneous injection, and intraperitoneal (abdomen injection) – cancer was observed in the lung, liver, kidney, nasal cavity, and stomach.

110. Prior to the withdrawal of ranitidine, it was considered a category B drug for birth defects, meaning it was considered safe to take during pregnancy. Yet animals exposed to NDMA during pregnancy birthed offspring with elevated rates of cancer in the liver and kidneys.

111. NDMA is a very small molecule. That allows it to pass through the blood-brain and placental barrier. This is particularly concerning as ranitidine has been marketed for pregnant women and young children for years.

112. Exposure to high levels of NDMA has been linked to liver damage in humans.⁵⁶

113. Numerous *in vitro* studies confirm that NDMA is a mutagen – causing genetic mutations in human and animal cells.

114. Overall, the animal data demonstrates that NDMA is carcinogenic in all animal species tested: mice; rats; Syrian golden, Chinese and European hamsters; guinea pigs; rabbits; ducks; mastomys; fish; newts; and frogs.

115. The EPA classified NDMA as a probable human carcinogen “based on the induction of tumors at multiple sites in different mammal species exposed to NDMA by various routes.”⁵⁷

116. Pursuant to EPA cancer guidelines, “tumors observed in animals are generally assumed to indicate that an agent may produce tumors in humans.”⁵⁸

117. In addition to the overwhelming animal data linking NDMA to cancer, there are

⁵⁶ See EPA Technical Fact Sheet, *supra* note 23.

⁵⁷ *Id.*

⁵⁸ See U.S. Env'tl. Protection Agency, Risk Assessment Forum, *Guidelines for Carcinogen Risk Assessment* (Mar. 2005), https://www3.epa.gov/airtoxics/cancer_guidelines_final_3-25-05.pdf.

numerous human epidemiological studies exploring the effects of dietary exposure to various cancers. These studies consistently show increased risks of various cancers.

118. In a 1995 epidemiological case-control study looking at NDMA dietary exposure with 220 cases, researchers observed a statistically significant 700% increased risk of gastric cancer in persons exposed to more than 0.51 micrograms/day.⁵⁹

119. In a 1995 epidemiological case-control study looking at NDMA dietary exposure with 746 cases, researchers observed statistically significant elevated rates of gastric cancer in persons exposed to more than 0.191 micrograms/day.⁶⁰

120. In another 1995 epidemiological case-control study looking at, in part, the effects of dietary consumption on cancer, researchers observed a statistically significant elevated risk of developing aerodigestive cancer after being exposed to NDMA at 0.179 micrograms/day.⁶¹

121. In a 1999 epidemiological cohort study looking at NDMA dietary exposure with 189 cases and a follow up of 24 years, researchers noted that “*N*-nitroso compounds are potent carcinogens” and that dietary exposure to NDMA more than doubled the risk of developing colorectal cancer.⁶²

122. In a 2000 epidemiological cohort study looking at occupational exposure of workers in the rubber industry, researchers observed significant increased risks for NDMA

⁵⁹ Pobel et al., *Nitrosamine, Nitrate and Nitrite in Relation to Gastric Cancer: A Case-control Study in Marseille, France*, 11 Eur. J. Epidemiol. 67-73 (1995).

⁶⁰ La Vecchia, et al., *Nitrosamine Intake & Gastric Cancer Risk*, 4 Eur. J. Cancer Prev. 469-74 (1995).

⁶¹ Rogers et al., *Consumption of Nitrate, Nitrite, and Nitrosodimethylamine and the Risk of Upper Aerodigestive Tract Cancer*, 5 Cancer Epidemiol. Biomarkers Prev. 29-36 (1995).

⁶² Knekt et al., *Risk of Colorectal and Other Gastro-Intestinal Cancers after Exposure to Nitrate, Nitrite and N-nitroso Compounds: A Follow-Up Study*, 80 Int. J. Cancer 852-56 (1999).

exposure for esophagus, oral cavity, and pharynx cancer.⁶³

123. In a 2011 epidemiological cohort study looking at NDMA dietary exposure with 3,268 cases and a follow up of 11.4 years, researchers concluded that “[d]ietary NDMA intake was significantly associated with increased cancer risk in men and women” for all cancers, and that “NDMA was associated with increased risk of gastrointestinal cancers” including rectal cancers.⁶⁴

124. In a 2014 epidemiological case-control study looking at NDMA dietary exposure with 1,760 cases, researchers found a statistically significant elevated association between NDMA exposure and rectal cancer.⁶⁵

125. NDMA is also known to be genotoxic – meaning, it can cause DNA damage in human cells. Indeed, multiple studies demonstrate that NDMA is genotoxic both *in vivo* and *in vitro*. However, recent studies have shown that the ability of NDMA to cause mutations in cells is affected by the presence of enzymes typically found in living humans, suggesting that “humans may be especially sensitive to the carcinogenicity of NDMA.”⁶⁶

126. In addition to studies demonstrating that NDMA directly causes cancer, research shows that exposure to NDMA (a:) can exacerbate existing but dormant (*i.e.*, not malignant) tumor cells; (b) promote otherwise “initiated cancer cells” to develop into cancerous tumors; and (c) reduce the ability of the body to combat cancer as NDMA is immunosuppressive. Thus, in addition to NDMA being a direct cause of cancer itself, NDMA can also be a contributing factor to a cancer

⁶³ Straif et al., *Exposure to High Concentrations of Nitrosamines and Cancer Mortality Among a Cohort of Rubber Workers*, 57 *Occup. Envtl. Med* 180–87 (2000).

⁶⁴ Loh et al., *N-nitroso Compounds and Cancer Incidence: The European Prospective Investigation into Cancer and Nutrition (EPIC)–Norfolk Study*, 93 *Am. J. Clinical Nutrition* 1053–61 (2011).

⁶⁵ Zhu et al., *Dietary N-nitroso Compounds and Risk of Colorectal Cancer: A Case-control Study in Newfoundland and Labrador and Ontario, Canada*, 111 *Brit. J. Nutrition* 6, 1109–17 (2014).

⁶⁶ World Health Org., *supra* note 33.

injury caused by some other source.

3. NDMA Is Discovered in Ranitidine-Containing Products, Leading to Market Withdrawal

127. On September 9, 2019, pharmacy and testing laboratory Valisure LLC and ValisureRX LLC (collectively, “Valisure”) filed a Citizen Petition calling for the recall of all Ranitidine-Containing Products due to detecting exceedingly high levels of NDMA when testing ranitidine pills using gas chromatography-mass spectrometry. FDA and European regulators started reviewing the safety of ranitidine with specific focus on the presence of NDMA.⁶⁷ This set off a cascade of recalls by Defendants.

128. On September 13, 2019, the FDA’s Director for Drug Evaluation and Research, Dr. Janet Woodcock, issued a statement warning that some ranitidine medicines may contain NDMA.⁶⁸

129. On September 24, 2019, Sandoz voluntarily recalled all of its Ranitidine-Containing Products due to concerns of a “nitrosamine impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled medicine.”⁶⁹

130. On September 26, 2019, Non-Parties Apotex, Walgreens, Walmart, and Rite Aid voluntarily recalled all ranitidine products and removed them from shelves.⁷⁰ Apotex issued a

⁶⁷ FDA Statement, Woodcock, *supra* note 31; Press Release, European Medicines Agency, *EMA to Review Ranitidine Medicines Following Detection of NDMA* (Sept. 13, 2019), <https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma>.

⁶⁸ FDA Statement, Woodcock, *supra* note 31.

⁶⁹ FDA News Release, U.S. Food & Drug Admin., *FDA Announces Voluntary Recall of Sandoz Ranitidine Capsules Following Detection of an Impurity* (Sept. 24, 2019), <https://www.fda.gov/news-events/press-announcements/fda-announces-voluntary-recall-sandoz-ranitidine-capsules-following-detection-impurity>.

⁷⁰ U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)* (Sept. 26, 2019), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>.

statement, noting that “Apotex has learned from the U.S. Food and Drug Administration and other Global regulators that some ranitidine medicines including brand and generic formulations of ranitidine regardless of the manufacturer, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA).”⁷¹

131. On September 28, 2019, Non-Party CVS stated that it would stop selling Zantac and its CVS Health Store-Brand ranitidine out of concern that it might contain a carcinogen.

132. On October 2, 2019, the FDA ordered manufacturers of ranitidine to test their products and recommended using a liquid chromatography with high resolution mass spectrometer (“LC-HRMS”) testing protocol, which “does not use elevated temperatures.”⁷²

133. On October 8, 2019, Defendant GSK voluntarily recalled all Ranitidine-Containing Products internationally.⁷³ As part of the recall, GSK publicly acknowledged that unacceptable levels of NDMA were discovered in Zantac and noted that “GSK is continuing with investigations into the potential source of the NDMA.”⁷⁴

134. On October 18 and 23, 2019, Defendant Sanofi and generic manufacturer Dr.

⁷¹ Company Announcement, U.S. Food & Drug Admin., *Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All Pack Sizes and Formats) Due to the Potential for Detection of an Amount of Unexpected Impurity, N-nitrosodimethylamine (NDMA) Impurity in the Product* (Sept. 25, 2019), <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-ranitidine-tablets-75mg-and-150mg-all-pack-sizes-and>.

⁷² U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)* (Oct. 2, 2019), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>.

⁷³ Press Release, Gov. UK, *Zantac – MHRA Drug Alert Issued as GlaxoSmithKline Recalls All Unexpired Stock* (Oct. 8, 2019), <https://www.gov.uk/government/news/zantac-mhra-drug-alert-issued-as-glaxosmithkline-recalls-all-unexpired-stock>.

⁷⁴ Justin George Varghese, *GSK Recalls Popular Heartburn Drug Zantac Globally After Cancer Scare*, Reuters (Oct. 8, 2019), <https://www.reuters.com/article/us-gsk-heartburn-zantac/gsk-recalls-popular-heartburn-drug-zantac-globally-after-cancer-scare-idUSKBN1WN1SL>.

Reddy's voluntarily recalled all of their Ranitidine-Containing Products.⁷⁵

135. On October 28, 2019, generic manufacturer Perrigo voluntarily recalled all of its Ranitidine-Containing Products.⁷⁶

136. In its recall notice, Perrigo stated, “[a]fter regulatory bodies announced that ranitidine may potentially contain NDMA, Perrigo promptly began testing of its externally sourced ranitidine API (active pharmaceutical ingredient) and ranitidine-based products. On October 8, 2019, Perrigo halted shipments of the product based upon preliminary results. Based on the totality of data gathered to date, Perrigo has made the decision to conduct this voluntary recall.”⁷⁷

137. On November 1, 2019, the FDA announced the results of recent testing, finding unacceptable levels of NDMA in Ranitidine-Containing Products, and requested that drug makers begin to voluntarily recall their Ranitidine-Containing Products if the FDA or manufacturers discovered NDMA levels above the acceptable limits.⁷⁸

138. On December 4, 2019, the FDA issued a statement notifying consumers who wished to continue taking ranitidine to consider limiting their intake of nitrite-containing foods, *e.g.*, processed meats and preservatives like sodium nitrite.⁷⁹ This advice *mirrored* an admonition

⁷⁵ U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)* (Oct. 23, 2019), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>.

⁷⁶ *Id.*

⁷⁷ Company Announcement, U.S. Food & Drug Admin., *Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the Product* (Oct. 23, 2019), <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n>.

⁷⁸ U.S. Food & Drug Admin., Laboratory Tests | Ranitidine, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine> (content current as of Nov. 1, 2019).

⁷⁹ U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)* (Dec. 4, 2019), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine>.

issued by Italian scientists in 1981 after finding that ranitidine reacted with nitrites *in vitro* to form toxic and mutagenic effects in bacteria. The prudent advice of Dr. Silvio de Flora published in October 1981 in *The Lancet* was to “avoid nitrosation as far as possible by, for example, suggesting a diet low in nitrates and nitrites, by asking patients not to take these at times close to (or with) meals or by giving inhibitors of nitrosation such as ascorbic acid.”⁸⁰ If GSK had only heeded Dr. de Flora’s advice in 1981, millions of people might have avoided exposure to NDMA formed as a result of ranitidine’s interaction with the human digestive system.

139. Between November 1, 2019, and February 27, 2020, generic manufacturers Amneal and Glenmark recalled their products from the market, citing NDMA concerns.⁸¹

140. On January 2, 2020, research laboratory, Emery Pharma, submitted a Citizen Petition to the FDA, showing that the ranitidine molecule is heat-labile and under certain temperatures progressively accumulates NDMA.

141. Emery’s Citizen Petition outlined its substantial concern that ranitidine is a time- and temperature-sensitive pharmaceutical product that develops NDMA when exposed to heat, a common occurrence during shipping, handling, and storage. Emery requested that the FDA issue a directive to manufacturers to clearly label ranitidine with a warning that “by-products that are probable carcinogens can be generated if exposed to heat.” In addition to warning about this condition, Emery requested agency directives to manufacturers and distributors to ship ranitidine products in temperature-controlled vehicles.⁸²

⁸⁰ Silvio de Flora, *Cimetidine, Ranitidine and Their Mutagenic Nitroso Derivatives*, *The Lancet*, Oct. 31, 1981, at 993-94.

⁸¹ See generally U.S. Food & Drug Admin., *FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)* <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine> (content current as of Apr. 16, 2020).

⁸² Emery Pharma FDA Citizen Petition (Jan. 2, 2020) <https://emerypharma.com/news/emery-pharma-ranitidine-fda-citizen-petition/>.

142. In response,⁸³ on April 1, 2020, the FDA recounted that a recall is an “effective methods [sic] of removing or correcting defective FDA-regulated products . . . particularly when those products present a danger to health.”⁸⁴ The FDA sought the voluntary consent of manufacturers to accept the recall “to protect the public health from products that present a risk of injury.”⁸⁵ The FDA found that the recall of all Ranitidine-Containing Products and a public warning of the recall was necessary because the “product being recalled presents a serious health risk.”⁸⁶ The FDA therefore sent Information Requests to all applicants and pending applicants of Ranitidine-Containing Products “requesting a market withdrawal.”⁸⁷

143. The FDA found its stability testing raised concerns that NDMA levels in some Ranitidine-Containing Products stored at room temperature can increase with time to unacceptable levels. In the same vein, FDA testing revealed that higher NDMA levels were found as the products approached their expiration dates. The FDA’s testing eroded the agency’s confidence that any Ranitidine-Containing Product would remain stable through its labeled expiration date. Consequently, the FDA requested a market withdrawal of all ranitidine products. The FDA also announced to the public that the Agency’s laboratory tests indicate that temperature and time contribute to an increase in NDMA levels in some ranitidine products. The FDA’s decision to withdraw the drug rendered moot Emery’s request for temperature-controlled shipping conditions.

144. The FDA’s reaction was consistent with comparable regulatory action throughout the world. Before the FDA acted, over 43 different countries and jurisdictions restricted or banned

⁸³ Letter of Janet Woodcock, U.S. Food & Drug Admin., Docket No. FDA-2020-P-0042 (Apr. 1, 2020), *available at* <https://emerypharma.com/wp-content/uploads/2020/04/FDA-2020-P-0042-CP-Response-4-1-2020.pdf>.

⁸⁴ *Id.* at 5 (*citing* 21 CFR 7.40(a)).

⁸⁵ *Id.*

⁸⁶ *Id.* at 7.

⁸⁷ *Id.* at 10 n.43.

Ranitidine-Containing Products.⁸⁸

145. The European Medicines Agency (“EMA”), the Union’s EU equivalent to the FDA, through an Article 31 Referral, determined the sale of all Ranitidine-Containing Products should be suspended on September 19, 2019. On April 30, 2020, the Human Medicines Committee of the EMA “has recommended the suspension of all ranitidine medicines in the EU due to the presence of low levels of an impurity called N-nitrosodimethylamine (NDMA).” The EMA recognizes NDMA as a probable human carcinogen and issued a “precautionary suspension of these medicines in the EU” because “NDMA has been found in several ranitidine medicines above levels considered acceptable, and there are unresolved questions about the source of the impurities.”⁸⁹

146. On September 17, 2020, after a ranitidine manufacturer requested that the EMA re-examine its decision and permit ranitidine to be marketed again in the EU, the EMA confirmed its prior recommendation to suspend all ranitidine medicines in the EU due to the presence of NDMA noting that it is a probable human carcinogen and that there is evidence that NDMA forms from the degradation of ranitidine itself with increasing levels seen over shelf life.⁹⁰

B. THE SCIENCE

1. How Ranitidine Transforms into NDMA


147. The ranitidine molecule itself contains the constituent molecules to form NDMA.

⁸⁸ Margaret Newkirk & Susan Berfield, *FDA Recalls Are Always Voluntary and Sometimes Haphazard – and The Agency Doesn’t Want More Authority to Protect Consumers*, Bloomberg Businessweek (Dec. 3, 2019), <https://www.bloomberg.com/graphics/2019-voluntary-drug-recalls-zantac/>.

⁸⁹ Eur. Med. Agency, *Suspension of Ranitidine Medicines in the EU* (Apr. 30, 2020), https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-suspension-ranitidine-medicines-eu_en.pdf.

⁹⁰ Eur. Med. Agency, *EMA Confirms Recommendation to Suspend All Ranitidine Medicines in the EU* (Nov. 24, 2020), https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-ema-confirms-recommendation-suspend-all-ranitidine-medicines-eu_en.pdf.

See Figure 1.



148. The degradation occurs independently in two parts of the ranitidine molecule, with the products of the degradation combining to produce NDMA.

149. The formation of NDMA by the reaction of DMA and a nitroso source (such as a nitrite) is well characterized in the scientific literature and has been identified as a concern for contamination of the U.S. water supply.⁹¹ Indeed, in 2003, alarming levels of NDMA in drinking water processed by wastewater-treatment plants were specifically linked to the presence of ranitidine.⁹²

150. The high levels of NDMA observed in Ranitidine-Containing Products are a function of various factors. The ranitidine molecule internally degrades to form NDMA. The degradation of ranitidine can increase over time under normal storage conditions, but more so with exposure to heat and/or humidity. Once in the body, ranitidine continues to degrade and can yield increasing levels of NDMA in the human digestive system, and when it interacts with nitrogenous

⁹¹ Ogawa et al., *Purification and Properties of a New Enzyme, NG, NG-dimethylarginine Dimethylaminohydrolase, from Rat Kidney*, 264 J. Bio. Chem. 17, 10205–209 (1989).

⁹² Mitch et al., *N-Nitrosodimethylamine (NDMA) as a Drinking Water Contaminant: A Review*, 20 Env. Eng. Sci. 5, 389–404 (2003).

products.

2. Formation of NDMA in the Environment of the Human Stomach

151. When the ranitidine molecule is exposed to the acidic environment of the stomach, particularly when accompanied by nitrites (a chemical commonly found in heartburn-inducing foods), the Nitroso molecule ($\text{O}=\text{N}$) and the DMA molecule ($\text{H}_3\text{C}-\text{N}-\text{CH}_3$) break off and reform as NDMA.

152. In 1981, Dr. Silvio de Flora, an Italian researcher from the University of Genoa, published the results of experiments he conducted on ranitidine in the well-known journal, *The Lancet*. When ranitidine was exposed to human gastric fluid in combination with nitrites, his experiment showed “toxic and mutagenic effects.”⁹³ Dr. de Flora hypothesized that these mutagenic effects could have been caused by the “formation of more than one nitroso derivative [which includes NDMA] under our experimental conditions.” *Id.* Dr. de Flora cautioned that, in the context of ranitidine ingestion, “it would seem prudent to . . . suggest[] a diet low in nitrates and nitrites, by asking patients not to take these at times close to (or with) meals.”⁹⁴ *Id.*

153. GSK knew of Dr. de Flora’s publication because, two weeks later, GSK responded in *The Lancet*, claiming that the levels of nitrite needed to induce the production of nitroso derivatives (*i.e.*, NDMA) were not likely to be experienced by people in the real world.⁹⁵

154. This response reflects GSK’s reputation for “adopting the most combative,

⁹³ De Flora, *supra* note 80.

⁹⁴ This admonition came two years before the FDA approved Zantac in 1983. Notwithstanding, in 1998 GSK applied for and obtained an indication for OTC Zantac “[f]or the prevention of meal-induced heartburn at a dose of 75 mg taken 30 to 60 minutes prior to a meal.” See Ctr. for Drug Eval. & Research, *Approval Package* (June 8, 1998), available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20520s1_Zantac.pdf. So GSK specifically invited patients to take Zantac shortly before eating heartburn-inducing food.

⁹⁵ R. T., Brittain et al., *Safety of Ranitidine*, *The Lancet* 1119 (Nov. 14, 1981).

scorched-earth positions in defense of its brands.”⁹⁶ The company has no compunctions against distorting objective science to maintain its lucrative monopoly franchises, and its egregious conduct surrounding Zantac is not some isolated incident.

155. GSK endangered patient health while reaping billions of dollars in profits from Paxil, Wellbutrin, and Avandia. As we now know, the company was involved in covering up scientific data, offering illegal kickbacks to prescribing physicians, intimidating witnesses, and defrauding Medicare to profit from these medicines. In the wake of Congressional hearings into the company’s outrageous misbehavior,⁹⁷ GSK’s actions resulted in a criminal investigation and the then-largest guilty plea by a pharmaceutical company for fraud and failure to report safety data in the country’s history.⁹⁸ There is currently an open investigation of GSK and Sanofi being conducted by the Department of Justice relating to the failure to disclose to the federal government information about the potential presence of NDMA in Zantac.⁹⁹

156. GSK attended an FDA Advisory Committee in May 1982 where its representative testified and presented evidence relating to the safety of Zantac, including the potential for ranitidine to form nitrosamines. However, GSK failed to disclose its new evidence relating to ranitidine and the formation of a nitrosamine, specifically the formation of NDMA.¹⁰⁰

⁹⁶ Jim Edwards, *GSK’s Alleged Coverup of Bad Avandia Data: A Snapshot of Its Poisonous Corporate Culture*, Moneywatch (July 13, 2010) <https://www.cbsnews.com/news/gsk-alleged-coverup-of-bad-avandia-data-a-snapshot-of-its-poisonous-corporate-culture/>.

⁹⁷ *Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia*, Senate Comm. on Finance, 111th Cong. 2d Sess. 1 (Comm. Print Jan. 2010).

⁹⁸ U.S. Dep’t of Justice, *GlaxoSmithKline to Plead Guilty and Pay \$3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data* (July 2, 2012), <https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report>.

⁹⁹ Sanofi, Half-Year Financial Report (2020), https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/2020_07_29_HY_financial_report_EN.pdf.

¹⁰⁰ GSKZAN0000050413.

157. One month later, in June 1982, GSK submitted its draft Summary Basis of Approval and labeling for Zantac. Again, GSK failed to submit or otherwise disclose its new evidence relating to ranitidine and the formation of NMDA.¹⁰¹

158. In its submission to the FDA, GSK discussed its findings from internal studies performed in 1980 that ranitidine formed a different nitrosamine, n-nitroso-nitrolic acid, a potent mutagen, but explained that these results had no “practical clinical significance”¹⁰²:

Although N-nitroso-nitrolic acid was a potent mutagen, it is not likely to be formed in the stomach of a patient ingesting ranitidine, as an unrealistically large amount of nitrite needs to be present to form and maintain the nitrosamine. For this reason, and also because ranitidine was not carcinogenic in life-span studies in rodents, the in vitro nitrosation of ranitidine to a mutagenic nitrosamine does not seem to have practical clinical significance.

159. In 1980 – before Zantac was approved by the FDA – GSK conducted another study to examine, among other things, how long-term use of ranitidine could affect the levels of nitrite in the human stomach.¹⁰³ Remarkably, GSK admitted that ranitidine use caused the proliferation of bacteria in the human stomach that are known to convert nitrates to nitrites, which leads to elevated levels of nitrite in the stomach environment. GSK acknowledged this could increase the risk of forming nitrosamines and, in turn, cancer, but then dismissed this risk because people were allegedly only expected to use Ranitidine-Containing Products for a short-term period:

¹⁰¹ GSKZNDAA0000071900.

¹⁰² Excerpted from the Summary Basis of Approval submitted to the FDA to obtain approval of Zantac in the early 1980s. This document was obtained through a Freedom of Information Act request to the FDA.

¹⁰³ The results of this study are discussed in the Summary Basis of Approval, obtained from the FDA.

The importance of this finding is not clear. High levels of nitrite could react with certain organic compounds to form nitrosamines, which are known carcinogens. To date, however, neither ranitidine nor cimetidine have been carcinogenic in rodents, so the level of human risk cannot be estimated from animal studies. Ranitidine is recommended only for short-term use and carcinogenic risk, if any, should thus be minimized.

160. GSK knew – and indeed specifically admitted – that ranitidine could react with nitrite in the human stomach to form nitrosamines and, at the same time, that long-term use of ranitidine could lead to elevated levels of nitrite in the human stomach. GSK also knew, but did not disclose, that it had new evidence showing that NDMA was generated by ranitidine under certain conditions.

161. In response to Dr. de Flora's findings, in 1982, GSK conducted a clinical study specifically investigating gastric contents in human patients.¹⁰⁴ The study, in part, specifically measured the levels of N-Nitroso compounds in human gastric fluid. GSK indicated that there were no elevated levels, and even published the results of this study five years later, in 1987. The study, however, was flawed. It did not use gold-standard mass spectrometry to test for NDMA, but instead, used a process that could not measure N-nitrosamines efficiently. And worse, in the testing it did do, GSK refused to test gastric samples that contained ranitidine in them out of concern that samples with ranitidine would contain "high concentrations of N-nitroso compounds being recorded."¹⁰⁵ In other words, GSK intentionally engineered the study to exclude the very samples most likely to contain a dangerous carcinogen.

162. Given the above information that was disclosed relating to the nitrosation potential

¹⁰⁴ Thomas et al., *Effects of One Year's Treatment with Ranitidine and of Truncal Vagotomy on Gastric Contents*, 6 Gut. Vol. 28, 726–38 (1987).

¹⁰⁵ *Id.*

and formation of nitrosamines, it is shocking that GSK conducted an internal study to assess the formation of NDMA and found that ranitidine, when exposed to sodium nitrite, formed hundreds of thousands of nanograms of NDMA. The GSK study was never published or disclosed to the public.

163. In 1983, the same year GSK started marketing Zantac in the United States, seven researchers from the University of Genoa published a study discussing ranitidine and its genotoxic effects (ability to harm DNA).¹⁰⁶ The researchers concluded “it appears that reaction of ranitidine with excess sodium nitrite under acid conditions gives rise to a nitroso-derivative (or derivatives) [like NDMA] capable of inducing DNA damage in mammalian cells.” *Id.*

164. Then, again in 1983, Dr. de Flora, along with four other researchers, published their complete findings.¹⁰⁷ The results “confirm our preliminary findings on the formation of genotoxic derivatives from nitrite and ranitidine.” Again, the authors noted that, “the widespread clinical use [of ranitidine] and the possibility of a long-term maintenance therapy suggest the prudent adoption of some simple measures, such as a diet low in nitrates and nitrites or the prescription of these anti-ulcer drugs at a suitable interval from meals.” This admonition carries weight considering GSK’s studies indicate that long-term ranitidine consumption, itself, leads to elevated levels of nitrites in the human gut.

165. In addition, as multiple Defendants have noted in internal documents and recent submissions to regulatory authorities, a mechanism for ranitidine to form NDMA [REDACTED]

[REDACTED]

[REDACTED]

¹⁰⁶ Maura et al., *DNA Damage Induced by Nitrosated Ranitidine in Cultured Mammalian Cells*, 18 Tox. Ltrts. 97-102 (1983).

¹⁰⁷ De Flora et al., *Genotoxicity of Nitrosated Ranitidine*, 4 Carcinogenesis 3, 255-60 (1983).

[REDACTED]

[REDACTED]

[REDACTED]¹⁰⁸ Therefore, this potential mechanism was disregarded.

166. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]¹⁰⁹

167. However, in 1985 GSK [REDACTED]

[REDACTED]

[REDACTED]¹¹⁰ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]¹¹¹

¹⁰⁸ SANOFI_ZAN_MDL-0000033849-SANOFI_ZAN_MDL_0000033891, at SANOFI_ZAN_MDL_0000033873.

¹⁰⁹ GSKZNDAA0000072103-GSKZNDAA0000072128.

¹¹⁰ GSKZAN0000369313, [REDACTED]

¹¹¹ GSKZNDAA0000636549.

(1%). The remainder of the administered dose is found in the stool [US Zantac Prescribing Information]. The furoic acid metabolite of ranitidine has been reported to be formed in rats [Eddershaw, 1996]. It would be predicted that formation of this metabolite may also result in the release of dimethylamine (DMA) which may be available to form NDMA on exposure to nitrite. However, in publications reporting metabolism data in humans [Carey, 1981; Martin, 1981; Martin, 1982] the furoic acid metabolite of ranitidine is not detected by the Total Ion Current (TIC) chromatography using HPLC-MS.

168. The high instability of the ranitidine molecule was elucidated in scientific studies investigating ranitidine as a source of NDMA in drinking water and specific mechanisms for the breakdown of ranitidine were proposed.¹¹² These studies underscore the instability of the NDMA group on the ranitidine molecule and its ability to form NDMA in the environment of water-treatment plants that supply many U.S. cities with water.

169. In 2002, researchers conducted a controlled study to evaluate the concentration of nitrosamines, including NDMA, in the gastric fluid and urine in children with gastritis before and after four to six weeks of treatment with ranitidine. The study reported statistically significant increases in the nitrosamine concentration, including NDMA, in the gastric juice and urine in 93.3% of children after taking ranitidine for only four weeks. The researchers noted that nitrosamines belong to the most potent known carcinogens and no organisms have been found that would be resistant to the harmful effects, that neoplastic lesions induced by nitroso compounds may develop in any organ, and that nitrosamines induced a wide spectrum of tumors in studies using animal models. In addition, the authors noted specifically that NDMA induced similar symptoms of acute poisoning in humans and animals. They advised that prophylactic measures to avoid nitrosamine formation include a diet high in fruits and inclusion of ascorbic acid as well as limiting intake of processed meat. The conclusion was that ranitidine should only be

¹¹² Le Roux et al., *NDMA Formation by Chloramination of Ranitidine: Kinetics and Mechanism*, 46 *Envtl. Sci. Tech.* 20, 11095-103 (2012).

recommended in children after careful consideration.¹¹³

170. Despite the direct evidence that children taking ranitidine were being exposed to dangerously high levels of carcinogenic nitrosamines including NDMA, Defendants recklessly continued to market and promote Zantac and/or ranitidine as safe and effective for children.

171. Similarly, in 2016, researchers at Stanford University conducted an experiment on healthy adult volunteers. They measured the NDMA in urine of healthy individuals over the course of 24 hours, administered one dose of ranitidine, and then measured the NDMA in the urine of the same individuals for another 24 hours. The study reported that on average, the level of NDMA increased by 400 times, to approximately 47,000 ng. The only change during that 24-hour period was the consumption of ranitidine. In the study, the scientists further explained that previous studies have indicated a high metabolic conversion rate of NDMA, meaning it will be processed by the human body. This study showed that ranitidine generates NDMA in the human body.¹¹⁴

172. Valisure is an online pharmacy that also runs an analytical laboratory that is ISO 17025 accredited by the International Organization for Standardization (“ISO”) – an accreditation recognizing the laboratories technical competence for regulatory purposes. Valisure’s mission is to help ensure the safety, quality, and consistency of medications and supplements in the market. In response to rising concerns about counterfeit medications, generics, and overseas manufacturing, Valisure developed proprietary analytical technologies that it uses in addition to

¹¹³ Krawczynski, et al. *Nitrosamines in Children with Chronic Gastritis*, Journal of the Polish Pediatric Society (GSKZAN0000235261).

¹¹⁴ Zeng et al., *Oral intake of Ranitidine Increases Urinary Excretion of N-nitrosodimethylamine*, 37 *Carcinogenesis* 625–34 (2016). While this study was recently retracted due to errors in its testing method, its publication put Defendants on notice that ranitidine forms NDMA, particularly when subjected to heat, posing a risk of harm to those who consume it, and thus should have prompted Defendants to conduct thorough research and analysis on that issue (including testing their pills using gas chromatography-mass spectrometry).

FDA standard assays to test every batch of every medication it dispenses.

173. In its September 9, 2019, Citizen’s Petition to the FDA,¹¹⁵ Valisure disclosed as part of its testing of Ranitidine-Containing Products that in every lot tested there were exceedingly high levels of NDMA. Valisure’s ISO 17025 accredited laboratory used FDA recommended GC/MS headspace analysis method FY19-005-DPA for the determination of NDMA levels. As per the FDA protocol, this method was validated to a lower limit of detection of 25 ng.¹¹⁶ The results of Valisure’s testing show levels of NDMA well above 2 million ng per 150 mg Zantac tablet, shown below in Table 1.

Table 1 – Ranitidine Samples Tested by Valisure Laboratory Using GC/MS Protocol

150 mg Tablets or equivalent	Lot #	NDMA per tablet (ng)
Reference Powder	125619	2,472,531
Zantac, Brand OTC	18M498M	2,511,469
Zantac (mint), Brand OTC	18H546	2,834,798
Wal-Zan, Walgreens	79L800819A	2,444,046
Wal-Zan (mint), Walgreens	8ME2640	2,635,006
Ranitidine, CVS	9BE2773	2,520,311
Zantac (mint), CVS	9AE2864	3,267,968
Ranitidine, Equate	9BE2772	2,479,872
Ranitidine (mint), Equate	8ME2642	2,805,259
Ranitidine, Strides	77024060A	2,951,649

174. This testing by GC-MS demonstrates the instability of the ranitidine molecule and its propensity to break down under higher temperatures.

¹¹⁵ Valisure, *Citizen Petition on Ranitidine* (Sept. 9, 2019), available at <https://www.valisure.com/wp-content/uploads/Valisure-Ranitidine-FDA-Citizen-Petition-v4.12.pdf>.

¹¹⁶ U.S. Food & Drug Admin., *Combined N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Impurity Assay, FY19-005-DPA-S* (Jan. 28, 2019).

175. Valisure was concerned that the extremely high levels of NDMA observed in its testing were a product of the modest oven heating parameter of 130 °C in the FDA recommended GC/MS protocol. So Valisure developed a low temperature GC/MS method that could still detect NDMA but would only subject samples to 37 °C, the average temperature of the human body. This method was validated to a lower limit of detection of 100 ng.

176. Valisure tested ranitidine tablets by themselves and in conditions simulating the human stomach. Industry standard “Simulated Gastric Fluid” (“SGF”: 50 mM potassium chloride, 85 mM hydrochloric acid adjusted to pH 1.2 with 1.25 g pepsin per liter) and “Simulated Intestinal Fluid” (“SIF”: 50 mM potassium chloride, 50 mM potassium phosphate monobasic adjusted to pH 6.8 with hydrochloric acid and sodium hydroxide) were used alone and in combination with various concentrations of nitrite, which is commonly ingested in foods like processed meats and is elevated in the stomach by antacid drugs. The inclusion of nitrite in gastric fluid testing is commonplace and helps simulate the environment of a human stomach.

177. Indeed, Ranitidine-Containing Products were specifically advertised to be used when consuming foods containing high levels of nitrates, such as tacos or pizza.¹¹⁷

178. The results of Valisure’s tests on ranitidine tablets in biologically relevant conditions demonstrate significant NDMA formation under simulated gastric conditions with nitrite present, demonstrating proof of concept. (*see* Table 2).

Table 2 – Valisure Biologically Relevant Tests for NDMA Formation

Ranitidine Tablet Studies	NDMA (ng/mL)	NDMA per tablet (ng)
Tablet without Solvent	Not Detected	Not Detected

¹¹⁷ See, e.g., Zantac television commercial, *Family Taco Night*, <https://www.ispot.tv/ad/dY7n/zantac-family-taco-night>; Zantac television commercial, *Spicy*, https://youtu.be/jzS2kuB5_wg; Zantac television commercial, *Heartburn*, <https://youtu.be/Z3QMwkSUIEg>; Zantac television commercial, *Zantac Heartburn Challenge*, <https://youtu.be/qvh9gyWqQns>.

Tablet	Not Detected	Not Detected
Simulated Gastric Fluid (“SGF”)	Not Detected	Not Detected
Simulated Intestinal Fluid (“SIF”)	Not Detected	Not Detected
SGF with 10 mM Sodium Nitrite	Not Detected	Not Detected
SGF with 25 mM Sodium Nitrite	236	23,600
SGF with 50 mM Sodium Nitrite	3,045	304,500

179. Following the release of Valisure Citizen’s Petition, the FDA conducted additional laboratory tests, which showed NDMA levels in all ranitidine samples it tested, including API and the finished drug, both tablets and syrup. The FDA developed SGF and SIF models to use with the LC-MS testing method to estimate the biological significance of *in vitro* findings. These models are intended to detect the formation of NDMA in systems that approximate the stomach and intestine.

180. When the scientific data is assessed overall, the literature demonstrates that the ingestion of ranitidine already containing NDMA combined with the presence of human-relevant levels of nitrite in the stomach – a substance that is commonly found in foods that induce heartburn and that is known to be elevated in people taking ranitidine for longer than a month – the ranitidine molecule transforms into more NDMA which would dramatically increase a person’s risk of developing cancer.


3. Formation of NDMA in Other Organs of the Human Body

181. In addition to the gastric fluid mechanisms investigated in the scientific literature, Valisure identified a possible enzymatic mechanism for the liberation of ranitidine’s DMA group via the human enzyme dimethylarginine dimethylaminohydrolase (“DDAH”), which can occur in other tissues and organs separate from the stomach.

182. Valisure explained that liberated DMA can lead to the formation of NDMA when exposed to nitrite present on the ranitidine molecule, nitrite freely circulating in the body, or other

potential pathways, particularly in weak acidic conditions such as that in the kidney or bladder. The original scientific paper detailing the discovery of the DDAH enzyme in 1989 specifically comments on the propensity of DMA to form NDMA: “This report also provides a useful knowledge for an understanding of the endogenous source of dimethylamine as a precursor of a potent carcinogen, dimethylnitrosamine [NDMA].”¹¹⁸

183. Valisure reported as illustrated in Figure 2, below, computational modelling demonstrates that ranitidine (shown in green) can readily bind to the DDAH-1 enzyme (shown as a cross-section in grey) in a manner similar to the natural substrate of DDAH-1 known as asymmetric dimethylarginine (“ADMA,” shown in blue).




184. Valisure reported that these results suggest that the enzyme DDAH-1 increases

¹¹⁸ Ogawa, *et al.*, *supra* note 91..

formation of NDMA in the human body when ranitidine is present; therefore, the expression of the DDAH-1 gene is useful for identifying organs most susceptible to this action.

185. Figure 3 below, derived from the National Center for Biotechnology Information, illustrates the expression of the DDAH-1 gene in various tissues in the human body.



186. DDAH-1 is most strongly expressed in the kidneys but also broadly distributed throughout the body, such as in the brain, colon, liver, small intestine, stomach, bladder, and prostate. Valisure noted that this offers both a general mechanism for NDMA formation in the human body from ranitidine and specifically raises concern for the effects of NDMA on numerous organs.

187. The possible enzymatic reaction of ranitidine to DDAH-1, or other enzymes, suggests that high levels of NDMA can form throughout the human body. Indeed, ranitidine metabolizes and circulates throughout the human body, crossing the placental and blood-brain barrier, within 1-2 hours. When ranitidine interacts with the DDAH-1 enzyme in various organs

throughout the body, it breaks down into NDMA. This observation is validated by the Stanford study, discussed above.


4. Formation of NDMA by Exposure to Heat, Moisture, and/or Time

188. The risk of creating NDMA by exposing ranitidine to heat has been well-known and documented. Early studies, including the one conducted by GSK in the early 1980s, demonstrated that nitrosamines were formed when ranitidine was exposed to heat. This point was underscored in the Valisure petition, which initially used a high heat testing method.

189. In response to Valisure, on October 2, 2019, the FDA recommended that researchers use the LC-HRMS protocol for detecting NDMA in ranitidine because the “testing method does not use elevated temperatures” and has been proven capable of detecting NDMA.

190. On January 2, 2020, Emery Pharma, an FDA-certified pharmaceutical testing laboratory, conducted a series of tests on ranitidine. The researchers exposed ranitidine to 70 °C for varying periods of time. The results showed that increasing levels of NDMA formed based on exposure to heat. As reported by Emery Pharma, the following diagram reveals how NDMA accumulates over time when exposed to 70 °C:

Figure 4 – Rate of Development of NDMA when Exposed to Heat



191. The researchers cautioned:

NDMA accumulates in ranitidine-containing drug products on exposure to elevated temperatures, which would be routinely reached during shipment and during storage. More importantly, these conditions occur post-lot release by the manufacturer. Hence, while NDMA levels in ranitidine may be acceptable at the source, they may not be so when the drug is purchased and subsequently at the time of consumption by the consumer.¹¹⁹

192. The results of this data demonstrate that in normal transport and storage, and especially when exposed to heat or humidity, the ranitidine molecule systematically breaks down into NDMA, accumulating over time in the finished product. Considering Ranitidine-Containing Products have an approved shelf life of 36 months, the possibility of the drug accumulating dangerously high levels of NDMA prior to consumption is very real – a point underscored by the FDA’s swift removal of the product from the market.

193. In fact, the FDA acknowledged that testing revealed that NDMA levels in ranitidine

¹¹⁹ Emery Pharma, *Emery Pharma Ranitidine: FDA Citizen Petition* (Jan. 2, 2020), available at <https://emerypharma.com/news/emery-pharma-ranitidine-fda-citizen-petition/>.

products stored at room temperature can increase with time to unacceptable levels.¹²⁰

194. In 2019, the findings by Valisure unleashed an avalanche of regulatory authorities throughout the world demanding that the manufacturers of Zantac and/or ranitidine conduct testing of their products for the presence of NDMA as well as investigate the root cause as to how NDMA was being generated. In April 2020, the FDA requested that manufacturers immediately remove all Ranitidine-Containing Products from the market.

195. In the interim between the Valisure findings being released to the public and the FDA announcement requesting recall of all ranitidine products in April 2020, the manufacturers were investigating the root cause of NDMA in their products.

196. After undertaking an investigation, GSK concluded that “the presence of NDMA in ranitidine drug substance is due to a slow degradation reaction occurring primarily in the solid state. The two constituent parts of NDMA, the nitroso group and the dimethylamino group, are both derived from internal degradation reactions which occur at slow rates with the ranitidine molecule.”¹²¹ Unsurprisingly, GSK [REDACTED]

[REDACTED]

[REDACTED]¹²² In addition, GSK’s testing revealed [REDACTED]

[REDACTED]

[REDACTED]¹²³

197. Similarly, [REDACTED]

[REDACTED]

¹²⁰ Woodcock Letter, *supra* note 83.

¹²¹ GSKZAN0000052019-GSKZAN0000052127

¹²² *Id.* p. 2.

¹²³ *Id.* p. 12.

[REDACTED]

[REDACTED]¹²⁴

198. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]¹²⁵

199. The FDA’s own testing found that ranitidine sold by Defendant Sanofi contained up to 360 ng of NDMA per 150 mg tablet—3 times the ADI¹²⁶ in just one dose—and Plaintiffs frequently took more than one dose a day.

200. [REDACTED]

[REDACTED]¹²⁷ [REDACTED]

[REDACTED]

[REDACTED]¹²⁸

201. Defendants could dictate the conditions under which API was transported to them. The labeling requirements do not apply to transporting API, in part because the finished product and API are packaged differently and may degrade under different conditions.

202. Based upon the documents produced by Defendants and based upon further information and belief, Defendants failed to ensure that their Ranitidine-Containing Products (in

¹²⁴ SANOFI_ZAN_MDL_0000151458

¹²⁵ SANOFI_ZAN_MDL_0000166517-527, at p. 11.

¹²⁶ <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine>. 1
microgram = 1000 nanograms.

¹²⁷ GSKAN0000883508. Despite multiple requests, to date no Defendant has provided Plaintiffs with product they can use for independent testing. As such, at this juncture Plaintiffs rely upon the testing performed by the FDA and Defendants themselves. Discovery is ongoing and it is anticipated that further information will be provided via expert reports and testimony.

¹²⁸ See, e.g., SANOFI_ZAN_MDL_0000038689.

both API and finished dose form) were kept safely from excessive heat and humidity.¹²⁹

5. Evidence Directly Links Ranitidine to Cancer

203. There are numerous studies, including epidemiological studies, that support the conclusion that NDMA and, specifically, NDMA in ranitidine, causes cancer in humans, including the Subject Cancers.

204. One epidemiology study, published in 2004, showed that men taking either ranitidine or cimetidine (Tagamet) had increased risks of bladder cancer.¹³⁰ Similarly, a more recent study revealed that individuals who consumed ranitidine have a 22% increase in bladder cancer as compared with non-users.¹³¹

205. In one epidemiology study specifically designed to look at breast cancer, ranitidine was shown to more than double the risk, an effect that was even more pronounced in those with specific gene mutations.¹³²

206. In another epidemiological study looking at various cancer risks and histamine H₂-receptor antagonists (or H₂ blockers), including ranitidine, the data showed that ranitidine consumption increased the risk of prostate, lung, esophageal, pancreatic, and kidney cancer. Of

¹²⁹ See, e.g., BOE_ZAN_MDL_0000203482 [REDACTED]
[REDACTED]; GSKZAN0000178835

[REDACTED]
[REDACTED]; DRLMDL0000087754

[REDACTED]; DRLMDL0000077957 (

¹³⁰ D. Michaud et al., *Peptic Ulcer Disease and the Risk of Bladder Cancer in a Prospective Study of Male Health Professionals*, 13 *Cancer Epi. Biomarkers & Prevention* 250-54 (Feb. 2004).

¹³¹ Cardwell, C. R., R. D. McDowell, C. M. Hughes, B. Hicks, and P. Murchie. *Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study*. *Am J Gastroenterol*. 2021.

¹³² Robert W. Mathes et al., *Relationship Between Histamine2-receptor Antagonist Medications and Risk of Invasive Breast Cancer*, 17 *Cancer Epi. Biomarkers & Prevention* 1, 67-72 (2008).

particular note, the study indicated that people under the age of 60 who took ranitidine were five times more likely to develop prostate cancer. In addition, there was more than a doubling of the risk of pancreatic cancer with ranitidine use.¹³³

207. A study published in 2018 demonstrated an increased risk of liver cancer associated with use of ranitidine in comparison with other H₂ blockers in the class. The purpose of the study was to determine whether there was an increased risk of liver cancer associated with proton pump inhibitors, a different class of medications indicated for the treatment of GERD. This finding is particularly notable as the authors adjusted for variables.¹³⁴

208. In 2018, a study found an increased risk in hepatocellular carcinoma associated with use of H₂ blockers.¹³⁵ The authors were evaluating the risk of cancer in association with proton pump inhibitors and looked at H₂ blockers as a confounder. The study only considered use of H₂ blockers within one year of cancer diagnosis and still found an increased odds ratio associated with use of H₂ blockers and hepatocellular carcinoma, a type of liver cancer.

209. A number of other studies have been published over the years showing an increased risk of various cancers associated with use of ranitidine and/or H₂ blockers.¹³⁶ These cancers

¹³³ Laurel A Habel et al., *Cimetidine Use and Risk of Breast, Prostate, and Other Cancers*, 9 *Pharmacoepidemiology & Drug Safety* 149–55 (2000).

¹³⁴ Kim Tu Tran et al., *Proton Pump Inhibitor and Histamine-2 receptor Antagonist Use and Risk of Liver Cancer in Two Population-based Studies*, 48 *Alimentary Pharmacology & Therapeutics* 1, 55-64 (2018).

¹³⁵ Y-H J Shao et al., *Association Between Proton Pump Inhibitors and the Risk of Hepatocellular Carcinoma*, 48 *Alimentary Pharmacology & Therapeutics* 4, 460-68 (2018).

¹³⁶ Mathes et al., *supra* note 132; *see also* Jeong Soo Ahn et al., *Acid Suppressive Drugs and Gastric Cancer: A Meta-analysis of Observational Studies*, 19 *World J. Gastroenterology* 16, 2560 (2013); Shih-Wei Lai et al., *Use of Proton Pump Inhibitors Correlates with Increased Risk of Pancreatic Cancer: A Case-control Study in Taiwan*, 46 *Kuwait Med J.* 1, 44-48 (2014); Poulsen et al., *Proton Pump Inhibitors and Risk of Gastric Cancer – A Population Based Cohort Study*, 100 *Brit. J. Cancer* 1503-07 (2009); E Wennerström, *Acid-suppressing Therapies and Subsite-specific Risk of Stomach Cancer*, 116 *Brit. J. Cancer* 9, 1234–38 (2017).

include breast, gastric, pancreatic, and stomach cancer. Additional research reports that ranitidine use was associated with a significant increase in the risk of bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancer.¹³⁷

210. Moreover, a 2015 meta-analysis demonstrated a 34% increased risk of gastric cancer when individuals consumed 190 ng to 270 ng of NDMA a day.¹³⁸ A 1998 study illustrates that with a daily intake of 270ng of NDMA, the risk of lung cancer is significantly increased.¹³⁹ And a 2011 study showed that there is a 46% increased risk of rectal cancer when 130 ng of NDMA are consumed a day.¹⁴⁰

211. In addition to studies demonstrating that NDMA and, specifically, NDMA in ranitidine, directly causes cancer, research shows that exposure to NDMA (a) can exacerbate existing but dormant (*i.e.*, not malignant) tumor cells; (b) promote otherwise “initiated cancer cells” to develop into cancerous tumors; and (c) reduce the ability of the body to combat cancer as NDMA is immunosuppressive. Thus, in addition to NDMA being a direct cause of cancer itself, NDMA can also be a contributing factor to a cancer injury caused by some other source.

C. DEFENDANTS’ KNOWLEDGE OF THE NDMA RISK

212. As early as 1981, two years before Zantac entered the market, research showed elevated rates of NDMA, when properly tested.¹⁴¹ This was known or should have been known Defendants as the information was available in medical literature.

¹³⁷ Richard H. Adamson & Bruce A. Chabne, *The Finding of N-Nitrosodimethylamine in Common Medicines*, The Oncologist, June 2020; 25(6): 460-62, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288647/>

¹³⁸ Song, et al. *Dietary Nitrates, Nitrites, and Nitrosamines Intake and the Risk of Gastric Cancer: A Meta-Analysis*, 7 Nutrients 9872-9895 (2015).

¹³⁹ DeStefani, et al., *Dietary Nitrosodimethylamine and the Risk of Lung Cancer: A Case Control Study from Uruguay*, 5 Cancer Epidemiology, Biomarkers & Prevention 670682 (Sept. 1996).

¹⁴⁰ Loh, et al., *supra* note 64.

¹⁴¹ See *supra* ¶¶138, 153 (discussing de Flora research).

213. In 1981, GSK, the originator of the ranitidine molecule, published a study focusing on the metabolites of ranitidine in urine using liquid chromatography.¹⁴² Many metabolites were listed, though there is no indication that the study looked for NDMA.

214. Indeed, in that same year, Dr. de Flora published a note discussing the results of his experiments showing that ranitidine was turning into mutagenic N-nitroso compounds, of which NDMA is one, in human gastric fluid when accompanied by nitrites – a substance commonly found in food and in the body.¹⁴³ GSK was aware of this study because GSK specifically responded to the note and attempted to discredit it. Defendants knew or should have known about this scientific exchange as it was published in a popular scientific journal. Defendants were obligated to investigate this issue properly. None did.

215. By 1987, after numerous studies raised concerns over ranitidine and cancerous nitroso compounds, GSK published a clinical study specifically investigating gastric contents in human patients and N-nitroso compounds.¹⁴⁴ That study specifically indicated that there were no elevated levels of N-nitroso compounds (of which NDMA is one). But the study was flawed. It used an analytical system called a “nitrogen oxide assay” for the determination of N-nitrosamines, which was developed for analyzing food and is a detection method that indirectly and non-specifically measures N-nitrosamines. Not only is that approach not accurate, but GSK also removed all gastric samples that contained ranitidine out of concern that samples with ranitidine would contain “high concentrations of N-nitroso compounds being recorded.” Without the chemical being present in any sample, any degradation into NDMA could not, by design, be

¹⁴² Carey et al., *Determination of Ranitidine and Its Metabolites in Human Urine by Reversed-phase Ion-pair High-performance Liquid Chromatography*, 255 J. Chromatography B: Biomedical Sci. & Appl. 1, 161-68 (1981).

¹⁴³ De Flora, *supra* note 80.

¹⁴⁴ Thomas et al., *supra* note 104.

observed. The inadequacy of that test was knowable in light of its scientific publication in 1987.

216. All Defendants either knew or should have known about the inadequacy of that study and should have investigated the issue properly and/or taken action to protect consumers from the NDMA risks in their products. None did.

D. THE FEDERAL REGULATORY LANDSCAPE

217. Plaintiffs reference federal law herein not in any attempt to enforce it, but only to demonstrate that their state-law tort claims do not impose any additional obligations on Defendants, beyond what is already required of them under federal law.

1. Federal Law Required the Defendants to Notify the FDA about the Presence of NDMA in Ranitidine-Containing Products

218. During the time that Defendants manufactured and sold Ranitidine-Containing Products in the United States, the weight of scientific evidence showed that ranitidine exposed users to unsafe levels of NDMA. Defendants failed to report these risks to the FDA.

219. Defendants concealed the ranitidine–NDMA link from ordinary consumers in part by not reporting it to the FDA, which relies on drug manufacturers (or others, such as those who submit citizen petitions) to bring new information about an approved drug like ranitidine to the agency’s attention.

220. Manufacturers of an approved drug are required by regulation to submit an annual report to the FDA containing, among other things, new information regarding the drug’s safety pursuant to 21 C.F.R. §314.81(b)(2):

The report is required to contain . . . [a] brief summary of significant new information from the previous year that might affect the safety, effectiveness, or labeling of the drug product. The report is also required to contain a brief description of actions the applicant has taken or intends to take as a result of this new information, for example, submit a labeling supplement, add a warning to the labeling, or initiate a new study.

221. Title 21 C.F.R. §314.81(b)(2)(v) provides that the manufacturer's annual report must also contain:

Copies of unpublished reports and summaries of published reports of new toxicological findings in animal studies and in vitro studies (*e.g.*, mutagenicity) conducted by, or otherwise obtained by, the [manufacturer] concerning the ingredients in the drug product.

222. Defendants ignored these regulations and, disregarding the scientific evidence available to them regarding the presence of NDMA in their products and the risks associated with NDMA, did not report to the FDA significant new information affecting the safety or labeling of Ranitidine-Containing Products.

223. Knowledge regarding the risk of NDMA in ranitidine was sufficiently available in the publicly available scientific literature such that any manufacturer, consistent with its heightened obligations to ensure the safety of its products, also should have known about the potential NDMA risks associated with ranitidine consumption.

224. Defendants never conducted or provided the relevant studies to the FDA, nor did they present the FDA with a proposed disclosure noting the various ways that ranitidine transforms into NDMA. Accordingly, because Defendants never properly disclosed the risks to the FDA, they never proposed any labeling or storage / transportation guidelines that would have addressed this risk. Thus, the FDA was never able to reject any proposed warning or proposal for transport / storage.

225. When the FDA eventually learned about the NDMA risks posed by Ranitidine-Containing Products, it ordered manufacturers to voluntarily remove the products from the market.

2. Good Manufacturing Practices

226. Under federal law, a manufacturer must manufacture, store, warehouse, and distribute pharmaceutical drugs in accordance with "Current Good Manufacturing Practices"

(“cGMPs”) to ensure they meet safety, quality, purity, identity, and strength standards.¹⁴⁵

227. Title 21 C.F.R. §210.1(a) states that the cGMPs establish “minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.” Entities at all phases of the design, manufacture, and distribution chain are bound by these requirements.

228. Pursuant to 21 C.F.R. §211.142(b), the warehousing of drug products shall provide for “[s]torage of drug products under appropriate conditions of temperature, humidity, and light so that the identity, strength, quality, and purity of the drug products are not affected.” In other words, Defendants had a duty and were obligated to properly store, handle, and warehouse ranitidine.

229. Based on the above, the Defendants had a duty and were obligated to ensure that its ranitidine was properly stored, handled, and warehoused by it and its suppliers.

230. Testing conducted by the FDA confirms that under accelerated conditions the elevated temperatures can lead to the presence of NDMA in the drug product.¹⁴⁶ FDA has also concluded that NDMA can increase in ranitidine under storage conditions allowed by the labels, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during normal distribution and handling.

231. FDA’s testing also showed that the level of NDMA in Ranitidine-Containing Products increases with time. And, while Emery’s Citizen Petition sought to obtain a directive

¹⁴⁵ 21 U.S.C. §351(a)(2)(B).

¹⁴⁶ FDA Statement, Woodcock, *supra* note 31.

regarding temperature-controlled shipping of ranitidine, which was necessary given the time and temperature sensitivity of the drug, that request was deemed moot by the FDA because the agency sought to withdraw Ranitidine-Containing Products altogether.

232. Nothing prevented any Defendant from, on their own, taking actions to prevent accumulation of NDMA in Zantac by ensuring that ranitidine was not exposed to heat or moisture over long periods and by ensuring storage and transport at the lower end of the temperature range contained on the labels.

233. Based on the public scientific information, Defendants knew or should have known that NDMA could form in ranitidine by exposure to heat, humidity, nitrites, the conditions of the human stomach, and/or over time in storage.

234. At no time did Defendants change the Zantac label to shorten the expiration date.

235. As previously alleged, ranitidine degrades into NDMA more quickly at higher temperatures, at higher humidity levels, and under other poor storage or handling conditions.

236. Defendants knew or should have known that ranitidine had an inherent risk of degrading into NDMA because it has both a nitroso (N) and dimethylamine (DMA), which are all the ingredients needed to form NDMA.

237. The Ranitidine-Containing Products Plaintiffs consumed had excessive levels of NDMA in part because they were subjected to high levels of humidity and were stored for a long period of time (often in humid locations such as bathrooms).

E. DEFENDANTS' TORTIOUS CONDUCT IN LABELING

1. Prescription Manufacturer GSK's Failure to Warn and Misrepresentations in the Labeling of Ranitidine-Containing Products

238. 21 U.S.C. §352(a)(1) provides, in pertinent part,

A drug or device shall be deemed to be misbranded –

(a) FALSE OR MISLEADING LABEL

(1) If its labeling is false or misleading in any particular.

239. A manufacturer is required to give adequate directions for the use of a pharmaceutical drug such that a “layman can use a drug safely and for the purposes for which it is intended,”¹⁴⁷ and conform to requirements governing the appearance of the label.¹⁴⁸

240. “Labeling” encompasses all written, printed, or graphic material accompanying the drug or device,¹⁴⁹ and, therefore, broadly encompasses nearly every form of promotional activity, including not only “package inserts” but also advertising.

241. “Most, if not all, labeling is advertising. The term ‘labeling’ is defined in the FDCA as including all printed matter accompanying any article. Congress did not, and we cannot, exclude from the definition printed matter which constitutes advertising.”¹⁵⁰

242. GSK was responsible for conducting stability testing, which must be “designed to assess the stability characteristics of drug products.”¹⁵¹ Manufacturers must adopt a written testing program that includes: “(1) Sample size and test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability; (2) Storage conditions for samples retained for testing; (3) Reliable, meaningful, and specific test methods; (4) Testing of the drug product in the same container-closure system as that in which the drug product is marketed; (5) Testing of drug products for reconstitution at the time of dispensing (as directed in the labeling) as well as after they are reconstituted.”¹⁵²

¹⁴⁷ 21 C.F.R. §201.5.

¹⁴⁸ *Id.* §201.15.

¹⁴⁹ *Id.*; 65 Fed. Reg. 14286 (Mar. 16, 2000).

¹⁵⁰ *United States v. Research Labs.*, 126 F.2d 42, 45 (9th Cir. 1942).

¹⁵¹ 21 C.F.R. §211.166(a).

¹⁵² *Id.*

243. The purpose of stability testing is, in part, to determine the “appropriate storage conditions and expiration dates.”¹⁵³ And, expiration dates, in turn, must be set to “assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use.”¹⁵⁴ An expiration date is “related to any storage conditions stated on the labeling, as determined by stability studies listed in §211.166.”¹⁵⁵

244. Notably, while generic medications must have the same active ingredients as their branded counterparts, the inactive ingredients, or excipients, may not necessarily be identical. For this reason, the stability of each generic drug may differ from manufacturer to manufacturer, or even from manufacturing process to manufacturing process.

245. GSK was required to conduct its own tests to determine and set accurate retest or expiration dates.

246. The FDA made clear when it first adopted the expiration-date provision that the regulation means what it says. The purpose of the expiration date is not merely to consider the “stability of a specific active ingredient.” Instead, a compliant expiration date must account for multiple factors, including “the stability of the inactive ingredients, the interaction of active and inactive ingredients, the manufacturing process, the dosage form, the container closure system, the conditions under which the drug product is shipped, stored, and handled by wholesalers and retailers, and the length of time between initial manufacture and final use.”¹⁵⁶

247. The FDA expressly recognizes that an initial expiration date may not be the final expiration date: “Where data from accelerated studies are used to project a tentative expiration

¹⁵³ *Id.*

¹⁵⁴ *Id.*, §211.137(a).

¹⁵⁵ *Id.*, §211.137(b).

¹⁵⁶ 43 Fed. Reg. 45059 (Sept. 29, 1978).

date that is beyond a date supported by actual shelf life studies, there must be stability studies conducted . . . until the tentative expiration date is verified or the appropriate expiration date determined.”¹⁵⁷

248. After a drug is approved, a manufacturer (brand or generic) can make changes to its drug application. To do so, manufacturers must comply with the requirements of §§314.70 and 314.71.¹⁵⁸

249. Some of the requirements in those regulations require a brand or generic manufacturer of an approved drug to obtain FDA approval before implementing a label change.¹⁵⁹

250. But the FDA has long recognized a “changes being effected” (“CBE”) supplement that permits a manufacturer to make immediate changes, subject to FDA’s post-change review.¹⁶⁰

251. A manufacturer of an approved drug can use the CBE supplement to immediately make an “[a]ddition to a specification or changes in the methods or controls to provide increased assurance that the drug substance or drug product will have the characteristics of identity, strength, quality, purity, or potency that it purports or is represented to possess.”¹⁶¹ “A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described.”¹⁶²

252. A manufacturer, therefore, need not seek FDA pre-approval to make changes to its stability studies to identify the appropriate expiration date – which must “assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use”¹⁶³ – or to

¹⁵⁷ 21 C.F.R. §211.166(b).

¹⁵⁸ *See id.*, §314.97(a) (requiring generics to comply with §§314.70, 314.71).

¹⁵⁹ *Id.*, §314.70(b).

¹⁶⁰ *Id.*, §314.70(c)(3), (c)(6).

¹⁶¹ *Id.*, §314.70(c)(6)(i).

¹⁶² 65 Fed. Reg. 83042 (Dec. 29, 2000).

¹⁶³ 21 C.F.R. §211.137(a).

ensure that the drug is shipped and stored under appropriate conditions.

253. A manufacturer of an approved drug can also use the CBE supplement to make changes “in the labeling to reflect newly acquired information” in order to “add or strengthen a contraindication, warning, precaution, or adverse reaction for which the evidence of a causal association satisfies the standard for inclusion in the labeling under §201.57(c) of this chapter”; “add or strengthen an instruction about dosage and administration that is intended to increase the safe use of the drug product”; and “delete false, misleading, or unsupported indications for use or claims for effectiveness.”¹⁶⁴

254. A manufacturer of an approved drug may make minor changes to a label with no approval or notice, so long as that change is described in an annual report. The illustrative but non-exhaustive list of minor changes includes “[a] change in the labeling concerning the description of the drug product or in the information about how the drug product is supplied, that does not involve a change in the dosage strength or dosage form.”¹⁶⁵

255. A “minor change” further includes “[a]n extension of an expiration dating period based upon full shelf life data on production batches obtained from a protocol approved in the NDA.”¹⁶⁶

256. At no time did GSK attempt to include a warning on the labels for Ranitidine-Containing Products that consumers were at elevated risk of developing cancer if the products were: (i) exposed to excessive heat; (ii) exposed to excessive moisture/humidity; (iii) consumed with high-nitrite foods; and (iv) consumed daily for a period of greater than a few months. The FDA never rejected such cancer warnings.

¹⁶⁴ *Id.*, §314.70(c)(6)(iii)(A), (C), (D).

¹⁶⁵ *Id.*, §314.70 (d)(2)(ix).

¹⁶⁶ *Id.*, §314.70 (d)(2)(vi); *see also id.*, §314.70(d)(2)(vii), (x).

257. At no time did GSK attempt to change its label to delete a false or misleading expiration date, or to add a proper expiration date to ensure that Ranitidine-Containing Products would not break down into NDMA prior to human consumption.

258. Based on the public scientific information, GSK knew or should have known that NDMA could form in ranitidine by exposure to heat, humidity, nitrites, the conditions of the human stomach, and/or over time in storage.

259. At no time did GSK change its label to shorten the expiration date. GSK had the ability to unilaterally make such label changes (for both prescription and OTC) without prior FDA approval pursuant to the CBE regulation. Had any Manufacturer Defendant attempted such label changes, the FDA would not have rejected them.

260. Because they failed to include appropriate expiration dates on their products, Defendants made failed to warn regarding and made false statements in the labeling of their products.

261. Because it failed to include a warning on the labels for Ranitidine-Containing Products that consumers were at elevated risk of developing cancer if the products were: (i) exposed to excessive heat; (ii) exposed to excessive moisture/humidity; (iii) consumed with high-nitrite foods; and (iv) consumed daily for a period of greater than a few months, GSK failed to warn regarding and made false statements in the labeling of its products.

2. The Brand OTC Defendants' Failure to Warn and Misrepresentations in the Labeling of OTC Ranitidine-Containing Products

262. The Brand OTC Defendants are GSK, Pfizer, BI, and Sanofi.

263. Each of these Brand OTC Defendants increased OTC Ranitidine-Containing Product demand through a fundamental and uniform message, parlayed through a multi-media campaign that OTC Zantac is safe, it can be used frequently, long-term, with high-nitrate and -

nitrite foods, and poses no serious health risks such as those associated with the consumption of NDMA—a known human carcinogen.

264. Examples of this campaign include a series of television, print, radio, and internet ads for OTC Zantac throughout the United States and to consumers that uniformly omitted the material safety risks that the products contained NDMA, that ranitidine was unstable, that NDMA content could increase through the lapse of time and when exposed to heat or humidity, and that it should not be used in connection with high-nitrate or -nitrite foods.

265. At the point of sale, Brand OTC Defendants sold Zantac packaged and labeled with misleading information and material omissions.

266. Title 21 U.S.C. §352(a)(1) provides, in pertinent part,

A drug or device shall be deemed to be misbranded –

(a) False or misleading label

(1) If its labeling is false or misleading in any particular.

267. The Brand OTC Defendants were required to give adequate directions for the use of a pharmaceutical drug such that a “layman can use a drug safely and for the purposes for which it is intended,” and conform to requirements governing the appearance of the label.

268. “Labeling” encompasses all written, printed or graphic material accompanying the drug or device, and, therefore, broadly encompasses nearly every form of promotional activity, including not only “package inserts” but also advertising.

269. “Most, if not all, labeling is advertising. The term ‘labeling’ is defined in the FDCA as including all printed matter accompanying any article. Congress did not, and we cannot, exclude from the definition printed matter which constitutes advertising.”

270. The Brand OTC Defendants were also responsible for conducting stability testing,

which must be “designed to assess the stability characteristics of drug products.” Manufacturers must adopt a written testing program that includes: “(1) Sample size and test intervals based on statistical criteria for each attribute examined to assure valid estimates of stability; (2) Storage conditions for samples retained for testing; (3) Reliable, meaningful, and specific test methods; (4) Testing of the drug product in the same container-closure system as that in which the drug product is marketed; (5) Testing of drug products for reconstitution at the time of dispensing (as directed in the labeling) as well as after they are reconstituted.”

271. The purpose of stability testing is, in part, to determine the “appropriate storage conditions and expiration dates.” And, expiration dates, in turn, must be set to “assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use.” An expiration date is “related to any storage conditions stated on the labeling, as determined by stability studies listed in §211.166.”

272. Each Brand OTC Manufacturer Defendant must conduct its own tests to determine and set accurate retest or expiration dates.

273. The FDA made clear when it first adopted the expiration-date provision that the regulation means what it says. The purpose of the expiration date is not merely to consider the “stability of a specific active ingredient.” Instead, a compliant expiration date must account for multiple factors, including “the stability of the inactive ingredients, the interaction of active and inactive ingredients, the manufacturing process, the dosage form, the container closure system, the conditions under which the drug product is shipped, stored, and handled by wholesalers and retailers, and the length of time between initial manufacture and final use.”

274. The FDA expressly recognizes that an initial expiration date may not be the final expiration date: “Where data from accelerated studies are used to project a tentative expiration

date that is beyond a date supported by actual shelf life studies, there must be stability studies conducted . . . until the tentative expiration date is verified or the appropriate expiration date determined.”

275. After a drug is approved, a brand manufacturer can make changes to its drug application. To do so, manufacturers must comply with the requirements of §§314.70 and 314.71.

276. Some of the requirements in those regulations require a brand manufacturer of an approved drug to obtain FDA approval before implementing a label change.

277. But the FDA has long recognized a “changes being effected” (“CBE”) supplement that permits a manufacturer to make immediate changes, subject to FDA’s post-change review.

278. A manufacturer of an approved drug can use the CBE supplement to immediately make an “[a]ddition to a specification or changes in the methods or controls to provide increased assurance that the drug substance or drug product will have the characteristics of identity, strength, quality, purity, or potency that it purports or is represented to possess.” “A specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria that are numerical limits, ranges, or other criteria for the tests described.”

279. A manufacturer, therefore, need not seek FDA pre-approval to make changes to its stability studies to identify the appropriate expiration date – which must “assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use”—or to ensure that the drug is shipped and stored under appropriate conditions.

280. A manufacturer of an approved drug can also use the CBE supplement to make changes “in the labeling to reflect newly acquired information” in order to “add or strengthen a contraindication, warning, precaution, or adverse reaction for which the evidence of a causal association satisfies the standard for inclusion in the labeling under §201.57(c) of this chapter”;

“add or strengthen an instruction about dosage and administration that is intended to increase the safe use of the drug product”; and “delete false, misleading, or unsupported indications for use or claims for effectiveness.”

281. A manufacturer of an approved drug may make minor changes to a label with no approval or notice, so long as that change is described in an annual report. The illustrative but non-exhaustive list of minor changes includes “[a] change in the labeling concerning the description of the drug product or in the information about how the drug product is supplied, that does not involve a change in the dosage strength or dosage form.”

282. A “minor change” further includes “[a]n extension of an expiration dating period based upon full shelf life data on production batches obtained from a protocol approved in the NDA.”

283. At no time did any Brand OTC Defendant attempt to include a warning on the labels for Ranitidine-Containing Products that consumers were at elevated risk of developing cancer if the products were: (i) exposed to excessive heat; (ii) exposed to excessive moisture/humidity; (iii) consumed with high-nitrite foods; and (iv) consumed daily for a period of greater than a few months. The FDA never rejected such cancer warnings.

284. At no time did any Brand OTC Defendant attempt to change its label to delete a false or misleading expiration date, or to add a proper expiration date to ensure that Ranitidine-Containing Products would not break down into NDMA prior to human consumption.

285. Based on the public scientific information, the any Brand OTC Defendants knew or should have known that NDMA could form in ranitidine by exposure to heat, humidity, nitrites, the conditions of the human stomach, and/or over time in storage.

286. At no time did any Brand OTC Manufacturer Defendant change its label to shorten

the expiration date. Brand OTC Defendants had the ability to unilaterally make such label changes (for both prescription and OTC) without prior FDA approval pursuant to the CBE regulation. Had any Brand OTC Manufacturer Defendant attempted such label changes, the FDA would not have rejected them.

287. Because they failed to include appropriate expiration dates on their products, Brand OTC Defendants failed to warn regarding and made false statements in the labeling of their products.

288. Because they failed to include a warning on the labels for Ranitidine-Containing Products that consumers were at elevated risk of developing cancer if the products were: (i) exposed to excessive heat; (ii) exposed to excessive moisture/humidity; (iii) consumed with high-nitrite foods; and (iv) consumed daily for a period of greater than a few months, Brand OTC Defendants failed to warn regarding and made false statements in the labeling of their products.

V. ADDITIONAL COUNT-SPECIFIC ALLEGATIONS

A. ADDITIONAL ALLEGATIONS SPECIFIC TO PLAINTIFFS' COUNTS FOR FAILURE TO WARN THROUGH WARNINGS AND PRECAUTIONS

289. Ranitidine leads to NDMA exposure in the following ways: (1) the NDMA levels in ranitidine increase as the drug breaks down in the human digestive system and interacts with various enzymes in the human body; and (2) the ranitidine molecule internally degrades to form NDMA, and the NDMA levels in the drug substance and the drug product increase over time under normal storage conditions, but more so with exposure to heat or humidity.

290. NDMA is a potent carcinogen in humans. Higher exposures to NDMA over longer time periods lead to even higher risks of cancer.

291. To mitigate degradation of ranitidine into NDMA in the stomach, consumers should

have been warned not to take ranitidine with or after meals or in combination with a high-nitrite diet. No Ranitidine-Containing Product contained this warning.

292. To mitigate degradation of ranitidine into NDMA over time, and in the presence of heat or humidity, consumers could have been and should have been warned to consume ranitidine shortly after manufacturing and to store it in a cool, dry place (e.g., not in a bathroom). No Ranitidine-Containing Product contained this warning.

293. To mitigate the risk of NDMA causing cancer, consumers should have been warned to consume ranitidine for only short periods of time. No Ranitidine-Containing Product warned that cancer could result from long-term ingestion of ranitidine.

294. Defendants knew or should have known about each of these risks in time to warn consumers.

295. As was alleged in more detail above, in 1981 Dr. de Flora published the results of experiments in *The Lancet* showing that ranitidine produced NDMA in combination with gastric fluid and nitrites. This study put all future manufacturers of ranitidine on notice of the risks of consuming ranitidine in combination with high-nitrite foods.

296. GSK responded in *The Lancet* in November 1981. This response shows that GSK was in fact aware of Dr. de Flora's research.

297. GSK told the FDA that Dr. de Flora's research has no "practical clinical significance."

298. GSK conducted another study around 1981 that found that ranitidine could cause nitrates to convert into nitrites in the human stomach, which, in combination with Dr. de Flora's research, would mean a heightened risk of NDMA formation. This should have sparked reconsideration of the claim that nitrites would not be high enough in the stomach for Dr. de Flora's

research to have practical significance.

299. In April 1982, GSK performed a study [REDACTED]

[REDACTED]

[REDACTED]

300. After Zantac had been approved for marketing by the FDA, GSK conducted a study on how ranitidine breaks down in the human stomach and concluded that the amount of nitrosamines formed was low. That study was published in 1987. However, GSK used a less reliable test (a nitrogen oxide assay) designed for use in food and discarded two-thirds of the samples because they contained ranitidine (which the study claimed might produce a false positive).

301. In 1983, after GSK's flawed study, but before it was published, a University of Genoa study determined that ranitidine could react with nitrite and produce NDMA, which could induce DNA damage.

302. Also in 1983, Dr. de Flora published his complete findings, confirming his initial results about the risks of NDMA breakdown in the human stomach in combination with nitrites. GSK did not modify its position.

303. In 2002, a study indicated that NDMA was found in the urine and gastric fluid of children after taking ranitidine for four weeks.

304. In 2012, a study indicated that ranitidine may be a source of NDMA in drinking water.

305. In 2016, a Stanford University study suggested that NDMA amounts in humans

increased after consuming ranitidine.

306. In 2019, Valisure tested ranitidine tablets to determine if they contained NDMA. Valisure's ISO 17025 accredited laboratory used FDA recommended GC/MS headspace analysis method FY19-005-DPA8 for the determination of NDMA levels. As per the FDA protocol developed for Valsartan, this method was validated to a lower limit of detection of 25 ng.¹⁶⁷ Valisure found when using the GC/MS headspace analysis method that ranitidine would transform into high levels of NDMA.

307. This testing by GC-MS demonstrates the instability of the ranitidine molecule and its propensity to break down under high temperatures.

308. Any Manufacturer Defendant could have studied ranitidine using the tests Valisure performed, and would have discovered that ranitidine transforms into NDMA when subjected to heat.

309. At all relevant times, Defendants designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, and/or sold Ranitidine-Containing Products, which are defective and unreasonably dangerous to consumers, including Plaintiffs, because they do not contain adequate warnings or instructions concerning the dangerous characteristics of ranitidine and NDMA. These actions were under the ultimate control and supervision of Defendants.

310. Defendants designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, sold, and/or otherwise released into the stream of commerce their Ranitidine-Containing Products, and in the course of the same, directly marketed the products to consumers and end users, including Plaintiffs, and, therefore, had a duty to warn of the risks associated with

¹⁶⁷ U.S. Food & Drug Admin., *Combined N-Nitrosodimethlyamine (NDMA) and N-Nitrosodiethylamine (NDEA) Impurity Assay, FY19-005-DPA-S* (Jan. 28, 2019).

the use of ranitidine.

311. At all relevant times, Defendants had a duty to properly manufacture, test, market, label, package, handle, distribute, store, sell, provide proper warnings, and/or take such steps as necessary to ensure their Ranitidine-Containing Products did not cause users and consumers to suffer from unreasonable and dangerous risks. Defendants had a continuing duty to warn Plaintiffs of dangers associated with ranitidine. Defendants, as manufacturers and sellers of pharmaceutical medication, are held to the knowledge of an expert in the field.

312. Defendants had a continuing duty to provide appropriate and accurate warnings and precautions.

313. At the time of manufacture, Defendants could have provided warnings or instructions regarding the full and complete risks of ranitidine because they knew or should have known of the unreasonable risks of harm associated with the use of and/or exposure to such products.

314. At all relevant times, Defendants failed and deliberately refused to investigate, study, test, or promote the safety or to minimize the dangers to users and consumers of their products and to those who would foreseeably use or be harmed by Defendants' Ranitidine-Containing Products.

315. Even though Defendants knew or should have known that ranitidine posed a grave risk of harm, they failed to exercise reasonable care to warn of the dangerous risks associated with use and exposure to Ranitidine-Containing Products. The dangerous propensities of Ranitidine-Containing Products and the carcinogenic characteristics of NDMA, as described above, were known to Defendants, or scientifically knowable to Defendants through appropriate research and testing by known methods, at the time they distributed, supplied or sold the product, but were not

known to end users and consumers, such as Plaintiffs.

316. Defendants knew or should have known that Ranitidine-Containing Products created significant risks of serious bodily harm to consumers, as alleged herein, and Defendants failed to adequately warn or instruct consumers, i.e., the reasonably foreseeable users, and physicians of the risks of exposure to Ranitidine-Containing Products. Defendants failed to warn and have wrongfully concealed information concerning the dangerous level of NDMA in Ranitidine-Containing Products, and further, have made false and/or misleading statements concerning the safety of ranitidine.

317. Defendants possessed new information or new analyses of existing information that empowered them unilaterally to change the warnings and precautions section of their Ranitidine-Containing Products' label.

318. Despite this ability, Defendants failed to warn of the risks of NDMA and their Ranitidine-Containing Products in the warnings and precautions section of their Ranitidine-Containing Products' label.

319. At all relevant times, the Ranitidine-Containing Products were defective at the time they left the Defendants' control. No extrinsic changes were made to alter the products Defendants manufactured. The warnings Plaintiffs and their doctors observed were not changed from when they left Defendants' control.

320. Plaintiffs were exposed to Defendants' Ranitidine-Containing Products without knowledge of their dangerous characteristics.

321. At all relevant times, Plaintiffs used and/or were exposed to the use of Defendants' Ranitidine-Containing Products while using them for their intended or reasonably foreseeable purposes, without knowledge of their dangerous characteristics.

322. Plaintiffs could not have reasonably discovered the defects and risks associated with Ranitidine-Containing Products prior to or at the time Plaintiffs consumed the drugs. Plaintiffs and their physicians relied upon the skill, superior knowledge, and judgment of Defendants to know about and disclose serious health risks associated with using Defendants' products.

323. Defendants knew or should have known that the minimal warnings disseminated with their Ranitidine-Containing Products were inadequate, failed to communicate adequate information on the dangers and safe use/exposure, and failed to communicate warnings and instructions that were appropriate and adequate to render the products safe for their ordinary, intended and reasonably foreseeable uses.

324. The information that Defendants did provide or communicate failed to contain relevant warnings, hazards, and precautions that would have enabled consumers such as Plaintiffs to avoid using the drug. Instead, Defendants disseminated information that was inaccurate, false, and misleading, and which failed to communicate accurately or adequately the comparative severity, duration, and extent of the risk of injuries with use of and/or exposure to ranitidine; continued to aggressively promote the efficacy of Ranitidine-Containing Products, even after they knew or should have known of the unreasonable risks from use or exposure; and concealed, downplayed, or otherwise suppressed, through aggressive marketing and promotion, any information or research about the risks and dangers of ingesting ranitidine.

325. Had Defendants provided adequate warnings and instructions and properly disclosed and disseminated the risks associated with their Ranitidine-Containing Products on the warnings and precautions section of their products' labels, Plaintiffs could have avoided the risk of developing injuries and could have obtained or used alternative medication. However, as a

result of Defendants' concealment of the dangers posed by their Ranitidine-Containing Products, Plaintiffs were not alerted, and so could not avert their injuries.

326. Defendants' conduct, as described above, was reckless. Defendants risked the lives of consumers and users of their products, including Plaintiffs, with knowledge of the safety problems associated with Ranitidine-Containing Products, and suppressed this knowledge from the general public. Defendants made conscious decisions not to warn or inform the unsuspecting public. Defendants' reckless conduct warrants an award of punitive damages.

327. Defendants' lack of adequate warnings and instructions in the warnings and precautions section of their Ranitidine-Containing Products' labels were a substantial factor in causing Plaintiffs' injuries.

B. ADDITIONAL ALLEGATIONS SPECIFIC TO PLAINTIFFS' COUNTS FOR FAILURE TO WARN THROUGH PROPER EXPIRATION DATES

328. Ranitidine leads to NDMA exposure in the following ways: (1) the NDMA levels in ranitidine increase as the drug breaks down in the human digestive system and interacts with various enzymes in the human body; and (2) the ranitidine molecule internally degrades to form NDMA, and the NDMA levels in the drug substance and the drug product increase over time under normal storage conditions, but more so with exposure to heat or humidity.

329. NDMA is a potent carcinogen in humans. Higher exposures to NDMA over longer time periods lead to even higher risks of cancer.

330. To mitigate degradation of ranitidine into NDMA over time, and in the presence of heat or humidity, consumers should be warned to consume ranitidine shortly after manufacturing. No Ranitidine-Containing Product contained this warning.

331. In fact, Ranitidine-Containing Products had expiration dating periods of one or two years, allowing gradual accumulation of more and more unsafe levels of NDMA. A much shorter

period of a matter of months would have ensured that ranitidine contained far lower levels of NDMA when consumed.

332. Defendants knew or should have known about each of these risks in time to warn consumers. Simple, widely available and cost-effective tests reveal these risks.

333. In setting expiration and/or retest dates for their ranitidine-containing drugs, Defendants were required to take into consideration the real-world conditions the drugs would be exposed to, including the conditions under which the drugs would be stored and shipped. See 21 C.F.R. §211.137.

334. In setting the expiration and/or retest dates for their ranitidine-containing drugs, Defendants were also required to base those dates on stability testing, which in turn must account for storage conditions. 21 C.F.R. §211.166.

335. Storage conditions must account for conditions, including the storage container, heat, light, and humidity, among other things.

336. At all relevant times, each Defendant failed to adhere to their duties to set accurate expiration dates based upon stability testing that complied with the manufacturers' duties to account for these real-world conditions. These actions were under the ultimate control and supervision of the Defendants.

337. Defendants designed, manufactured, tested, marketed, labeled, packaged, handled, distributed, stored, and/or sold Ranitidine-Containing Products, which are defective and unreasonably dangerous to consumers, including Plaintiffs, because they do not contain adequate warnings or instructions concerning the dangerous characteristics of ranitidine and NDMA.

338. At all relevant times, Defendants failed and deliberately refused to investigate, study, test, or promote the safety or to minimize the dangers to users and consumers of their

products and to those who would foreseeably use or be harmed by Defendants' Ranitidine-Containing Products.

339. Even though Defendants knew or should have known that ranitidine posed a grave risk of harm, they failed to exercise reasonable care to warn of the dangerous risks associated with use and exposure to Ranitidine-Containing Products. The dangerous propensities of Ranitidine-Containing Products and the carcinogenic characteristics of NDMA, as described above, were known to Defendants, or scientifically knowable to Defendants through appropriate research and testing by known methods, at the time they distributed, supplied or sold the product, but were not known to end users and consumers, such as Plaintiffs.

340. Defendants knew or should have known that Ranitidine-Containing Products created significant risks of serious bodily harm to consumers, as alleged herein, and Defendants failed to adequately warn or instruct consumers, i.e., the reasonably foreseeable users, and/or physicians of the risks of exposure to Ranitidine-Containing Products. Defendants failed to warn and have wrongfully concealed information concerning the dangerous level of NDMA in Ranitidine-Containing Products, and further, have made false and/or misleading statements concerning the safety of ranitidine.

341. At all relevant times, the Ranitidine-Containing Products were defective at the time they left the Defendants' control. No extrinsic changes were made to alter the products Defendants manufactured and sold. The expiration dates Plaintiffs and their doctors observed were not changed from when they left Defendants' control.

342. Plaintiffs were exposed to Defendants' Ranitidine-Containing Products without knowledge of their dangerous characteristics.

343. At all relevant times, Plaintiffs used and/or were exposed to the use of Defendants'

Ranitidine-Containing Products while using them for their intended or reasonably foreseeable purposes, without knowledge of their dangerous characteristics.

344. Plaintiffs could not have reasonably discovered the defects and risks associated with Ranitidine-Containing Products prior to or at the time Plaintiffs consumed the drugs. Plaintiffs and their physicians relied upon the skill, superior knowledge, and judgment of Defendants to know about and disclose serious health risks associated with using Defendants' products.

345. Defendants knew or should have known that the expiration dating periods disseminated with their Ranitidine-Containing Products were inadequate because they were long enough for dangerous levels of NDMA to build up in ranitidine.

346. This alleged failure to warn is not limited to the information contained on the section of the Ranitidine-Containing Products' label devoted to health warnings. Defendants were able, in accord with federal law, to comply with relevant state law by providing a short expiration dating period that would accurately warn consumers not to consume ranitidine after significant portions of it had progressively deteriorated into NDMA. But Defendants did not disclose these known risks through any medium.

347. Had Defendants provided adequate warnings and instructions and properly disclosed and disseminated the risks associated with their Ranitidine-Containing Products, Plaintiffs could have avoided the risk of developing injuries and could have obtained or used alternative medication. However, as a result of Defendants' concealment of the dangers posed by their Ranitidine-Containing Products, Plaintiffs were not alerted, and so could not avert their injuries.

348. Defendants' conduct, as described above, was reckless. Defendants risked the lives

of consumers and users of their products, including Plaintiffs, with knowledge of the safety problems associated with Ranitidine-Containing Products, and suppressed this knowledge from the general public. Defendants made conscious decisions not to redesign, warn or inform the unsuspecting public. Defendants' reckless conduct warrants an award of punitive damages. Defendants' lack of adequate warnings and instructions accompanying their Ranitidine-Containing Products were a substantial factor in causing Plaintiffs' injuries.

**C. ADDITIONAL ALLEGATIONS SPECIFIC TO PLAINTIFFS' COUNTS
REGARDING NEGLIGENT PRODUCT CONTAINERS**

349. As alleged above, GSK was required to conduct stability testing, which was required to take the container into account.

350. As previously alleged, ranitidine degrades into NDMA more quickly at higher temperatures, at higher humidity levels, and under other poor storage or handling conditions.

351. GSK knew or should have known that ranitidine had an inherent risk of degrading into NDMA because it has both a nitroso (N) and dimethylamine (DMA), which are all the ingredients needed to form NDMA.

352. The Ranitidine-Containing Products Plaintiffs consumed had excessive levels of NDMA in part because they were subjected to high levels of humidity and were stored for a long period of time (often in humid locations such as bathrooms).

353. A substantial factor in NDMA formation was the container system manufacturers chose. Pill bottles with large numbers of units of ranitidine are likely to be stored for long periods by consumers after the seal is broken. This exposes the remaining units to humidity over time, which produces NDMA.

354. A different container would have reduced the amount of NDMA Plaintiffs consumed in several ways:

- (a) Placing each unit of ranitidine in a blister pack or similar individually packaged container would ensure humidity control until the consumer used each unit.
- (b) Reducing the number of units of ranitidine in each bottle to a low number would ensure the unused units were subject to humidity for only a shorter time period, since consumers would purchase new bottles more frequently.

355. GSK could have unilaterally changed the container system it sold. FDA guidance specifically allows changing the number of units in a non-sterile drug under its Changes Being Effected regulation. *See* FDA, Guidance for Industry, Changes to an Approved NDA or ANDA, Revision 1, at 21 (Apr. 2004), <https://www.fda.gov/media/71846/download> (“A change in the number of units (e.g., tablets, capsules) or labeled amount (e.g., grams, milliliters) of a nonsterile drug product in a unit-of-use container.”).

356. FDA guidance also would treat changing to a unit-dose container such as a blister-pack to be a moderate change that could be implemented through the Changes Being Effected regulation. *See id.* at 20–21 (only requiring pre-approval for sterile drug products, when moving from unit dose containers to multiple dose containers, rather than non-sterile drug products moving to unit dose containers).

357. A reasonably prudent manufacturer would have changed the containers for Ranitidine-Containing Products to protect the products from humidity and reduce the time between manufacture and consumption, both of which would reduce the amount of NDMA produced.

358. GSK’s negligence was a substantial factor in causing Plaintiffs’ injuries.

359. GSK’s conduct, as described above, was reckless. GSK regularly risked the lives of consumers and users of its products, including Plaintiffs, with full knowledge of the dangers of their products. GSK has made conscious decisions not to change the containers for its Ranitidine-Containing Products.

**D. ADDITIONAL ALLEGATIONS SPECIFIC TO PLAINTIFFS' COUNTS FOR
NEGLIGENT STORAGE AND TRANSPORTATION**

360. As alleged above, ranitidine degrades into NDMA more quickly at higher temperatures, at higher humidity levels, and under other poor storage or handling conditions.

361. GSK was well aware of the need to maintain sensitive pharmaceutical drugs under proper shipping and storage conditions, and that maintaining the highest safety techniques is best for the consumer. GSK is and was well aware of the importance of precise temperature control down to the degree as well as the importance of precise humidity control. More precise, colder transportation is, of course, more expensive than less precise, warmer transportation.

362. The temperature and humidity specifications placed on Ranitidine-Containing Products also affect the stability of Ranitidine-Containing Products.

363. NDMA forms due to chemical reactions in the human body, and degradation before consumption (principally heat, humidity, or time). Testing is performed before consumption and the age of the ranitidine is documented, so neither time nor degradation in the body should produce substantial variation. The best inference must be that substantial variation in heat and humidity is causing differing amounts of NDMA to form.

364. GSK is aware that Ranitidine is highly sensitive to humidity and moisture. Ranitidine that is subjected to humidity and/or moisture, degrades quickly and forms excessive amount of NDMA.

365. GSK must account for these heat and humidity conditions and specifications in order to set proper shipping, storage and handling policies as well as accurate retest and expiration dates.

366. Testing of the quantity of NDMA in ranitidine performed to date has shown substantial variation among different batches. Some ranitidine has much more NDMA when

tested, and some has less.

367. GSK admits that substantial variation exists in NDMA levels in their Ranitidine-Containing Products, and that levels increase over time but more so when subjected to heat and humidity.

368. Different Ranitidine-Containing Products listed slightly different storage and transportation requirements, but a common label requirement was “store at 20°C to 25°C (68°F to 77°F)” and “avoid excessive heat or humidity.”

369. GSK transported finished drug product from their facilities to distributor warehouses, as well as storing finished drug products in their facilities.

370. GSK systematically caused Ranitidine-Containing Products to be exposed to excessive levels of heat and/or humidity during manufacture, storage, shipping and handling that violated the instructions on the finished products’ labels and caused ranitidine to degrade more quickly thereby increasing the levels of NDMA in the product.

371. Based upon the documents produced by Defendants and based upon further information and belief, GSK failed to ensure that their finished Ranitidine-Containing Products were stored and transported safely and were not exposed to excessive heat and humidity.

372. Based upon the documents produced by Defendants and based upon further information and belief, GSK failed to ensure that API they stored, transported, or over which they could control storage or transportation, were not exposed to excessive heat and humidity.

373. GSK failed to implement rigorous policies to ensure substantial compliance with the heat and/or humidity requirements on product labels. This failure led to widespread noncompliance.

374. For example, GSK shipped Ranitidine-Containing Products through the mail. This

method of transportation – whether through the United States Postal Service or large common carriers such as FedEx and UPS – does not guarantee controlled temperature or humidity. Because of GSK’s choice to allow this method of transportation, Ranitidine-Containing Products shipped through the mail were systematically subject to excessive heat or humidity on days when the weather was hot or humid. In addition, GSK failed to properly monitor temperature and/or humidity levels during storage and transport.

375. Based upon the documents produced by Defendants and based upon further information and belief, GSK failed to ensure that its Ranitidine-Containing Products were stored and transported safely and were not exposed to excessive heat and humidity and systematically exposed ranitidine to excessive levels of heat and humidity that violated the instructions on the products’ labels.

376. GSK, directly or indirectly, transported, stored, handled, and/or sold Ranitidine-Containing Products that were used by Plaintiffs.

377. At all relevant times, GSK had a duty to exercise reasonable care in the storage and transportation of ranitidine API and Ranitidine-Containing Products to ensure the products were not unreasonably dangerous to consumers and users.

378. At all relevant times, GSK knew or should have known of the need for storing and transporting finished Ranitidine-Containing Products within the labeled temperature range and at low humidity, and for storing and transporting Ranitidine-Containing Products and ranitidine API at a reasonable, low temperature that would prevent degradation, and at low humidity.

379. GSK ignored this risk. It did not ensure ranitidine API and Ranitidine-Containing Products were stored at low humidity or within the temperature range on the label. Instead, ranitidine API and Ranitidine-Containing Products were subjected to excessive humidity and/or

heat during transportation and shipping which caused the drug to degrade leading to the formation of excessive levels of NDMA.

380. Ignoring the risks of degradation and NDMA forming was unreasonable and reckless.

381. Plaintiffs did not know the nature and extent of the injuries that could result from the intended use of and/or exposure to Ranitidine-Containing Products.

382. GSK's negligence was a substantial factor in causing Plaintiffs' injuries.

VI. PLAINTIFFS' USE OF RANITIDINE-CONTAINING PRODUCTS AND ADDITIONAL MEDICAL MONITORING ALLEGATIONS

A. Plaintiffs Have a Significantly Increased Risk of Contracting a Subject Cancer Because the Zantac They Consumed Exposed them to NDMA at Levels Exceeding FDA's Acceptable Daily Intake.

383. As discussed in more detail above, Plaintiffs regularly ingested Ranitidine-Containing Products as a part of their treatment for gastric ulcers, heartburn, acid indigestion, sour stomach, and other gastrointestinal conditions.

384. Plaintiffs used Zantac-branded Ranitidine-Containing Products designed, manufactured and/or sold by Defendants. Those products, unbeknownst to Plaintiffs, transformed into dangerous levels of NDMA.

385. Based on prevailing scientific evidence, exposure to NDMA caused by consuming Defendants' Ranitidine-Containing Products causes cancer in humans, including the serious and potentially fatal Subject Cancers.

386. Thus as a direct and proximate result of consuming Defendants' Ranitidine-Containing Products products for years, Plaintiffs are at a significantly increased risk of contracting a Subject Cancer. Plaintiffs' lengthy duration of exposure to NDMA from Defendants' products warrants additional medical testing not routinely provided to the public at large.

387. It is undisputed that NDMA is a genotoxic and mutagenic carcinogen.

388. The FDA has set an acceptable daily intake (“ADI”) level for NDMA at 96 ng. An ADI is the “daily intake which, during up to an entire life of a human, appears to be without adverse effects or harm to the health of the consumer.” 21 C.F.R. 556.3.

389. The FDA’s ADI for NDMA can also be stated as 0.32 ppm for ranitidine.

390. According to the FDA, consumption of 96 ng of NDMA a day over a lifetime *increases* the risk of developing cancer by 0.001% (1:100,000). All consumers have a heightened risk of contracting cancer.

391. Stated differently, according to the FDA, exposure to 2,452 micrograms of NDMA imposes a 1:100,000 chance of cancer.¹⁶⁸

392. Exposure to more than 2,452 µg of NDMA, or 96 ng per day, is unacceptable and harmful by definition.

393. The risk of cancer increases as the level of NDMA exposure increases.

394. The FDA set its ADI for a reason—to protect individuals from harm, including cancer. It expects that pharmaceuticals that will expose a patient to more than 96 ng of NDMA a day will be recalled.

395. The Ranitidine-Containing Products regularly consumed by Plaintiffs, including those manufactured, marketed, and/or sold by Defendants, contained NDMA in amounts many times greater than the 96 ng ADI, significantly increasing the risk that Plaintiffs will contract a Subject Cancer.

396. Emery’s testing, discussed *supra*, confirmed that ranitidine is unstable and has a propensity to break down under higher temperatures, such as during storage and transport, forming

¹⁶⁸ 96 ng x 365 days x 70 years = 2,452,800 ng, or 2,452 µg.

NDMA.

397. The FDA’s own testing found that ranitidine sold by Defendant Sanofi contained up to 360 ng of NDMA per 150 mg tablet—3 times the ADI¹⁶⁹ in just one dose—and Plaintiffs frequently took more than one dose a day.

398. [REDACTED]

[REDACTED]¹⁷⁰ [REDACTED]

[REDACTED]¹⁷¹

399. The Defendants’ figures do not include the increase in NDMA formation as a result of temperature and humidity imposed by storage and transportation conditions, as some of their samples were maintained in retention rooms in pristine conditions, or further formation of NDMA post-ingestion.

400. Following its evaluation of the Citizen Petition, the FDA initially stated that Ranitidine-Containing Products that contained NDMA in excess of the ADI were too dangerous to sell and should be recalled.¹⁷²

401. Shortly thereafter, the FDA revised its directive. It concluded that because the level of NDMA continues to increase in ranitidine post-manufacture *it could not confirm that any*

¹⁶⁹ <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-tests-ranitidine>. 1

microgram = 1000 nanograms.

¹⁷⁰ GSKAN0000883508. Despite multiple requests, to date no Defendant has provided Plaintiffs with product they can use for independent testing. As such, at this juncture Plaintiffs rely upon the testing performed by the FDA and Defendants themselves. Discovery is ongoing and it is anticipated that further information will be provided via expert reports and testimony.

¹⁷¹ SANOFI_ZAN_MDL_0000038689.

¹⁷² Thus while at times the FDA has referred to the levels of NDMA in the Ranitidine-Containing Products it tested as “low,” such levels nonetheless exceeded the ADI, posed a significantly increased risk of harm, and necessitated recall and, ultimately, market withdrawal. Expert testimony will explain the significance of this exposure and the concomitant risk of cancer.

*Ranitidine Containing Product was safe from heightened levels of NDMA, full market withdrawal of ranitidine was warranted.*¹⁷³

402. There are numerous studies, including epidemiological studies, that support the conclusion that NDMA and, specifically, NDMA in ranitidine, causes cancer in humans, including the Subject Cancers.

403. One epidemiology study, published in 2004, showed that men taking either ranitidine or cimetidine (Tagamet) had increased risks of bladder cancer.¹⁷⁴ Similarly, a more recent study revealed that individuals who consumed ranitidine have a 22% increase in bladder cancer as compared with non-users.¹⁷⁵

404. In one epidemiology study specifically designed to look at breast cancer, ranitidine was shown to more than double the risk, an effect that was even more pronounced in those with specific gene mutations.¹⁷⁶

405. In another epidemiological study looking at various cancer risks and histamine H₂-receptor antagonists (or H₂ blockers), including ranitidine, the data showed that ranitidine consumption increased the risk of prostate, lung, esophageal, pancreatic, and kidney cancer. Of particular note, the study indicated that people under the age of 60 who took ranitidine were five times more likely to develop prostate cancer. In addition, there was more than a doubling of the risk of pancreatic cancer with ranitidine use.¹⁷⁷

406. A study published in 2018 demonstrated an increased risk of liver cancer associated with use of ranitidine in comparison with other H₂ blockers in the class. The purpose of the study

¹⁷³ FDA Letter, Woodcock, *supra* note 83.

¹⁷⁴ Michaud et al., *supra* note 130.

¹⁷⁵ Cardwell, C. R., R. D. McDowell, C. M. Hughes, B. Hicks, and P. Murchie. *Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study*. Am J Gastroenterol. 2021.

¹⁷⁶ Mathes, et al., *supra* note 132.

¹⁷⁷ Habel, et al., *supra* note 133.

was to determine whether there was an increased risk of liver cancer associated with proton pump inhibitors, a different class of medications indicated for the treatment of GERD. This finding is particularly notable as the authors adjusted for variables.¹⁷⁸

407. In 2018, a study found an increased risk in hepatocellular carcinoma associated with use of H₂ blockers.¹⁷⁹ The authors were evaluating the risk of cancer in association with proton pump inhibitors and looked at H₂ blockers as a confounder. The study only considered use of H₂ blockers within one year of cancer diagnosis and still found an increased odds ratio associated with use of H₂ blockers and hepatocellular carcinoma, a type of liver cancer.

408. A number of other studies have been published over the years showing an increased risk of various cancers associated with use of ranitidine and/or H₂ blockers.¹⁸⁰ These cancers include breast, gastric, pancreatic, and stomach cancer. Additional research reports that ranitidine use was associated with a significant increase in the risk of bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancer.¹⁸¹

409. Moreover, a 2015 meta-analysis demonstrated a 34% increased risk of gastric cancer when individuals consumed 190 ng to 270 ng of NDMA a day.¹⁸² A 1998 study illustrates that with a daily intake of 270ng of NDMA, the risk of lung cancer is significantly increased.¹⁸³ And a 2011 study showed that there is a 46% increased risk of rectal cancer when 130 ng of NDMA are consumed a day.¹⁸⁴

410. In addition to studies demonstrating that NDMA and, specifically, NDMA in

¹⁷⁸ Tran, et al., *supra* note 134.

¹⁷⁹ Shao, et al., *supra* note 135.

¹⁸⁰ Mathes et al., *supra* note 132; *see also supra*, note 136.

¹⁸¹ Adamson et al., *supra* note 137.

¹⁸² Song, et al., *supra*, note 138.

¹⁸³ DeStefani, et al., *supra*, note 139.

¹⁸⁴ Loh, et al., *supra* note 64.

ranitidine, directly causes cancer, research shows that exposure to NDMA (a) can exacerbate existing but dormant (*i.e.*, not malignant) tumor cells; (b) promote otherwise “initiated cancer cells” to develop into cancerous tumors; and (c) reduce the ability of the body to combat cancer as NDMA is immunosuppressive. Thus, in addition to NDMA being a direct cause of cancer itself, NDMA can also be a contributing factor to a cancer injury caused by some other source.

411. Thus Plaintiffs, all of whom consumed Ranitidine-Containing Products for lengthy periods of time, were exposed to NDMA at levels many times greater than the FDA’s ADI and are at a significantly increased risk of contracting the Subject Cancers. A reasonably prudent physician would recommend that Plaintiffs undergo diagnostic testing (medical monitoring) beyond that routinely recommended to the public at large.

412. As a direct and proximate result of Defendants’ unlawful conduct alleged herein, Plaintiffs have sustained a significantly increased risk of developing the Subject Cancers. Accordingly, they have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring that a reasonably prudent physician would deem necessary.

B. Plaintiffs and the Class Members Require Diagnostic Medical Testing that Differs from Routine Medical Care.

413. Physicians evaluate a person’s exposure to toxic and carcinogenic substances, including NDMA, when determining what diagnostic medical testing and treatment is necessary.

414. A reasonably prudent physician would conclude that Plaintiffs’ exposure to significant levels of NDMA over a lengthy period of time necessitates specialized testing (with resultant treatment) that is not generally given to the public at large as a part of routine medical care.

415. The available monitoring regime, discussed in greater detail below, is reasonably necessary and specific for individuals exposed to products known to significantly increase the risk

of the Subject Cancers because of exposure to NDMA. It is different from that normally recommended in the absence of exposure to this risk of harm (whether in kind and/or frequency) and is not generally available in a general practitioner setting.

416. The available medical monitoring regime will mitigate the development of and health effects associated with the Subject Cancers, improving prognosis, outcome, and quality of life, and reducing medical costs.

417. Medical monitoring programs typically begin with screening to determine whether more invasive or costly tests are warranted. This screening may be conducted via questionnaire, in-person before a medical practitioner, or via a tele-health appointment.

418. When the medical practitioner reviewing the questionnaire or conducting the screening appointment determines additional testing for purposes of diagnosis is required, the testing for the Subject Cancers (bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancers) may include one or more of the tests described below, subject to the then-state-of-the-art standard of care or recommendations of the practitioners skilled in the diagnosis and treatment of the respective Subject Cancer.

419. Screening and testing in the medical monitoring program will likely occur for an extended period of time. This permits the medical practitioners to monitor changes in symptoms or follow anomalies that may appear in imaging or other tests over time, and accommodates latency periods associated with the Subject Cancers.

420. The following are examples only, and are subject to change, based on expert testimony and/or developing standards of care.

421. **Bladder Cancer.** Tests and procedures exist to detect bladder cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose

bladder cancer to be included in a medical monitoring program may include but not be limited to cystoscopy, in which a scope is used to examine the inside of a patient's bladder; urine cytology, which analyzes a sample of urine to check for cancer cells in conjunction with imaging tests, such as computerized tomography urogram or retrograde pyelogram, which allow the physician to examine the structures of a patient's urinary tract.

422. The testing described above for bladder cancer is different than that normally recommended in the absence of Plaintiffs' exposure. It is not conducted or analyzed by a general practitioner or recommended to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including urologists, who specialize in diseases of the urinary tract and the male reproductive system, or urinary tract specialists.

423. While urinalysis may be conducted by a general practitioner to identify blood in the patient's urine, urinalysis is not a reliable method for diagnosing bladder cancer.

424. **Breast Cancer.** Tests and procedures exist to detect breast cancer early. Tests and procedures used to diagnose breast cancer to be included in a medical monitoring program may include but not be limited to a screening and/or diagnostic mammogram, breast ultrasound, and breast magnetic resonance imaging ("MRI").

425. This testing is different than that normally recommended in the absence of Plaintiffs' exposure. It is conducted at a different time and/or frequency than is recommended for the public at large as a part of routine medical care. Further, it is conducted and analyzed by medical practitioners skilled in the respective areas, including radiologists, who specialize in diagnosing and treating injuries and diseases using medical imaging procedures.

426. While an initial physical examination may be part of routine medical care, the

Centers for Disease Control recommends that clinicians should not use clinical breast examination to screen for breast cancer.

427. **Colorectal/intestinal cancer.** A procedure and test exist to detect colon cancer early, but they are different and more extensive than routine medical care.

428. The procedure and test used to diagnose colon cancer to be included in a medical monitoring program may include but not be limited to a colonoscopy, prescribed earlier and at a greater frequency than otherwise necessary. A colonoscopy uses a scope to examine the inside of the patient's colon. If any suspicious areas are found, the doctor can pass surgical tools through the tube to take tissue samples (biopsies) for analysis.

429. This testing is different than that normally recommended the absence of Plaintiffs' exposure. It is prescribed earlier and a greater frequency than appropriate for the public at large as a part of routine medical care. Further, it is conducted and analyzed by medical practitioners skilled in the respective areas, including gastroenterologists, which specialize in gastrointestinal diseases and have received specialized training in colonoscopy; pathologists, who specialize in evaluating cells, tissues and organs to diagnose disease; and cytologists, who specialize in the study of cells.

430. While blood tests may be used to test for a chemical sometimes produced by colon cancers (carcinoembryonic antigen, or CEA) as part of routine medical care, they cannot definitively diagnose colon cancer.

431. **Esophageal cancer.** Tests and procedures exist to detect esophageal cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose esophageal cancer may include a barium swallow study, in which the patient swallows a liquid that includes barium and then undergoes X-rays; and an upper endoscopy, in which the

physician passes a flexible tube equipped with a video lens (video endoscope) down the patient's throat and into their esophagus, looking for cancer or areas of irritation.

432. This testing is different than that normally recommended in the absence of Plaintiffs' exposure. For example, it is not conducted or analyzed by a general practitioner or recommended to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including radiologists or trained radiology technicians, who perform the barium swallow studies; and gastroenterologists, who specializes in the gastrointestinal tract and perform the endoscopy.

433. **Gastric cancer.** Tests and procedures exist to detect gastric cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose gastric cancer to be included in a medical monitoring program may include but not be limited to a barium swallow study and an upper endoscopy.

434. A barium swallow study is performed by a radiologist or trained radiology technician, and an endoscopy is typically conducted by a gastroenterologist, who specializes in the gastrointestinal tract. These tests are different than what is normally recommended in the absence of Plaintiffs' exposure and are not recommended to the public at large as a part of routine medical care.

435. **Kidney cancer.** Tests and procedures exist to detect kidney cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose kidney cancer to be included in a medical monitoring program may include but not be limited to imaging tests, which might include ultrasound, X-ray, CT or MRI, and which allow the physician to visualize a kidney tumor or abnormality.

436. This testing is different than that normally recommended the absence of Plaintiffs'

exposure. For example, it is not conducted or analyzed by a general practitioner or recommended to the general public as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including but not limited to radiologists, who specialize in diagnosing and treating injuries and diseases using medical imaging procedures.

437. While blood tests may be used to determine if there is a kidney problem as part of routine medical care, they cannot definitively diagnose kidney cancer.

438. **Liver cancer.** Tests and procedures exist to detect liver cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose liver cancer to be included in a medical monitoring program may include but not be limited to imaging tests, including ultrasound, X-ray, CT or MRI, and which allow the physician to visualize a liver tumor or abnormality.

439. This testing is different than that normally recommended in the absence of Plaintiffs' exposure. For example, it is not conducted or analyzed by a general practitioner or recommended to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including but not limited to radiologists, who specialize in diagnosing and treating injuries and diseases using medical imaging procedures.

440. While blood tests may be used to determine if there is a liver function abnormality as part of routine medical care, they cannot definitively diagnose liver cancer.

441. **Lung cancer.** Tests and procedures exist to detect lung cancer early, but they are different and more extensive than routine medical care. Tests and procedures used to diagnose lung cancer to be included in a medical monitoring program may include but not be limited to imaging tests, including X-rays or CT scans that allow the physician to visualize a lung tumor or

abnormality, and sputum cytology, which is the analysis of sputum (the mixture of saliva and mucus from the respiratory tract) under a microscope and which can reveal the presence of lung cancer cells.

442. This testing is different than that normally recommended the absence of Plaintiffs' exposure. For example, it is not conducted or analyzed by a general practitioner or available to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including but not limited to radiologists, who specialize in diagnosing and treating injuries and diseases using medical imaging procedures; pathologists, who specialize in interpreting laboratory tests and evaluating cells, tissues and organs to diagnose disease; and cytologists, who specialize in the study of cells.

443. **Pancreatic cancer.** Tests and procedures exist to detect pancreatic cancer early, but it is typically not diagnosed early because signs and symptoms of the disease do not appear until the disease is advanced, making monitoring particularly important. The tests and procedures to detect pancreatic cancer are different and more extensive than routine medical care.

444. Tests and procedures used to diagnose pancreatic cancer to be included in a medical monitoring program may include but not be limited to imaging tests such as ultrasound, X-ray, CT, MRI, or positron emission topography ("PET") scans, and which allow the physician to visualize a pancreatic tumor or abnormality, or endoscopic ultrasound, which uses an ultrasound device inside the abdomen to image the pancreas.

445. This testing is different than that normally recommended the absence of Plaintiffs' exposure. For example, it is not conducted or analyzed by a general practitioner or available to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including but not limited to radiologists, who specialize

in diagnosing and treating injuries and diseases using medical imaging procedures; and gastroenterologists, which specialize in gastrointestinal diseases.

446. While blood tests may be used to test for certain proteins (tumor markers) shed by pancreatic cancer cells, the tests are not always reliable because some people with pancreatic cancer do not have elevated markers and thus the tests cannot definitively diagnose pancreatic cancer.

447. **Prostate cancer.** Tests and procedures exist to detect prostate cancer early, but they are not provided or recommended as part of routine medical care. Most medical organizations do not recommend screening for prostate cancer as part of routine medical care absent risk factors. Thus, the tests and procedures to detect prostate cancer are different and more extensive than routine medical care.

448. Tests and procedures used to diagnose prostate cancer to be included in a medical monitoring program may include but not be limited to the following.

449. Initial screening tests may detect abnormalities of the prostate but will not diagnose prostate cancer. Initial screening may include a digital rectal exam, in which a physician inserts a gloved, lubricated finger into the patient's rectum to examine their prostate, which is adjacent to the rectum, to identify any abnormalities in the texture, shape or size of the gland; and a Prostate-specific antigen (PSA) test, in which a blood sample is analyzed for excessive levels of PSA, a substance that's naturally produced by the prostate gland.

450. If prostate cancer screening detects an abnormality, tests and procedures used to diagnose prostate cancer include but may not be limited to measuring free PSA (to measure whether the percent of unbound PSA suggests the presence of cancer), a Transrectal ultrasound, in which a small probe is inserted into the patient's rectum to create a picture of the prostate gland,

and an MRI.

451. This testing is different than that normally recommended the absence of Plaintiffs' exposure. For example, it is not conducted or analyzed by a general practitioner or available to the public at large as a part of routine medical care. Rather, it is conducted and analyzed by medical practitioners skilled in the respective areas, including but not limited to radiologists, who specialize in diagnosing and treating injuries and diseases using medical imaging procedures.

452. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical communities specializing in the diagnosis and treatment of the Subject Cancers.

453. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

454. Plaintiffs' physicians would not have prescribed and/or recommended Ranitidine-Containing Products to Plaintiffs, would have changed the way in which they treated Plaintiffs' relevant conditions, changed the way they warned Plaintiffs about the signs and symptoms of serious adverse effects of Ranitidine-Containing Products, and discussed with Plaintiffs the true risks of cancer, had Defendants provided said physicians with an appropriate and adequate warning regarding the risks associated with the use of Ranitidine-Containing Products.

455. Upon information and belief, Plaintiffs' physicians were unaware of the increased risk of multiple types of cancer associated with the use of Ranitidine-Containing Products due to ranitidine's transformation into NDMA and, if they had been informed, would have used, prescribed, and/or recommended alternative therapies to Plaintiffs.

456. Plaintiffs would not have used Ranitidine-Containing Products had Plaintiffs

known of or been fully and adequately informed by Defendants of the true increased risks and serious dangers of taking the drugs.

VII. TOLLING / FRAUDULENT CONCEALMENT

457. Plaintiffs assert all applicable statutory and common law rights and theories related to the tolling or extension of any applicable statute of limitations, including equitable tolling, delayed discovery, discovery rule, and/or fraudulent concealment.

458. The discovery rule applies to toll the running of the statute of limitations until Plaintiffs knew, or through the exercise of reasonable care and diligence should have known, of facts that Plaintiffs had been injured, the cause of the injury, and the tortious nature of the wrongdoing that caused the injury.

459. The nature of Plaintiffs' injuries, damages, or their causal relationship to Defendants' conduct was not discovered, and through reasonable care and due diligence could not have been discovered until a date within the applicable statute of limitations for filing Plaintiffs' claims.

460. Plaintiffs bring this medical monitoring complaint within the applicable statute of limitations. Specifically, Plaintiffs bring this action within the prescribed time limits following Plaintiffs' awareness of their risk of injury and Plaintiffs' knowledge of the wrongful cause. Prior to such time, Plaintiffs did not know and had no reason to know of their injuries and/or the wrongful cause of those injuries.

461. The running of the statute of limitations is tolled due to equitable tolling. Defendants are estopped from relying on any statutes of limitation or repose by virtue of their acts of fraudulent concealment, through affirmative misrepresentations and omissions to Plaintiffs and defects associated with Ranitidine-Containing Products as they transform into NDMA.

Defendants affirmatively withheld and/or misrepresented facts concerning the safety of ranitidine. As a result of Defendants' misrepresentations and concealment, Plaintiffs and Plaintiffs' physicians were unaware, and could not have known or have learned through reasonable diligence, of facts related to Defendants' misrepresentations or omissions, that Plaintiffs had been exposed to the risks alleged herein, or that those risks were the direct and proximate result of the wrongful acts and/or omissions of Defendants.

462. Given Defendants' affirmative actions of concealment by failing to disclose this known but non-public information about the defects – information over which Defendants had exclusive control – and because Plaintiffs could not reasonably have known that Defendants' Ranitidine-Containing Products were defective, Defendants are estopped from relying on any statutes of limitations or repose that might otherwise be applicable to the claims asserted herein.

VIII. CLASS ALLEGATIONS

A. CLASS DEFINITIONS

463. Plaintiffs bring this action in their individual capacities and on behalf of their respective State Classes (described below), pursuant to Federal Rules of Civil Procedure 23(a), (b)(2)-(3), and/or (c)(4).

1. Prescription GSK Medical Monitoring Class

464. Plaintiffs identified in the table below bring claims against Defendant GSK on behalf of themselves and their respective State GSK Prescription Medical Monitoring Class, each of which is defined as “All individuals who used GSK’s prescription Zantac while a resident of [State] and have not been diagnosed with a Subject Cancer”:

Plaintiff Name	State of Usage
Golbenaz Bakhtiar	CA
Jeffrey Pisano	CO

Michael Galloway	FL
Alexander Monger	FL
Laura Monger	FL
Michael Tomlinson	FL
Teresa Dowler	IN
Alberta Griffin	MD
Ronda Lockett	MO
Michael Galloway	OH
Felicia Ball	PA

2. OTC Medical Monitoring Classes

GSK

465. Plaintiffs identified in the table below bring claims against Defendant GSK on behalf of themselves and their respective State GSK OTC Medical Monitoring Class, each of which is defined as “All individuals who used GSK’s OTC Zantac while a resident of [State] and have not been diagnosed with a Subject Cancer”:

Plaintiff Name	State of Usage
Richard Obrien	CA
Jeffrey Pisano	CO
Michael Galloway	FL
Ricardo Moròn	FL
Ronda Lockett	MO
Jonathan Ferguson	NV

Pfizer

466. Plaintiffs identified in the table below bring claims against Defendant Pfizer on behalf of themselves and their respective State Pfizer OTC Medical Monitoring Class, each of which is defined as “All individuals who used Pfizer’s OTC Zantac while a resident of [State] and

have not been diagnosed with a Subject Cancer”:

Plaintiff Name	State of Usage
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jeffrey Pisano	CO
Gustavo Velasquez	FL
Joshua Winans	FL
Ricardo Moròn	FL
Alberta Griffin	MD
Ida Adams	MD; WV
Ronda Lockett	MO
Jonathan Ferguson	NV
Chris Troyan	OH
Michael Galloway	FL; OH

BI

467. Plaintiffs identified in the table below bring claims against Defendant BI on behalf of themselves and their respective State BI OTC Medical Monitoring Class, each of which is defined as “All individuals who used BI’s OTC Zantac while a resident of [State] and have not been diagnosed with a Subject Cancer”:

Plaintiff Name	State of Usage
Tangie Sims	AZ
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jonathan Ferguson	CA
Jeffrey Pisano	CO

Ronald Ragan	CO
Clifton McKinnon	FL
Gustavo Velasquez	FL
Joshua Winans	FL
Marva Mccall	FL
Michael Tomlinson	FL
Ricardo Moròn	FL
Teresa Dowler	IN
Alberta Griffin	MD
Ida Adams	MD; WV
Antrenise Campbell	MO
Lorie Kendall-Songer	MO
Cesar Pinon	NV
Chris Troyan	OH
Michael Galloway	OH
Teresa Waters	UT

Sanofi

468. Plaintiffs identified in the table below bring claims against Defendant Sanofi on behalf of themselves and their respective State Sanofi OTC Medical Monitoring Class, each of which is defined as “All individuals who used Sanofi’s OTC Zantac while a resident of [State] and have not been diagnosed with a Subject Cancer”:

Plaintiff Name	State of Usage
Tangie Sims	AZ
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jeffrey Pisano	CO
Ronald Ragan	CO

Gustavo Velasquez	FL
Joshua Winans	FL
Michael Tomlinson	FL
Ricardo Moròn	FL
Teresa Dowler	IN
Alberta Griffin	MD
Ida Adams	MD
Lorie Kendall-Songer	MO
Chris Troyan	OH
Michael Galloway	OH
Teresa Waters	UT

B. FED. R. CIV. P. 23 REQUIREMENTS

469. Each of the proposed State Classes meets the requirements of Federal Rules of Civil Procedure 23(a), 23(b)(2), 23(b)(3) and/or 23(c)(4).

470. **Numerosity.** The members of each State Class are so numerous that joinder is impracticable. Zantac has for decades been one of the most popular medications for relief of heartburn, acid reflux, and similar conditions and, thus, it is reasonable to infer that each State Class includes thousands of members who are geographically dispersed.

471. **Typicality.** Plaintiffs' claims are typical of the claims of putative State Class members in that Plaintiffs' claims arise out of the same common course of conduct that gives rise to the claims of the other State Class members. Each Plaintiff, like each State Class member, took prescription and/or OTC Zantac, manufactured or sold by Defendants, which are not safe for human consumption and, thus, Plaintiffs, like each State Class member, face an increased risk of developing any of the Subject Cancers. Plaintiffs, like each State Class member, were injured through Defendants' common course of misconduct, and Plaintiffs are advancing the same legal

theories on behalf of themselves and the State Class members.

472. ***Adequacy.*** Plaintiffs will fairly and adequately protect the interests of the State Class members. Plaintiffs' interests and the interests of all other members of each respective State Class are identical and not antagonistic. Plaintiffs intend to vigorously prosecute this case and will fairly and adequately protect the State Class members' interests. Plaintiffs have retained counsel who are competent and experienced in litigating class actions, including litigation of this kind.

473. ***Commonality and Predominance.*** There are numerous questions of law and fact common to the State Classes, and these common questions predominate over any issues affecting only individual State Class members. Questions common to the State Classes include, but are not limited to, the following:

- (a) whether Zantac contains, or is likely to contain, or exposed State Class members to, unacceptable levels of NDMA;
- (b) whether consumption of Zantac increases the risk of developing any of the Subject Cancers;
- (c) whether Defendants knew or should have known that Zantac contains, or is likely to contain, unacceptable levels of NDMA;
- (d) whether Defendants knew or should have known that consumption of Zantac increased the risk of developing any of the Subject Cancers;
- (e) whether Defendants acted to conceal the fact that Zantac exposes users to unacceptable quantities of NDMA;
- (f) whether Defendants acted to conceal the fact that consumption of Zantac increased the risk of developing cancer;
- (g) whether Defendants' warnings regarding the risks of cancer were adequate;
- (h) whether Defendants failed to warn consumers regarding the appropriate expiration dates for Zantac;
- (i) whether Defendants were negligent in labeling, marketing, advertising, promoting and/or manufacturing and/or selling Zantac;

- (j) whether Defendants were negligent in labeling, marketing, advertising, and/or promoting Zantac and its safety when used within the expiration dates;
- (k) whether Defendants were negligent in labeling, marketing, advertising, and/or promoting Zantac and its safety when used beyond the expiration dates;
- (l) whether Defendants were negligent in their storage and/or transportation of Zantac;
- (m) whether Defendants are liable for failing to warn of the risks associated with use of Zantac;
- (n) whether Plaintiffs and State Class members are entitled to medical monitoring relief as a result of their increased risk of developing the Subject Cancers based on use of Zantac; and
- (o) the type and format of medical monitoring relief, declaratory relief and/or injunctive relief that is appropriate.

474. ***Superiority.*** A class action is superior to other available means for the fair and efficient adjudication of this controversy, and no unusual difficulties are likely to be encountered in the management of this class action. The quintessential purpose of the class action mechanism is to permit litigation against wrongdoers even when damages to an individual plaintiff may not be sufficient to justify individual litigation. Here, the damages suffered by Plaintiffs and the State Class are relatively small compared to the burden and expense required to individually litigate their claims against Defendants, and thus, individual litigation to redress Defendants' wrongful conduct would be impracticable. Individual litigation by each State Class member would also strain the court system, create the potential for inconsistent or contradictory judgments, and increase the delay and expense to all parties and the court system. By contrast, the class action device presents fewer management difficulties and provides the benefits of a single adjudication, economies of scale, and comprehensive supervision by a single court.

475. ***Injunctive and Declaratory Relief.*** Class certification is also appropriate under Rule 23(b)(2) because Defendants acted and refused to act on grounds generally applicable to the State Class as a whole, such that final declaratory and/or injunctive relief is appropriate with

respect to the State Class as a whole. Such declaratory and/or injunctive relief includes, but is not limited to, implementation and funding of a medical monitoring program for Plaintiffs and State Class members that is sufficient to monitor their health and ensure the early detection and diagnosis of diseases, specifically the Subject Cancers.

476. Plaintiffs reserve the right to seek certification of Rule 23(c)(4) of common questions related to Defendants' knowledge, conduct, products, and duties.

IX. CAUSES OF ACTION

A. CAUSES OF ACTION AGAINST DEFENDANT GSK WITH RESPECT TO PRESCRIPTION ZANTAC

477. Plaintiffs identified in the table below bring claims against Defendant GSK with respect to prescription Zantac on behalf of themselves and their respective State GSK Prescription Medical Monitoring Class under the laws of their respective states of usage. Each Plaintiff incorporates by reference the allegations specific to them from Section III.B. and the allegations set forth in Section VI, *supra*, into their respective claims below.

Plaintiff Name	State of Usage
Golbenaz Bakhtiar	CA
Jeffrey Pisano	CO
Michael Galloway	FL
Alexander Monger	FL
Laura Monger	FL
Michael Tomlinson	FL
Teresa Dowler	IN
Alberta Griffin	MD
Ronda Lockett	MO
Michael Galloway	OH
Felicia Ball	PA

1. California

COUNT 1:

Negligence – Failure to Warn Through Warnings and Precautions – California

478. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

479. This cause of action is brought by Golbenaz Bakhtiar, individually and on behalf of the California GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

480. The allegations in this Count apply to GSK during the time periods in which it was manufacturing Ranitidine-Containing Products. The relevant time periods are alleged in paragraphs 60-79, which are incorporated by reference.

481. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

482. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

483. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under

hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

484. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

485. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the California GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

486. The latent injuries from which Plaintiff and the California GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

487. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

488. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and

treatment of the Subject Cancers.

489. By monitoring and testing Plaintiffs, the risk that Plaintiff and the California GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

490. Plaintiff and the California GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiff and the California GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiff and the California GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

491. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

492. Plaintiff and the California GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the California GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 2:
Negligence – Failure to Warn Through Proper Expiration Dates – California

493. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

494. This cause of action is brought by Golbenaz Bakhtiar, individually and on behalf of the California GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

495. The allegations in this Count apply to GSK during the time periods in which it was manufacturing Ranitidine-Containing Products. The relevant time periods are alleged in paragraphs 60-79, which are incorporated by reference.

496. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

497. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

498. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiff that Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

499. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs

would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

500. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the California GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

501. The latent injuries from which Plaintiffs and the California GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

502. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

503. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

504. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

505. Plaintiffs and the California GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

506. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

507. Plaintiffs and the California GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 3:
Negligent Product Containers – California

508. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261

(describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

509. This cause of action is brought by Golbenaz Bakhtiar, individually and on behalf of the California GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

510. The allegations in this Count apply to GSK during the time periods in which it was manufacturing Ranitidine-Containing Products. The relevant time periods are alleged in paragraphs 60-79, which are incorporated by reference.

511. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

512. Under California law, a pharmaceutical manufacturer, including Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

513. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

514. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and the California GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

515. The latent injuries from which Plaintiffs and the California GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers

because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

516. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

517. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

518. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

519. Plaintiffs and the California GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiff and the California GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

520. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK Prescription Medical Monitoring Class members in writing that they

may require frequent medical monitoring for the purpose of diagnosis.

521. Plaintiffs and the California GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the California GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 4:
Negligent Storage and Transportation – California

522. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

523. This cause of action is brought by Golbenaz Bakhtiar, individually and on behalf of the California GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

524. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

525. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

526. Under California law, a pharmaceutical manufacturer, including Defendant, has a

duty to exercise reasonable care in transporting and storing products.

527. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

528. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the California GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

529. The latent injuries from which Plaintiffs and the California GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

530. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

531. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

532. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

533. Plaintiffs and the California GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

534. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

535. Plaintiffs and the California GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

2. Colorado

COUNT 5:
Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions –
Colorado

536. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

537. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

538. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

539. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

540. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

541. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

542. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk

of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

543. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

544. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

545. The latent injuries from which Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

546. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

547. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

548. By monitoring and testing Plaintiffs, the risk Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

549. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

550. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

551. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a Court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 6:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Colorado

552. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

553. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

554. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

555. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

556. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

557. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

558. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe

when consumed long after manufacture, when in fact the products degraded into NDMA over time.

559. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

560. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

561. The latent injuries from which Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

562. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

563. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

564. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

565. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

566. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

567. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 7:
Medical Monitoring – Negligent Product Containers – Colorado

568. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

569. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

570. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

571. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

572. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

573. Under Colorado law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

574. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

575. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses

associated with ongoing medical monitoring.

576. The latent injuries from which Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

577. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

578. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

579. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

580. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

581. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

582. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 8:

Medical Monitoring – Negligent Storage and Transportation – Colorado

583. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

584. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

585. The allegations in this Count apply to GSK during the time period in which it was

manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

586. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

587. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

588. Under Colorado law, Defendant has a duty to exercise reasonable care in transporting and storing products.

589. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

590. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

591. The latent injuries from which Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

592. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

593. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

594. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

595. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

596. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

597. Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class have an

inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

3. Florida

COUNT 9: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Florida

598. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

599. This cause of action is brought by Michael Galloway, Alexander Monger, Laura Monger, and Michael Tomlinson, individually and on behalf of the Florida GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

600. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

601. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

602. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

603. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

604. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

605. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

606. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Florida GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

607. The latent injuries from which Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals

exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

608. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

609. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

610. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

611. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

612. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b)

notifying all Florida GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

613. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 10:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida

614. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

615. This cause of action is brought by Michael Galloway, Alexander Monger, Laura Monger, and Michael Tomlinson, individually and on behalf of the Florida GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

616. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

617. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

618. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

619. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

620. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

621. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

622. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Florida GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

623. The latent injuries from which Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals

exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

624. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

625. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

626. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

627. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

628. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b)

notifying all Florida GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

629. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 11:
Medical Monitoring – Negligent Product Containers – Florida

630. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

631. This cause of action is brought by Michael Galloway and Michael Tomlinson, individually and on behalf of the Florida GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

632. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

633. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

634. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

635. Under Florida law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

636. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

637. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold. These high levels of NDMA caused Plaintiffs' injuries.

638. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and Florida GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

639. The latent injuries from which Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

640. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the

development of, and health effects associated with, the Subject Cancers.

641. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

642. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

643. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

644. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

645. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court,

Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 12:

Medical Monitoring – Negligent Storage and Transportation – Florida

646. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

647. This cause of action is brought by Michael Galloway, Alexander Monger, Laura Monger, and Michael Tomlinson, individually and on behalf of the Florida GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

648. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

649. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

650. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

651. Under Florida law, Defendant has a duty to exercise reasonable care in transporting and storing products.

652. Defendant breached this duty by failing to implement or enforce policies to ensure

Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

653. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and Florida GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

654. The latent injuries from which Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

655. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

656. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

657. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses

without adequate treatment will be significantly reduced.

658. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

659. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

660. Plaintiffs and the Florida GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

4. Indiana

COUNT 13:

Negligence – Failure to Warn Through Warnings and Precautions – Indiana

661. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

662. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

663. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

664. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

665. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

666. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were unreasonably inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

667. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

668. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

669. The latent injuries from which Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

670. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

671. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

672. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

673. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will

facilitate the diagnoses of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

674. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

675. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 14:

Negligence – Failure To Warn Through Proper Expiration Dates – Indiana

676. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein. This cause of action is brought by Teresa Dowler, individually and

on behalf of the Indiana GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

677. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

678. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

679. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

680. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

681. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

682. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

683. The latent injuries from which Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not

generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

684. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

685. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

686. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

687. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

688. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

689. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 15:
Negligent Product Containers – Indiana

690. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

691. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

692. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

693. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-

Specific Allegations) as to GSK.

694. Under Indiana law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

695. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

696. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

697. The latent injuries from which Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

698. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

699. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

700. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

701. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

702. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

703. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 16:
Negligent Storage and Transportation – Indiana

704. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

705. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

706. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

707. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

708. Under Indiana law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in transporting and storing products.

709. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

710. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with

ongoing medical monitoring.

711. The latent injuries from which Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

712. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

713. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

714. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

715. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

716. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

717. Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

5. Maryland

COUNT 17:

Negligence – Failure to Warn Through Warnings and Precautions – Maryland

718. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

719. This cause of action is brought by Alberta Griffin, individually and on behalf of the Maryland GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

720. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

721. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

722. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

723. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

724. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

725. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Maryland GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

726. The latent injuries from which Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment)

that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

727. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

728. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

729. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

730. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

731. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

732. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 18:

Negligence – Failure To Warn Through Proper Expiration Dates – Maryland

733. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

734. This cause of action is brought by Alberta Griffin, individually and on behalf of the Maryland GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

735. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

736. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-

Specific Allegations) as to GSK.

737. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

738. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

739. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

740. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Maryland GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

741. The latent injuries from which Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

742. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers.

This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

743. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

744. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

745. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

746. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

747. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without

a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

**COUNT 19:
Negligent Product Containers – Maryland**

748. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

749. This cause of action is brought by Alberta Griffin, individually and on behalf of the Maryland GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

750. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

751. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

752. Under Maryland law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

753. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

754. As a direct and proximate result of this failure, excessive levels of NDMA built up

in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and Maryland GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

755. The latent injuries from which Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

756. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

757. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

758. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

759. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class

members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

760. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

761. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 20:
Negligent Storage and Transportation – Maryland

762. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

763. This cause of action is brought by Alberta Griffin, individually and on behalf of the

Maryland GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

764. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

765. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

766. Under Maryland law, Defendant had a duty to exercise reasonable care in transporting and storing products.

767. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

768. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, transported, and, therefore, Plaintiffs and Maryland GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

769. The latent injuries from which Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally

recommended in the absence of exposure to this risk of harm.

770. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

771. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

772. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

773. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

774. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

775. Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

6. Missouri

COUNT 21:

Negligence – Failure to Warn Through Warnings and Precautions – Missouri

776. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

777. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

778. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

779. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

780. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care

to provide an adequate warning of the risks of its products.

781. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

782. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

783. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

784. The latent injuries from which Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

785. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers.

This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

786. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

787. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

788. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

789. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

790. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without

a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 22:

Negligence – Failure to Warn Through Proper Expiration Dates – Missouri

791. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

792. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

793. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

794. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

795. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

796. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

797. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

798. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

799. The latent injuries from which Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

800. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

801. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

802. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK

Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

803. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

804. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

805. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 23: Negligent Product Containers – Missouri

806. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216

(describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

807. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

808. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

809. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

810. Under Missouri law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

811. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

812. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

813. The latent injuries from which Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment)

that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

814. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

815. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

816. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

817. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

818. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

819. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 24: Negligent Storage and Transportation – Missouri

820. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

821. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

822. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

823. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

824. Under Missouri law, Defendant has a duty to exercise reasonable care in transporting and storing products.

825. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

826. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

827. The latent injuries from which Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

828. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

829. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and

treatment of the Subject Cancers.

830. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

831. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

832. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

833. Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

7. Ohio

COUNT 25:
Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio

834. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

835. This cause of action is brought by Michael Galloway, individually and on behalf of the Ohio GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

836. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

837. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

838. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

839. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

840. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

841. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

842. The latent injuries from which Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

843. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

844. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

845. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio GSK

Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

846. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

847. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

848. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 26:

Strict Liability – Failure To Warn Through Proper Expiration Dates – Ohio

849. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

850. This cause of action is brought by Michael Galloway, individually and on behalf of the Ohio GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

851. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

852. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

853. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

854. Defendant breached this duty for the Ranitidine-Containing it manufactured. The warnings included on each Ranitidine-Containing Product were inadequate because The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

855. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the

use of the Ranitidine-Containing Products.

856. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

857. The latent injuries from which Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

858. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

859. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

860. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

861. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members seek

creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

862. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

863. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 27:
Negligent Product Containers – Ohio

864. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and

injury), as if fully stated herein.

865. This cause of action is brought by Michael Galloway, individually and on behalf of the Ohio GSK Prescription Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

866. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

867. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

868. Under Ohio law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

869. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

870. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold. These high levels of NDMA caused Plaintiffs’ injuries.

871. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

872. The latent injuries from which Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not

generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

873. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

874. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

875. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

876. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

877. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

878. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 28:
Negligent Storage and Transportation – Ohio

879. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

880. This cause of action is brought by Michael Galloway, individually and on behalf of the Ohio GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

881. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

882. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-

Specific Allegations) as to GSK.

883. Under Ohio law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in transporting and storing products.

884. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

885. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

886. The latent injuries from which Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

887. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

888. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

889. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

890. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

891. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

892. Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

8. Pennsylvania

COUNT 29: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Pennsylvania

893. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein. This cause of action is brought by Felicia Ball, individually and on behalf of the Pennsylvania GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

894. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

895. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

896. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

897. Under Pennsylvania law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning.

898. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under

hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

899. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

900. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

901. The latent injuries from which Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

902. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

903. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and

treatment of the Subject Cancers.

904. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

905. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

906. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Pennsylvania GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

907. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 30:
Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates –
Pennsylvania

908. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

909. This cause of action is brought by Felicia Ball, individually and on behalf of the Pennsylvania GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

910. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

911. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

912. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject CancersRanitidine-Containing Products").

913. Under Pennsylvania law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning.

914. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe

when consumed long after manufacture, when in fact the products degraded into NDMA over time.

915. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

916. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

917. The latent injuries from which Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

918. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

919. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

920. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

921. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

922. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Pennsylvania GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

923. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 31:
Medical Monitoring – Negligent Product Containers – Pennsylvania

924. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

925. This cause of action is brought by Felicia Ball, individually and on behalf of the Pennsylvania GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

926. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

927. Plaintiffs incorporate herein by reference Paragraphs 349-359 (Additional Count-Specific Allegations) as to GSK.

928. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

929. Under Pennsylvania law, a pharmaceutical manufacturer, like Defendant, has a duty to exercise reasonable care in choosing and making the containers for its products.

930. Defendant breached this duty by failing to utilize containers that would minimize the NDMA produced in its Ranitidine-Containing Products.

931. As a direct and proximate result of this failure, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant sold, and, therefore, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and

will suffer economic losses and expenses associated with ongoing medical monitoring.

932. The latent injuries from which Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

933. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

934. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

935. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

936. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

937. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Pennsylvania GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

938. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 32:

Medical Monitoring – Negligent Storage and Transportation – Pennsylvania

939. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein. This cause of action is brought by Felicia Ball, individually and on behalf of the Pennsylvania GSK Prescription Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

940. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs

60-79, which are incorporated by reference.

941. Plaintiffs incorporate herein by reference Paragraphs 360-382 (Additional Count-Specific Allegations) as to GSK.

942. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

943. Under Pennsylvania law, Defendant has a duty to exercise reasonable care in transporting and storing products.

944. Defendant breached this duty by failing to implement or enforce policies to ensure Ranitidine-Containing Products and ranitidine API remained free from excessive heat and humidity.

945. As a direct and proximate result of these systematic failures, excessive levels of NDMA built up in the Ranitidine-Containing Products Defendant manufactured, stored, and transported, and, therefore, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

946. The latent injuries from which Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

947. The medical monitoring regime should include, but is not limited to, baseline tests

and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

948. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

949. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

950. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members as frequently and appropriately as necessary.

951. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Pennsylvania GSK Prescription Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

952. Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk

of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Pennsylvania GSK Prescription Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

B. CAUSES OF ACTION AGAINST DEFENDANT GSK WITH RESPECT TO OTC ZANTAC

953. Plaintiffs identified in the table below bring claims against Defendant GSK with respect to OTC Zantac on behalf of themselves and their respective State GSK OTC Medical Monitoring Class under the laws of their respective states of usage. Each Plaintiff incorporates by reference the allegations specific to them from Section III.B. and the allegations set forth in Section VI, *supra*, into their respective claims below.

Plaintiff Name	State of Usage
Richard Obrien	CA
Jeffrey Pisano	CO
Michael Galloway	FL
Ricardo Moròn	FL
Ronda Lockett	MO
Jonathan Ferguson	NV

1. California

COUNT 33:

Negligence – Failure to Warn Through Warnings and Precautions – California

954. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

955. This cause of action is brought by Richard Obrien, individually and on behalf of the California GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

956. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

957. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

958. Under California law, manufacturers, like Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

959. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under

hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

960. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

961. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and California GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

962. The latent injuries from which Plaintiffs and the California GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

963. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

964. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and

treatment of the Subject Cancers.

965. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

966. Plaintiffs and the California GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

967. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

968. Plaintiffs and the California GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 34:
Negligence – Failure to Warn Through Proper Expiration Dates – California

969. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

970. This cause of action is brought by Richard Obrien, individually and on behalf of the California GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

971. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

972. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

973. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

974. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

975. Plaintiffs or their doctors would have read and heeded these warnings had they been

included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

976. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and California GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

977. The latent injuries from which Plaintiffs and the California GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

978. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

979. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

980. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses

without adequate treatment will be significantly reduced.

981. Plaintiffs and the California GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

982. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

983. Plaintiffs and the California GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

984.

2. Colorado

COUNT 35: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Colorado

985. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

986. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

987. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

988. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

989. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

990. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

991. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after

manufacture.

992. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

993. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

994. The latent injuries from which Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

995. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

996. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

997. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

998. Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

999. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1000. Plaintiffs and the Colorado GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 36:
Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates –
Colorado

1001. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1002. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1003. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1004. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

1005. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing various types of serious and potentially fatal Subject Cancers.

1006. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1007. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1008. Plaintiffs or their doctors would have read and heeded these warnings had they been

included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1009. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1010. The latent injuries from which Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1011. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1012. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1013. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses

without adequate treatment will be significantly reduced.

1014. Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1015. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1016. Plaintiffs and the Colorado GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

3. Florida

COUNT 37: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – Florida

1017. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1018. This cause of action is brought by Michael Galloway and Ricardo Moron, individually and on behalf of the Florida GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1019. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1020. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

1021. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1022. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1023. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after

manufacture.

1024. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1025. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Florida GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1026. The latent injuries from which Plaintiffs and the Florida GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1027. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1028. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1029. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1030. Plaintiffs and the Florida GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1031. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1032. Plaintiffs and the Florida GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 38:
Medical Monitoring – Negligent Failure to Warn Through Proper Expiration Dates –
Florida

1033. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1034. This cause of action is brought by Michael Galloway and Ricardo Moron, individually and on behalf of the Florida GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1035. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1036. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

1037. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1038. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1039. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1040. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1041. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Florida GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing the Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1042. The latent injuries from which Plaintiffs and the Florida GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1043. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1044. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1045. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida GSK

OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1046. Plaintiffs and the Florida GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1047. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1048. Plaintiffs and the Florida GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

4. Missouri

COUNT 39:

Negligence – Failure to Warn Through Warnings and Precautions – Missouri

1049. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1050. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1051. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1052. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

1053. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1054. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1055. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the

use of the Ranitidine-Containing Products.

1056. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1057. The latent injuries from which Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1058. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1059. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1060. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1061. Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members seek

creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1062. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1063. Plaintiffs and the Missouri GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 40:

Negligence – Failure to Warn Through Proper Expiration Dates – Missouri

1064. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to

warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1065. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1066. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1067. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

1068. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1069. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1070. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1071. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1072. The latent injuries from which Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1073. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1074. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1075. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1076. Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1077. Accordingly, Defendant should be required to establish a medical monitoring

program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1078. Plaintiffs and the Missouri GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

5. Nevada

COUNT 41:

Negligence – Failure to Warn Through Warnings and Precautions – Nevada

1079. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK’s failure to warn), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1080. This cause of action is brought by Jonathan Ferguson, individually and on behalf of the Nevada GSK OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against GSK (for the purposes of this Count, “Defendant”).

1081. The allegations in this Count apply to GSK during the time period in which it was

manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1082. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to GSK.

1083. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1084. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1085. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1086. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1087. The latent injuries from which Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals

exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1088. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1089. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1090. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1091. Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1092. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b)

notifying all Nevada GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1093. Plaintiffs and the Nevada GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 42:

Negligence – Failure to Warn Through Proper Expiration Dates – Nevada

1094. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 238-261 (describing GSK's failure to warn), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1095. This cause of action is brought by Jonathan Ferguson, individually and on behalf of the Nevada GSK OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against GSK (for the purposes of this Count, "Defendant").

1096. The allegations in this Count apply to GSK during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1097. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to GSK.

1098. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1099. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1100. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1101. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1102. The latent injuries from which Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1103. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the

development of, and health effects associated with, the Subject Cancers.

1104. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1105. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1106. Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Nevada GSK OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1107. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Nevada GSK OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1108. Plaintiffs and the Nevada GSK OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs

and the Nevada GSK OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

C. CAUSES OF ACTION AGAINST DEFENDANT PFIZER WITH RESPECT TO OTC ZANTAC

1109. Plaintiffs identified in the table below bring claims against Defendant Pfizer with respect to prescription Zantac on behalf of themselves and their respective State Pfizer OTC Medical Monitoring Class under the laws of their respective states of usage. Each Plaintiff incorporates by reference the allegations specific to them from Section III.B. and the allegations set forth in Section VI, *supra*, into their respective claims below.

Plaintiff Name	State of Usage
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jeffrey Pisano	CO
Gustavo Velasquez	FL
Joshua Winans	FL
Ricardo Moròn	FL
Alberta Griffin	MD
Ida Adams	MD; WV
Ronda Lockett	MO
Jonathan Ferguson	NV
Chris Troyan	OH
Michael Galloway	FL; OH

1. California

COUNT 43:

Negligence – Failure to Warn Through Warnings and Precautions – California

1110. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1111. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, and Virginia Aragon, individually and on behalf of the California Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1112. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1113. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1114. Under California law, manufacturers, like Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1115. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1116. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1117. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and California Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1118. The latent injuries from which Plaintiffs and the California Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1119. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1120. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1121. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California Pfizer

OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1122. Plaintiffs and the California Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1123. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1124. Plaintiffs and the California Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the California Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 44:

Negligence – Failure to Warn Through Proper Expiration Dates – California

1125. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1126. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, and Virginia Aragon, individually and on behalf of the California Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1127. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1128. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1129. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1130. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1131. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the

use of the Ranitidine-Containing Products.

1132. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and California Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1133. The latent injuries from which Plaintiffs and the California Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1134. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1135. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1136. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1137. Plaintiffs and the California Pfizer OTC Medical Monitoring Class members seek

creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1138. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1139. Plaintiffs and the California Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

2. Colorado

COUNT 45: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Colorado

1140. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216

(describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1141. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1142. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1143. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1144. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1145. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1146. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1147. Plaintiff or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs

would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1148. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiff and Colorado Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1149. The latent injuries from which Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1150. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1151. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1152. By monitoring and testing Plaintiff, the risk that Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1153. Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1154. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1155. Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the Colorado Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 46:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Colorado

1156. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216

(describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1157. This cause of action is brought by Jeffrey Pisano, individually and on behalf of the Colorado Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1158. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1159. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1160. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1161. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1162. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1163. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1164. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1165. The latent injuries from which Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1166. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1167. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1168. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1169. Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will

facilitate the diagnoses of Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1170. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1171. Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

3. Florida

COUNT 47: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Florida

1172. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs'

use of ranitidine and injury), as if fully stated herein.

1173. This cause of action is brought by Gustavo Velasquez, Joshua Winans, Ricardo Moron and Michael Galloway, individually and on behalf of the Florida Pfizer OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Pfizer (for the purposes of this Count, “Defendant”).

1174. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1175. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1176. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1177. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1178. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1179. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs

would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1180. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Florida Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1181. The latent injuries from which Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1182. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1183. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1184. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1185. Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1186. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1187. Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 48:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Florida

1188. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216

(describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1189. This cause of action is brought by Gustavo Velasquez, Joshua Winans, Ricardo Moron, and Michael Galloway, individually and on behalf of the Florida Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1190. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1191. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1192. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1193. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1194. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1195. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs

would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1196. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1197. The latent injuries from which Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1198. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1199. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1200. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1201. Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1202. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1203. Plaintiffs and the Florida Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

4. Maryland

COUNT 49:

Negligence – Failure to Warn Through Warnings and Precautions – Maryland

1204. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216

(describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1205. This cause of action is brought by Alberta Griffin and Ida Adams, individually and on behalf of the Maryland Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1206. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1207. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1208. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1209. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1210. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1211. As a direct and proximate result of Defendant's failure to provide adequate

warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Maryland Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1212. The latent injuries from which Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1213. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1214. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1215. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1216. Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class

members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1217. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1218. Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 50:

Negligence – Failure to Warn Through Proper Expiration Dates – Maryland

1219. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1220. This cause of action is brought by Alberta Griffin and Ida Adams, individually and

on behalf of the Maryland Pfizer OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Pfizer (for the purposes of this Count, “Defendant”).

1221. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1222. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1223. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1224. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1225. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1226. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Maryland Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1227. The latent injuries from which Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not

generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1228. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1229. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1230. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1231. Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1232. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1233. Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

5. Missouri

COUNT 51:

Negligence – Failure to Warn Through Warnings and Precautions – Missouri

1234. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1235. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri Pfizer OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Pfizer (for the purposes of this Count, “Defendant”).

1236. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1237. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1238. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1239. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1240. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1241. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1242. The latent injuries from which Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the

absence of exposure to this risk of harm.

1243. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1244. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1245. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1246. Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1247. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1248. Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 52:

Negligence – Failure to Warn Through Proper Expiration Dates – Missouri

1249. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1250. This cause of action is brought by Ronda Lockett, individually and on behalf of the Missouri Pfizer OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Pfizer (for the purposes of this Count, “Defendant”).

1251. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1252. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1253. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1254. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1255. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1256. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1257. The latent injuries from which Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1258. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1259. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1260. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1261. Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1262. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1263. Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

6. Nevada

COUNT 53:

Negligence – Failure to Warn Through Warnings and Precautions – Nevada

1264. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1265. This cause of action is brought by Jonathan Ferguson, individually and on behalf of the Nevada Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1266. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1267. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1268. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1269. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1270. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1271. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1272. The latent injuries from which Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1273. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1274. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1275. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada Pfizer

OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1276. Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1277. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Nevada Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1278. Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 54:

Negligence – Failure to Warn Through Proper Expiration Dates – Nevada

1279. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1280. This cause of action is brought by Jonathan Ferguson, individually and on behalf of the Nevada Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1281. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1282. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1283. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1284. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1285. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1286. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Nevada Pfizer OTC

Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1287. The latent injuries from which Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1288. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1289. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1290. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1291. Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, Defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for

the medical monitoring and diagnosis of Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1292. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Nevada Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1293. Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Nevada Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

7. Ohio

COUNT 55:

Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio

1294. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1295. This cause of action is brought by Chris Troyan and Michael Galloway,

individually and on behalf of the Ohio Pfizer OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Pfizer (for the purposes of this Count, “Defendant”).

1296. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1297. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1298. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1299. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1300. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1301. As a direct and proximate result of Defendant’s failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Ohio Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses

associated with ongoing medical monitoring.

1302. The latent injuries from which Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1303. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1304. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1305. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1306. Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1307. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1308. Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 56:

Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio

1309. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1310. This cause of action is brought by Chris Troyan and Michael Galloway, individually and on behalf of the Ohio Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1311. The allegations in this Count apply to Pfizer during the time period in which it was

manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1312. Plaintiffs incorporate herein Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1313. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1314. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1315. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1316. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Ohio Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1317. The latent injuries from which Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals

exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1318. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1319. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1320. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1321. Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1322. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b)

notifying all Ohio Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1323. Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

8. West Virginia

COUNT 57:

Medical Monitoring – Negligent Failure To Warn Through Warnings And Precautions – West Virginia

1324. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1325. This cause of action is brought by Ida Adams, individually and on behalf of the West Virginia Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1326. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1327. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Pfizer.

1328. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1329. Under West Virginia law, a manufacturer, like Defendant, has a duty to provide an adequate warning of the risks of its products if it is reasonably foreseeable that the product would be unreasonably dangerous if distributed without a particular warning.

1330. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each its Ranitidine-Containing Products were unreasonably inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1331. Plaintiff or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1332. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of its Ranitidine-Containing Products, Plaintiff and West Virginia Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1333. The latent injuries from which Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not

generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1334. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1335. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1336. By monitoring and testing Plaintiff, the risk that Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1337. Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1338. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all West Virginia Pfizer OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1339. Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the West Virginia Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 58:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
West Virginia

1340. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1341. This cause of action is brought by Ida Adams, individually and on behalf of the West Virginia Pfizer OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Pfizer (for the purposes of this Count, "Defendant").

1342. The allegations in this Count apply to Pfizer during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1343. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Pfizer.

1344. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1345. Under West Virginia law, a manufacturer, like Defendant, has a duty to provide an adequate warning of the risks of its products if it is reasonably foreseeable that the product would be unreasonably dangerous if distributed without a particular warning.

1346. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1347. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1348. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1349. The latent injuries from which Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of

ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1350. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1351. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1352. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1353. Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1354. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all West Virginia Pfizer OTC Medical Monitoring Class members in writing that they

may require frequent medical monitoring for the purpose of diagnosis.

1355. Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the West Virginia Pfizer OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

D. CAUSES OF ACTION AGAINST DEFENDANT BI WITH RESPECT TO OTC ZANTAC

1356. Plaintiffs identified in the table below bring claims against Defendant BI with respect to prescription Zantac on behalf of themselves and their respective State BI OTC Medical Monitoring Class under the laws of their respective states of usage. Each Plaintiff incorporates by reference the allegations specific to them from Section III.B. and the allegations set forth in Section VI, *supra*, into their respective claims below.

Plaintiff Name	State of Usage
Tangie Sims	AZ
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jonathan Ferguson	CA
Jeffrey Pisano	CO
Ronald Ragan	CO
Karen Foster	FL
Clifton McKinnon	FL
Gustavo Velasquez	FL
Joshua Winans	FL

Plaintiff Name	State of Usage
Marva Mccall	FL
Michael Tomlinson	FL
Ricardo Moròn	FL
Teresa Dowler	IN
Alberta Griffin	MD
Ida Adams	MD; WV
Antrenise Campbell	MO
Lorie Kendall-Songer	MO
Cesar Pinon	NV
Chris Troyan	OH
Michael Galloway	OH
Teresa Waters	UT

1. Arizona

COUNT 59:

Negligence – Failure to Warn Through Warnings and Precautions – Arizona

1357. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1358. This cause of action is brought by Tangie Sims, individually and on behalf of the Arizona BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”) , against BI (for the purposes of this Count, “Defendant”).

1359. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs

60-79, which are incorporated by reference.

1360. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1361. Under Arizona law manufacturers, like Defendants, have a duty of reasonable care to adequately warn of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1362. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1363. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1364. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Arizona BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancers ("Subject Cancers") and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1365. The latent injuries from which Plaintiffs and the Arizona BI OTC Medical

Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1366. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1367. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1368. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Arizona BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1369. Plaintiffs and the Arizona BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Arizona BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Arizona BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1370. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be

determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Arizona BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1371. Plaintiffs and the Arizona BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Arizona BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 60:

Negligence – Failure to Warn Through Proper Expiration Dates – Arizona

1372. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1373. This cause of action is brought by Tangie Sims, individually and on behalf of the Arizona BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”) , against BI (for the purposes of this Count, “Defendant”).

1374. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1375. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1376. Under Arizona law, manufacturers, like Defendant, have a duty of reasonable care to adequately warn of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1377. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1378. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1379. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Arizona BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal bladder, breast, colorectal/intestinal, esophageal, gastric, kidney, liver, lung, pancreatic, and prostate cancers ("Subject Cancers") and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1380. The latent injuries from which Plaintiffs and the Arizona BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of

ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1381. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1382. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1383. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Arizona BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1384. Plaintiffs and the Arizona BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Arizona BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Arizona BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1385. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Arizona BI OTC Medical Monitoring Class members in writing that they may require

frequent medical monitoring for the purpose of diagnosis.

1386. Plaintiffs and the Arizona BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Arizona BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

2. California

COUNT 61:

Negligence – Failure to Warn Through Warnings and Precautions – California

1387. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1388. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, Virginia Aragon, and Jonathan Ferguson, individually and on behalf of the California BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1389. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1390. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-

Specific Allegations) as to BI.

1391. Under California law, manufacturers, like Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1392. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1393. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1394. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and California BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1395. The latent injuries from which Plaintiffs and the California BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of

ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1396. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1397. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1398. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1399. Plaintiffs and the California BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1400. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California BI OTC Medical Monitoring Class members in writing that they may

require frequent medical monitoring for the purpose of diagnosis.

1401. Plaintiffs and the California BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 62:

Negligence – Failure to Warn Through Proper Expiration Dates – California

1402. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1403. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, Virginia Aragon, and Jonathan Ferguson, individually and on behalf of the California BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1404. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1405. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1406. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1407. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1408. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1409. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and California BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1410. The latent injuries from which Plaintiffs and the California BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1411. The medical monitoring regime should include, but is not limited to, baseline tests

and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1412. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1413. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1414. Plaintiffs and the California BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1415. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1416. Plaintiffs and the California BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term

physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

3. Colorado

COUNT 63: Medical Monitoring – Negligence – Failure To Warn Through Warnings And Precautions – Colorado

1417. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1418. This cause of action is brought by Jeffrey Pisano and Ronald Ragan, individually and on behalf of the Colorado BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against BI (for the purposes of this Count, "Defendant").

1419. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1420. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1421. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1422. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1423. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1424. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1425. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Colorado BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1426. The latent injuries from which Plaintiffs and the Colorado BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1427. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1428. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1429. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1430. Plaintiffs and the Colorado BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1431. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1432. Plaintiffs and the Colorado BI OTC Medical Monitoring Class have an inadequate

remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 64:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Colorado

1433. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1434. This cause of action is brought by Jeffrey Pisano and Ronald Ragan, individually and on behalf of the Colorado BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1435. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1436. Plaintiffs incorporate herein Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1437. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1438. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1439. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1440. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1441. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Colorado BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1442. The latent injuries from which Plaintiffs and the Colorado BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1443. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers.

This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1444. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1445. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1446. Plaintiffs and the Colorado BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1447. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1448. Plaintiffs and the Colorado BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-

approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

4. Florida

COUNT 65: Medical Monitoring – Negligence – Failure to Warn Through Warnings and – Precautions—Florida

1449. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1450. This cause of action is brought by Karen Foster, Clifton McKinnon, Gustavo Velasquez, Joshua Winans, Marva McCall, Michael Tomlinson, and Ricardo Moron, individually and on behalf of the Florida BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1451. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1452. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1453. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1454. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1455. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1456. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1457. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Florida BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1458. The latent injuries from which Plaintiffs and the Florida BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the

absence of exposure to this risk of harm.

1459. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1460. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1461. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1462. Plaintiffs and the Florida BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1463. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1464. Plaintiffs and the Florida BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 66:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates – Florida

1465. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1466. This cause of action is brought by Karen Foster, Clifton McKinnon, Gustavo Velasquez, Joshua Winans, Marva McCall, Michael Tomlinson, and Ricardo Moron, individually and on behalf of the Florida BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1467. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1468. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1469. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1470. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1471. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1472. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1473. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Florida BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1474. The latent injuries from which Plaintiffs and the Florida BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the

absence of exposure to this risk of harm.

1475. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1476. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1477. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1478. Plaintiffs and the Florida BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1479. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1480. Plaintiffs and the Florida BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

5. Indiana

COUNT 67:

Negligence – Failure to Warn Through Warnings And Precautions – Indiana

1481. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1482. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1483. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1484. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1485. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care

to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

1486. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1487. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1488. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Indiana BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1489. The latent injuries from which Plaintiffs and the Indiana BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1490. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers.

This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1491. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1492. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1493. Plaintiffs and the Indiana BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1494. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1495. Plaintiffs and the Indiana BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-

approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 68: Negligence – Failure to Warn Through Proper Expiration Dates – Indiana

1496. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1497. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1498. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1499. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1500. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

1501. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1502. Plaintiffs or their doctors would have read and heeded these warnings had they been

included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1503. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Indiana BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1504. The latent injuries from which Plaintiffs and the Indiana BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1505. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1506. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1507. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without

adequate treatment will be significantly reduced.

1508. Plaintiffs and the Indiana BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1509. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1510. Plaintiffs and the Indiana BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

6. Maryland

COUNT 69:

Negligence –Failure to Warn Through Warnings and Precautions – Maryland

1511. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1512. This cause of action is brought by Alberta Griffin and Ida Adams, individually and on behalf of the Maryland BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against BI (for the purposes of this Count, "Defendant").

1513. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1514. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1515. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1516. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1517. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1518. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Maryland BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1519. The latent injuries from which Plaintiffs and the Maryland BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1520. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1521. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1522. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1523. Plaintiffs and the Maryland BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will

facilitate the diagnoses of Plaintiffs and the Maryland BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1524. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1525. Plaintiffs and the Maryland BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 70:

Negligence – Failure to Warn Through Proper Expiration Dates – Maryland

1526. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1527. This cause of action is brought by Alberta Griffin and Ida Adams, individually and on behalf of the Maryland BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1528. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1529. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1530. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1531. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1532. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1533. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Maryland BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1534. The latent injuries from which Plaintiffs and the Maryland BI OTC Medical

Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1535. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1536. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1537. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1538. Plaintiffs and the Maryland BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1539. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be

determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1540. Plaintiffs and the Maryland BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

7. Missouri

COUNT 71:

Negligence – Failure to Warn Through Warnings and Precautions –Missouri

1541. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1542. This cause of action is brought by Antrenise Campbell and Lorie Kendall-Songer, individually and on behalf of the Missouri BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1543. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs

60-79, which are incorporated by reference.

1544. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1545. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1546. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1547. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1548. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Missouri BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1549. The latent injuries from which Plaintiffs and the Missouri BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of

ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1550. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1551. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1552. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1553. Plaintiffs and the Missouri BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1554. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri BI OTC Medical Monitoring Class members in writing that they may require

frequent medical monitoring for the purpose of diagnosis.

1555. Plaintiffs and the Missouri BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 72:

Negligence –Failure to Warn Through Proper Expiration Dates – Missouri

1556. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1557. This cause of action is brought by Antrenise Campbell and Lorie Kendall-Songer, individually and on behalf of the Missouri BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1558. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1559. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1560. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care

to provide an adequate warning of the risks of its products.

1561. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1562. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1563. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Missouri BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1564. The latent injuries from which Plaintiffs and the Missouri BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1565. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1566. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1567. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1568. Plaintiffs and the Missouri BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1569. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1570. Plaintiffs and the Missouri BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri BI OTC Medical Monitoring Class members will continue to face an

unreasonable risk of injury and disability and remain undiagnosed.

8. Nevada

COUNT 73:

Negligence – Failure to Warn Through Warnings and Precautions – Nevada

1571. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1572. This cause of action is brought by Cesar Pinon, individually and on behalf of the Nevada BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”) , against BI (for the purposes of this Count, “Defendant”).

1573. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1574. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1575. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1576. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after

manufacture.

1577. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1578. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Nevada BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1579. The latent injuries from which Plaintiffs and the Nevada BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1580. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1581. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1582. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1583. Plaintiffs and the Nevada BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Nevada BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Nevada BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1584. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Nevada BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1585. Plaintiffs and the Nevada BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Nevada BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 74:
Negligence –Failure to Warn Through Proper Expiration Dates – Nevada

1586. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1587. This cause of action is brought by Cesar Pinon, individually and on behalf of the Nevada BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs") , against BI (for the purposes of this Count, "Defendant").

1588. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1589. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1590. Under Nevada law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1591. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1592. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1593. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Nevada BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1594. The latent injuries from which Plaintiffs and the Nevada BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1595. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1596. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1597. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Nevada BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1598. Plaintiffs and the Nevada BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will

facilitate the diagnoses of Plaintiffs and the Nevada BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Nevada BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1599. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Nevada BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1600. Plaintiffs and the Nevada BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Nevada BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

9. Ohio

COUNT 75:

Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio

1601. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs'

use of ranitidine and injury), as if fully stated herein.

1602. This cause of action is brought by Chris Troyan and Michael Galloway, individually and on behalf of the Ohio BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against BI (for the purposes of this Count, “Defendant”).

1603. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1604. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1605. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1606. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1607. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1608. As a direct and proximate result of Defendant’s failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Ohio BI OTC Medical

Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1609. The latent injuries from which Plaintiffs and the Ohio BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1610. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1611. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1612. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1613. Plaintiffs and the Ohio BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring

and diagnosis of Plaintiffs and the Ohio BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1614. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1615. Plaintiffs and the Ohio BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 76:

Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio

1616. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1617. This cause of action is brought by Chris Troyan and Michael Galloway, individually and on behalf of the Ohio BI OTC Medical Monitoring Class (for the purposes of this

Count, “Plaintiffs”) , against BI (for the purposes of this Count, “Defendant”).

1618. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1619. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1620. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1621. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1622. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1623. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Ohio BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1624. The latent injuries from which Plaintiffs and the Ohio BI OTC Medical Monitoring

Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1625. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1626. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1627. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1628. Plaintiffs and the Ohio BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1629. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be

determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1630. Plaintiffs and the Ohio BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

10. Utah

COUNT 77:

Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Utah

1631. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1632. This cause of action is brought by Teresa Waters, individually and on behalf of the Utah BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against BI (for the purposes of this Count, "Defendant").

1633. The allegations in this Count apply to BI during the time period in which it was

manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1634. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to BI.

1635. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1636. Under Utah law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1637. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1638. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1639. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Utah BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1640. The latent injuries from which Plaintiffs and the Utah BI OTC Medical Monitoring

Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1641. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1642. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1643. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Utah BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1644. Plaintiffs and the Utah BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Utah BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Utah BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1645. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be

determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Utah BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1646. Plaintiffs and the Utah BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Utah BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 78:
Medical Monitoring – Negligence – Failure To Warn Through Proper Expiration Dates – Utah

1647. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1648. This cause of action is brought by Teresa Waters, individually and on behalf of the Utah BI OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”) , against BI (for the purposes of this Count, “Defendant”).

1649. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs

60-79, which are incorporated by reference.

1650. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to BI.

1651. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1652. Under Utah law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1653. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1654. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1655. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Utah BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1656. The latent injuries from which Plaintiffs and the Utah BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting

Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1657. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1658. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1659. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Utah BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1660. Plaintiffs and the Utah BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Utah BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Utah BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1661. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Utah BI OTC Medical Monitoring Class members in writing that they may require

frequent medical monitoring for the purpose of diagnosis.

1662. Plaintiffs and the Utah BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Utah BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

11. West Virginia

COUNT 79: Medical Monitoring – Negligent Failure to Warn Through Warnings and Precautions – West Virginia

1663. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1664. This cause of action is brought by Ida Adams, individually and on behalf of the West Virginia BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against BI (for the purposes of this Count, "Defendant").

1665. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1666. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-

Specific Allegations) as to BI.

1667. Plaintiff's exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1668. Under West Virginia law, a manufacturer, like Defendant, has a duty to provide an adequate warning of the risks of its products if it is reasonably foreseeable that the product would be unreasonably dangerous if distributed without a particular warning.

1669. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each its Ranitidine-Containing Products were unreasonably inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1670. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1671. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of its Ranitidine-Containing Products, Plaintiff and West Virginia BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1672. The latent injuries from which Plaintiff and the West Virginia BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals

exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1673. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1674. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1675. By monitoring and testing Plaintiff, the risk that Plaintiff and the West Virginia BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1676. Plaintiff and the West Virginia BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiff and the West Virginia BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiff and the West Virginia BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1677. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b)

notifying all West Virginia BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1678. Plaintiff and the West Virginia BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiff and the West Virginia BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

**COUNT 80:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
West Virginia**

1679. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1680. This cause of action is brought by Ida Adams, individually and on behalf of the West Virginia BI OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against BI (for the purposes of this Count, "Defendant").

1681. The allegations in this Count apply to BI during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1682. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-

Specific Allegations) as to BI.

1683. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1684. Under West Virginia law, a manufacturer, like Defendant, has a duty to provide an adequate warning of the risks of its products if it is reasonably foreseeable that the product would be unreasonably dangerous if distributed without a particular warning.

1685. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1686. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1687. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1688. The latent injuries from which Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the

absence of exposure to this risk of harm.

1689. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1690. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1691. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1692. Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1693. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all West Virginia BI OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1694. Plaintiffs and the West Virginia BI OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the West Virginia BI OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

E. CAUSES OF ACTION AGAINST DEFENDANT SANOFI WITH RESPECT TO OTC ZANTAC

1695. Plaintiffs identified in the table below bring claims against Defendant Sanofi with respect to prescription Zantac on behalf of themselves and their respective State Sanofi OTC Medical Monitoring Class under the laws of their respective states of usage. Each Plaintiff incorporates by reference the allegations specific to them from Section III.B. and the allegations set forth in Section VI, *supra*, into their respective claims below.

Plaintiff Name	State
Tangie Sims	AZ
Golbenaz Bakhtiar	CA
Richard Obrien	CA
Virginia Aragon	CA
Jeffrey Pisano	CO
Ronald Ragan	CO
Gustavo Velasquez	FL
Joshua Winans	FL
Michael Tomlinson	FL
Ricardo Moròn	FL
Teresa Dowler	IN
Alberta Griffin	MD

Plaintiff Name	State
Ida Adams	MD
Lorie Kendall-Songer	MO
Chris Troyan	OH
Michael Galloway	OH
Teresa Waters	UT

1. Arizona

COUNT 81:

Negligence – Failure to Warn Through Warnings and Precautions – Arizona

1696. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1697. This cause of action is brought by Tangie Sims, individually and on behalf of the Arizona Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1698. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1699. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1700. Under Arizona law manufacturers, like Defendants, have a duty of reasonable care to adequately warn of a particular risk that was known or knowable in light of the generally

recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1701. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1702. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1703. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Arizona Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1704. The latent injuries from which Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1705. The medical monitoring regime should include, but is not limited to, baseline tests

and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1706. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1707. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1708. Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1709. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Arizona Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1710. Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of

long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 82:
Negligence –Failure to Warn Through Proper Expiration Dates – Arizona

1711. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1712. This cause of action is brought by Tangie Sims, individually and on behalf of the Arizona Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1713. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1714. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1715. Under Arizona law, manufacturers, like Defendant, have a duty of reasonable care to adequately warn of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1716. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1717. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1718. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Arizona Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1719. The latent injuries from which Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1720. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1721. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1722. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1723. Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1724. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Arizona Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1725. Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Arizona Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

2. California

COUNT 83:

Negligence –Failure to Warn Through Warnings and Precautions –California

1726. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1727. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, and Virginia Aragon, individually and on behalf of the California Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1728. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1729. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1730. Under California law, manufacturers, like Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1731. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk

of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1732. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1733. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and California Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1734. The latent injuries from which Plaintiffs and the California Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1735. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1736. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1737. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1738. Plaintiffs and the California Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1739. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1740. Plaintiffs and the California Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 84:
Negligence – Failure to Warn Through Proper Expiration Dates – California

1741. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1742. This cause of action is brought by Golbenaz Bakhtiar, Richard Obrien, and Virginia Aragon, individually and on behalf of the California Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1743. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1744. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1745. Under California law, manufacturers, including Defendant, have a duty of reasonable care to warn of particular risks that are known or knowable in light of the generally recognized and prevailing scientific and medical knowledge available at the time of manufacture and distribution.

1746. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1747. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1748. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and California Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1749. The latent injuries from which Plaintiffs and the California Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1750. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1751. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1752. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the California

Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1753. Plaintiffs and the California Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the California Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the California Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1754. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all California Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1755. Plaintiffs and the California Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the California Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

3. Colorado

COUNT 85: Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Colorado

1756. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1757. This cause of action is brought by Jeffrey Pisano and Ronald Ragan, individually and on behalf of the Colorado Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1758. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1759. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1760. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1761. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1762. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after

manufacture.

1763. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1764. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Colorado Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1765. The latent injuries from which Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1766. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1767. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1768. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1769. Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1770. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1771. Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 86:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Colorado

1772. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1773. This cause of action is brought by Jeffrey Pisano and Ronald Ragan, individually and on behalf of the Colorado Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1774. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1775. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1776. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1777. Under Colorado law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate warnings or instructions for use that adequately inform the user of any specific risk of harm that may be involved in any intended or reasonably expected use.

1778. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1779. Plaintiffs or their doctors would have read and heeded these warnings had they been

included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1780. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Colorado Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1781. The latent injuries from which Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1782. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1783. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1784. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses

without adequate treatment will be significantly reduced.

1785. Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1786. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Colorado Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1787. Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Colorado Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

4. Florida

COUNT 87: Medical Monitoring –Negligence –Failure to Warn Through Warnings and Precautions – Florida

1788. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24

(describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1789. This cause of action is brought by Gustavo Velasquez, Joshua Winans, Michael Tomlinson, and Ricardo Moron, individually and on behalf of the Florida Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1790. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1791. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1792. Plaintiffs' exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1793. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1794. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under

hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1795. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1796. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Florida Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1797. The latent injuries from which Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1798. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1799. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and

treatment of the Subject Cancers.

1800. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1801. Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1802. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1803. Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 88:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Florida

1804. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1805. This cause of action is brought by Gustavo Velasquez, Joshua Winans, Michael Tomlinson, and Ricardo Moron, individually and on behalf of the Florida Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1806. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1807. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1808. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1809. Under Florida law, a manufacturer, like Defendant, has the duty of reasonable care to provide an adequate warning of a particular risk that was known or knowable in light of the generally recognized and prevailing best scientific and medical knowledge available at the time of manufacture and distribution.

1810. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1811. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1812. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1813. The latent injuries from which Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1814. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1815. The available monitoring regime is reasonably necessary according to

contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1816. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1817. Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1818. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Florida Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1819. Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Florida Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

5. Indiana

COUNT 89:

Negligence – Failure to Warn Through Warnings and Precautions – Indiana

1820. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1821. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1822. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1823. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1824. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

1825. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1826. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1827. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Indiana Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1828. The latent injuries from which Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1829. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1830. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1831. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana Sanofi

OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1832. Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1833. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1834. Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 90:

Negligence – Failure to Warn Through Proper Expiration Dates – Indiana

1835. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1836. This cause of action is brought by Teresa Dowler, individually and on behalf of the Indiana Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1837. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1838. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1839. Under Indiana law, a manufacturer, like Defendant, has a duty of reasonable care to provide adequate instructions for safe use and a warning as to dangers inherent in improper use.

1840. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiff that Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1841. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1842. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Indiana Sanofi OTC Medical

Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1843. The latent injuries from which Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1844. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1845. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1846. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1847. Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for

the medical monitoring and diagnosis of Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1848. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Indiana Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1849. Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Indiana Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

6. Maryland

COUNT 91:

Negligence – Failure to Warn Through Warnings and Precautions – Maryland

1850. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1851. This cause of action is brought by Alberta Griffin and Ida Adams, individually and

on behalf of the Maryland Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1852. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1853. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1854. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1855. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1856. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1857. As a direct and proximate result of Defendant’s failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Maryland Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1858. The latent injuries from which Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1859. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1860. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1861. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1862. Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1863. Accordingly, Defendant should be required to establish a medical monitoring

program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1864. Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 92:

Negligence – Failure to Warn Through Proper Expiration Dates – Maryland

1865. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1866. This cause of action is brought by Alberta Griffin and Ida Adams, individually and on behalf of the Maryland Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1867. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs

60-79, which are incorporated by reference.

1868. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1869. Under Maryland law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of a danger it knew or should have had known about.

1870. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1871. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1872. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Maryland Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1873. The latent injuries from which Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1874. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1875. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1876. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1877. Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1878. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Maryland Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1879. Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class have an

inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Maryland Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

7. Missouri

COUNT 93:

Negligence – Failure to Warn Through Warnings and Precautions – Missouri

1880. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1881. This cause of action is brought by Lorie Kendall-Songer, individually and on behalf of the Missouri Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1882. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1883. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1884. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1885. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1886. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1887. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Missouri Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1888. The latent injuries from which Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1889. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the

development of, and health effects associated with, the Subject Cancers.

1890. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1891. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1892. Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1893. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1894. Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court,

Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 94:

Negligence – Failure to Warn Through Proper Expiration Dates – Missouri

1895. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant’s knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers’ failure to warn), and 383-462 (describing Plaintiffs’ use of ranitidine and injury), as if fully stated herein.

1896. This cause of action is brought by Lorie Kendall-Songer, individually and on behalf of the Missouri Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1897. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1898. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1899. Under Missouri law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1900. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiff that Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1901. Plaintiffs or their doctors would have read and heeded these warnings had they been

included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1902. As a direct and proximate result of Defendant's failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Missouri Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1903. The latent injuries from which Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1904. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1905. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1906. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses

without adequate treatment will be significantly reduced.

1907. Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1908. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Missouri Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1909. Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Missouri Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

8. Ohio

COUNT 95:

Strict Liability – Failure to Warn Through Warnings and Precautions – Ohio

1910. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the

formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1911. This cause of action is brought by Chris Troyan and Michael Galloway, individually and on behalf of the Ohio Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against Sanofi (for the purposes of this Count, "Defendant").

1912. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1913. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1914. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1915. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1916. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the

use of the Ranitidine-Containing Products.

1917. As a direct and proximate result of Defendant's failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Ohio Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1918. The latent injuries from which Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1919. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1920. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1921. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1922. Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members seek

creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1923. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1924. Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 96:

Strict Liability – Failure to Warn Through Proper Expiration Dates – Ohio

1925. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs'

use of ranitidine and injury), as if fully stated herein.

1926. This cause of action is brought by Chris Troyan and Michael Galloway, individually and on behalf of the Ohio Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1927. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1928. Plaintiffs incorporate herein by reference Paragraphs 328-348 (Additional Count-Specific Allegations) as to Sanofi.

1929. Under Ohio law, a manufacturer, like Defendant, has the duty to provide an adequate warning of the risks associated with its product that it knows or should have known about, and a duty to provide adequate post-marketing warnings or instructions.

1930. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on each Ranitidine-Containing Product were inadequate because The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1931. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1932. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Ohio Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and

potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1933. The latent injuries from which Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1934. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1935. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1936. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1937. Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class

members as frequently and appropriately as necessary.

1938. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Ohio Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1939. Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Ohio Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

9. Utah

COUNT 97:

Medical Monitoring – Negligence – Failure to Warn Through Warnings and Precautions – Utah

1940. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1941. This cause of action is brought by Teresa Waters, individually and on behalf of the

Utah Sanofi OTC Medical Monitoring Class (for the purposes of this Count, “Plaintiffs”), against Sanofi (for the purposes of this Count, “Defendant”).

1942. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1943. Plaintiffs incorporate herein by reference Paragraphs 289-327 (Additional Count-Specific Allegations) as to Sanofi.

1944. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1945. Under Utah law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1946. Defendant breached this duty for its Ranitidine-Containing Products. The warnings included on Ranitidine-Containing Products were inadequate because they did not warn of the risk of cancer when taken over long periods, when stored under humid conditions, when stored under hot conditions, when consumed with a high-nitrite diet, and when consumed long after manufacture.

1947. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1948. As a direct and proximate result of Defendant’s failure to provide adequate warnings of the risk of Ranitidine-Containing Products, Plaintiffs and Utah Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing Subject

Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1949. The latent injuries from which Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1950. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1951. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1952. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1953. Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class

members as frequently and appropriately as necessary.

1954. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Utah Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1955. Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

COUNT 98:
Medical Monitoring – Negligence – Failure to Warn Through Proper Expiration Dates –
Utah

1956. Plaintiffs incorporate by reference each allegation set forth in paragraphs 6-24 (describing Defendants), 81-146 (describing the recall of ranitidine), 147-202 (describing the formation of ranitidine), 203-211 (describing evidence linking ranitidine to cancer), 212-216 (describing Defendant's knowledge), 226-237 (describing good manufacturing practices), 262-288 (describing Brand OTC Manufacturers' failure to warn), and 383-462 (describing Plaintiffs' use of ranitidine and injury), as if fully stated herein.

1957. This cause of action is brought by Teresa Waters, individually and on behalf of the Utah Sanofi OTC Medical Monitoring Class (for the purposes of this Count, "Plaintiffs"), against

Sanofi (for the purposes of this Count, “Defendant”).

1958. The allegations in this Count apply to Sanofi during the time period in which it was manufacturing Ranitidine-Containing Products. The relevant time period is alleged in paragraphs 60-79, which are incorporated by reference.

1959. Plaintiffs incorporate herein by reference as to Sanofi.

1960. Plaintiffs’ exposure to Ranitidine-Containing Products has significantly increased their risk of developing serious and potentially fatal Subject Cancers.

1961. Under Utah law, a manufacturer, like Defendant, has a duty of reasonable care to provide an adequate warning of the risks of its products.

1962. Defendant breached this duty for its Ranitidine-Containing Products. The expiration date improperly instructed Plaintiffs that its Ranitidine-Containing Products were safe when consumed long after manufacture, when in fact the products degraded into NDMA over time.

1963. Plaintiffs or their doctors would have read and heeded these warnings had they been included with the Ranitidine-Containing Products. Had such warnings been provided, Plaintiffs would have been made aware of the risks of developing the Subject Cancers associated with the use of the Ranitidine-Containing Products.

1964. As a direct and proximate result of Defendant’s failure to provide an adequate warning of the risks of Ranitidine-Containing Products, Plaintiffs and Utah Sanofi OTC Medical Monitoring Class members have sustained a significantly increased risk of developing serious and potentially fatal Subject Cancers and have suffered and will suffer economic losses and expenses associated with ongoing medical monitoring.

1965. The latent injuries from which Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members suffer require specialized testing (with resultant treatment) that is not

generally given to the public at large. The available monitoring regime is specific for individuals exposed to products known to significantly increase the risk of the Subject Cancers because of ingesting Ranitidine-Containing Products and is different from that normally recommended in the absence of exposure to this risk of harm.

1966. The medical monitoring regime should include, but is not limited to, baseline tests and diagnostic examination that will assist in early detection and diagnosing the Subject Cancers. This diagnostic program will facilitate treatment and interventions that will mitigate the development of, and health effects associated with, the Subject Cancers.

1967. The available monitoring regime is reasonably necessary according to contemporary scientific principles within the medical community specializing in the diagnosis and treatment of the Subject Cancers.

1968. By monitoring and testing Plaintiffs, the risk that Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members will suffer long-term injuries, disease, and losses without adequate treatment will be significantly reduced.

1969. Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members seek creation of a Court-supervised, defendant-funded medical monitoring program which will facilitate the diagnoses of Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members for the Subject Cancers. The medical monitoring should include a trust fund to pay for the medical monitoring and diagnosis of Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members as frequently and appropriately as necessary.

1970. Accordingly, Defendant should be required to establish a medical monitoring program that includes, among other things: (a) establishing a trust fund, in an amount to be determined, to pay for the medical monitoring of everyone who has taken Ranitidine-Containing

Products for the purpose of diagnosis, as frequently and appropriately as necessary; and (b) notifying all Utah Sanofi OTC Medical Monitoring Class members in writing that they may require frequent medical monitoring for the purpose of diagnosis.

1971. Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class have an inadequate remedy at law in that monetary damages alone cannot compensate them for the risk of long-term physical and economic losses due to ingesting Ranitidine-Containing Products. Without a court-approved medical monitoring program as described herein, or established by the Court, Plaintiffs and the Utah Sanofi OTC Medical Monitoring Class members will continue to face an unreasonable risk of injury and disability and remain undiagnosed.

X. PRAYER FOR RELIEF

Plaintiffs, on behalf of themselves and the proposed State Classes, respectfully request that the Court:

- A. Determine that this action may be maintained as a class action pursuant to Federal Rules of Civil Procedure 23(a), 23(b)(2), 23(b)(3), and/or 23(c)(4), direct that reasonable notice of this action be given to the State Classes, appoint Plaintiffs as named representatives of their respective State Classes, and appoint Plaintiffs' counsel as Class Counsel;
- B. Enter judgment against Defendants and in favor of Plaintiffs and the State Classes;
- C. Grant equitable relief in the form of a medical monitoring program to be funded by Defendants;
- D. Award Plaintiffs and the State Classes their costs of suit, including reasonable attorneys' fees, as provided by law;
- E. Award any other relief that is deemed just and proper.

XI. JURY DEMAND

Pursuant to Federal Rule of Civil Procedure 38, Plaintiffs, on behalf of themselves and the State Classes, demand a trial by jury on all issues to triable.

DATED: August 2, 2021.

Respectfully submitted,

/s/ Tracy A. Finken

Tracy A. Finken
Email: tfinken@anapolweiss.com
ANAPOL WEISS
One Logan Square
130 North 18th Street, Suite 1600
Philadelphia, PA 19103
Tel: (215) 735-1130

/s/ Michael L. McGlamry

Michael L. McGlamry
Email: efile@pmkm.com
POPE McGLAMRY, P.C.
3391 Peachtree Road NE, Suite 300
Atlanta, GA 30326
Tel: (404) 523-7706

By: /s/ Robert C. Gilbert

Robert C. Gilbert, FBN 561861
Email: gilbert@kolawyers.com
KOPELOWITZ OSTROW FERGUSON
WEISELBERG GILBERT
2800 Ponce de Leon Boulevard, Suite 1100
Coral Gables, FL 33134
Tel: (305) 384-7269

/s/ Adam Pulaski

Adam Pulaski
Email: adam@pulaskilawfirm.com
PULASKI KHERKHER, PLLC
2925 Richmond Avenue, Suite 1725
Houston, TX 77098
Tel: (713) 664-4555

Plaintiffs' Co-Lead Counsel

Rosemarie Riddell Bogdan
Email: Rosemarie.bogdan@1800law1010.com
MARTIN, HARDING & MAZZOTTI
1222 Troy-Schenectady Road
PO Box 15141
Albany, NY 12212
Tel.: (518) 862-1200

Elizabeth A. Fegan
Email: beth@feganscott.com
FEGAN SCOTT, LLC
150 S. Wacker Dr., 24th Floor
Chicago, IL 60606
Tel.: (312) 741-1019

Mark J. Dearman, FBN 0982407
Email: mdearman@rgrdlaw.com
ROBBINS GELLER RUDMAN & DOWD
120 East Palmetto Park Road, Suite 500
Boca Raton, FL 33432
Tel.: (561) 750-3000

Marlene J. Goldenberg
Email: mjgoldenberglaw@goldenberglaw.com
GOLDENBERG LAW, PLLC
800 LaSalle Avenue, Suite 2150
Minneapolis, MN 55402
Tel.: (612) 333-4662

Ashley Keller
Email: ack@kellerlenkner.com
KELLER | LENKNER
150 N. Riverside Plaza, Suite 4270
Chicago, IL 60606
Tel.: (312) 741-5222

Roopal P. Luhana
Email: luhana@chaffinluhana.com
CHAFFIN LUHANA LLP
600 Third Avenue, 12th Floor
New York, NY 10016
Tel.: (888) 480-1123

Ricardo M. Martinez-Cid, FBN 383988
Email: RMartinez-Cid@Podhurst.com
PODHURST ORSECK, P.A.
SunTrust International Center
One S.E. 3rd Avenue, Suite 2300
Miami, FL 33130
Tel.: (305) 358-2800

Melanie H. Muhlstock
Email: mmuhlstock@yourlawyer.com
PARKER WAICHMAN LLP
6 Harbor Park DrivePort
Washington, NY 11050
Tel.: (516) 466-6500

Carmen S. Scott
Email: cscott@motleyrice.com
MOTLEY RICE LLC
28 Bridgeside Blvd.
Mount Pleasant, SC 29464
Tel.: (843) 216-9160

Sarah N. Westcot, FBN 1018272
Email: swestcot@bursor.com
BURSOR & FISHER, P.A.
2665 S. Bayshore Drive, Suite 220
Miami, FL 33133
Tel.: (305) 330-5512

Frederick Longer
Email: flonger@lfsblaw.com
LEVIN SEDRAN & BERMAN
510 Walnut Street, Suite 500
Philadelphia, PA 19106
Tel.: (215) 592-1500

Francisco R. Maderal, FBN 0041481
Email: frank@colson.com
COLSON HICKS EIDSON
255 Alhambra Circle, Penthouse
Coral Gables, FL 33134
Tel.: (305) 476-7400

Lauren S. Miller
Email: lmiller@corywatson.com
CORY WATSON, P.C.
2131 Magnolia Ave S
Birmingham, AL 35205
Tel.: (205) 328-2200

Daniel A. Nigh, FBN 30905
Email: dnigh@levinlaw.com
LEVIN PAPANTONIO THOMAS
MITCHELL RAFFERTY & PROCTOR, P.A.
316 South Baylen Street, Suite 600
Pensacola, FL 32502
Tel.: (888) 435-7001

Mikal C. Watts
Email: mcwatts@wattsguerra.com
WATTS GUERRA LLP
4 Dominion Drive
Building 3, Suite 100
San Antonio, TX 78257
Tel.: (800) 294-0055

Conlee S. Whiteley
Email: c.whiteley@kanner-law.com
KANNER & WHITELEY, L.L.C.
701 Camp Street
New Orleans, LA 70130
Tel.: (504) 524-5777

Frank Woodson
Email: Frank.Woodson@BeasleyAllen.com
BEASLEY ALLEN LAW FIRM
218 Commerce Street
Montgomery, AL 36104
Tel.: (334) 269-2343

R. Brent Wisner
Email: rbwisner@baumhedlundlaw.com
BAUM HEDLUND ARISTEI &
GOLDMAN, P.C.
10940 Wilshire Boulevard, 17th Floor
Los Angeles, CA 90024
Tel.: (310) 207-3233

Plaintiffs' Steering Committee
Plaintiffs' Law and Briefing Committee Co-Chairs
Plaintiffs' Liaison Counsel

Paige Boldt
Email: pboldt@wattsguerra.com
WATTS GUERRA LLP
5726 W. Hausman Rd., Ste. 119
San Antonio, TX 78249
Tel: (210) 447-0500

Je Yon Jung
Email: JJung@maylightfootlaw.com
MAY LIGHTFOOT, PLLC
3200 Martin Luther King Jr. Avenue S.E.
3rd Floor
Washington, DC 20032
Tel: (202) 918-1824

Adam W. Krause
Email: adam@krauseandkinsman.com
KRAUSE AND KINSMAN, LLC
4717 Grand Avenue, Suite 250
Kansas City, MO 64112
Tel: (816) 760-2700

Nicola Larmond-Harvey, FBN 0105312
Email: nicola@saunderslawyers.com
SAUNDERS & WALKER, P.A.
3491 Gandy Boulevard North, Suite 200
Pinellas Park, FL 33781
Tel: (727) 579-4500

Bradford B. Lear
Email: Lear@learwerts.com
LEAR WERTS LLP
103 Ripley Street
Columbia, MO 65203
Tel: (573) 875-1992

Plaintiffs' Leadership Development Committee

CERTIFICATE OF SERVICE

I hereby certify that on August 2, 2021, I electronically filed the foregoing document with the Clerk of the Court using CM/ECF and that the foregoing document is being served on all counsel of record or parties registered to receive CM/ECF Electronic Filings.

/s/ Robert C. Gilbert

ROBERT C. GILBERT